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ABSTRACT
Adoptive cell transfer (ACT) using T cell receptor (TCR) gene-modified T cells is an
exciting and rapidly evolving field. Numerous basic science and clinical studies have
demonstrated various levels of feasibility, safety, and efficacy using TCR-engineered T
cells to treat cancer and viral infections. Although evidence suggests their use can be
effective, how effective and how to improve these therapeutics are still remaining
questions.
Because TCR affinity is thought to play the central role in defining T cell
specificity and sensitivity, the field has adopted the theory that creating affinityenhanced TCRs creates better functioning T cells; but, enhanced affinity creates the
opportunity for cross-reactivity. TCR cross-reactivity against off-tumor/on-target or offtarget antigens has caused serious adverse events, including death, in recent clinical
trials using high affinity TCR-engineered T cells. However, the use cross-reactive TCRs
could offer therapeutic benefit for diseases where targeted antigens are susceptible to
mutation via genomic instability.
The proper choice and design of therapeutic TCRs mandate a broader
understanding of the basic principles governing antigen recognition by a T cell. In light of
what is known about TCRs and T cell function, numerous factors still need to be
addressed. These include: (1) what kinetic or cellular parameters are most important in
xxvii

facilitating antigen recognition; (2) how is T cell function affected by alterations in TCRpeptide-major histocompatibility complex (pMHC) interactions; (3) how can we
structurally rationalize the cross-reactivity of a TCR; and (4) how might the crossreactivity of a TCR augment or inhibit therapeutic efficacy. These biologic questions
addressed in this dissertation utilize traditional and novel approaches to characterize
TCR gene-modified T cells harboring an HLA-A2-restricted TCR cross-reactive against
naturally occurring mutant HCV NS3:1406-1415 epitopes, serving as a model to study
antigen recognition.
Overall, contrary to what is generally accepted in the field, we found that TCRpMHC affinity is not necessarily the most important factor dictating antigen recognition.
Other cellular parameters, including ligand density, TCR density, and co-receptor
signaling greatly influenced recognition of altered pMHC ligands. Modifying any of these
parameters changed functional responses, sometimes independent of affinity.
Additionally, we found that the field’s interpretation of antigen recognition may be
narrowed and misguided when evaluation of T cell function is limited to a single
cytokine. Functional phenotypes by seven-parameter flow cytometry revealed that T cell
functional profiles are more complex than were previously believed. Evaluation of a
single functional phenotype, such as IFNγ, did not accurately reflect the functional
behavior of a T cell culture. Combining functional studies with structural analysis of the
TCR-pMHC interface helps bring clarity to these unexpected results.
In summary, we have established a new working model highlighting the
previously unappreciated and complex relationship between kinetic, cellular, and
xxviii

structural parameters governing antigen recognition and T cell function. Together, our
data suggest the field is oversimplifying the biology of T cells and the fundamentals of
antigen recognition. This enhanced understanding will not only help steer rational,
structure-guided design of TCRs to generate better functioning T cells for ACT, but will
also impact the way in which we study other immune cell and receptor types, approach
epitope discovery, and evaluate vaccine design. In this way, we have provided a new
foundation in which to evaluate the design and implementation of novel
immunotherapies.
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CHAPTER ONE
REVIEW OF LITERATURE
Introduction
Immunotherapy is one of the most promising and innovative approaches to treat
cancer, viral infections, and other immune-modulated diseases. Adoptive
immunotherapy using gene-modified T cells is an exciting and rapidly evolving field.
Exploiting knowledge of basic T cell biology and immune cell receptors has fostered
innovative approaches to modify immune cell function. Novel and more efficient
technologies have been developed to redirect T cell specificity by introducing designed
receptors. The ability to engineer T cells to manifest desired phenotypes and functions is
now a thrilling reality.
TCR-transduced T cells offer the ability to target a wide variety of self and
nonself targets through the normal biology of a T cell. But to produce an optimally
functioning gene-modified T cell, a firm understanding of the basic principles governing
antigen recognition is required. Yet, many diseases targeted by such immunotherapies
are genetically unstable, leading to immune escape. Investigation into how a T cell might
be limited by changes in its target, affecting therapeutic efficacy, is also essential.
A potential solution to immune escape by antigen mutation is the use of crossreactive TCRs given their ability to recognize a spectrum of related antigens. But the
1
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potential for unwanted off-target reactivity, leading to adverse events in the clinic,
warrants a closer examination into what factors govern T cell specificity. Conventionally,
antigen recognition is thought to be dictated by the affinity between the TCR-pMHC
interaction [1], but recent evidence suggests traditionally measured affinity interactions
may not fully explain the complex relationship between T cell specificity and T cell
reactivity [2]. Furthermore, current strategies used to randomly enhance the affinity of
TCRs, hoping to improve their therapeutic efficacy [3, 4], may be too blinded. Thus, a
greater understanding of antigen recognition by TCR-gene modified T cells may help lay
the groundwork for more optimal therapeutic strategies.
The studies discussed in this dissertation explore structure-function relationships
between a T cell receptor (TCR) and its peptide major histocompatibility complex
(pMHC) ligand using hepatitis C virus (HCV) mutant epitopes as a model for genomic
instability. A more complete appreciation of how altered TCR-pMHC affinity influences
antigen recognition in light of genomic instability may aid in the rational design of TCRs
for safer and more effective TCR-based immunotherapies.
TCR-Mediated Antigen Recognition
T cells play a central role in mediating cellular immunity. These multi-functional
effector cells protect us from disease throughout our entire lives with their ability to
recognize bacterial, viral, and cancer-associated antigens. The specificity of a T cell is
mediated by the TCR, a cell surface heterodimer that facilitates target cell recognition
[5]. There are two types of T cells, which can be distinguished by the TCRs expressed on

3

their surface. αβ T cells express a highly variable αβTCR whereas γδ T cells express a
highly conserved γδTCR [6, 7]. TCRs mediate recognition of foreign or self-peptides
bound to MHC molecule displayed by other cells [8-13]. This interaction between the
TCR and its pMHC ligand plays a crucial role in determining the specificity and reactivity
of an individual T cell. For the purpose of these studies, we will focus on αβ T cells/TCRs.
Cell surface expression of the TCR requires its association with the CD3 complex
[14-19]. Upon TCR-pMHC engagement, a cascade begins with the initiation of a series of
signaling events starting with the phosphorylation of ITAM’s on the CD3 ζ chain, leading
to full T cell activation and function [20]. The CD4 and CD8 co-receptors play a critical
role in T cell activation and function by enhancing the binding of the TCR to the pMHC
[21-24] and promoting the signaling by localizing lck to the TCR/CD3 complex [21, 25,
26] (Fig. 1). Consequently, a specific TCR-pMHC interaction (thought to be primarily
driven by affinity) translates into a signaling cascade to facilitate functional recognition
of the presence of pathogens or transformed cells. This complex process ultimately
leads to target cell killing, or the secretion of pro-inflammatory cytokines that recruit
and support other immune effectors, described in a later section. There are many
important factors involved in antigen recognition and T cell function which should be
thoroughly evaluated when considering how to generate the most effective anti-tumor
T cells by introducing a foreign TCR.
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Figure 1. TCR-mediated target cell recognition. Depicted is the structure of an MHC
class I-restricted TCR interacting with a tumor or virus-infected cell. TCR α and β chains
are specific to both MHC and presented antigenic peptide. The TCR complexes with
various CD3 components on the cell surface, and the CD8 co-receptor stabilizes the TCRpMHC interaction while recruiting lck to facilitate TCR signaling. ITAMs are denoted as
colored octagons. Lck = lymphocyte-specific protein tyrosine kinase; ZAP70 = zeta-chainassociated protein kinase 70; P=phosphate group; Black arrows=downstream signaling.
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TCR Diversity
All higher vertebrates maintain a large and diverse repertoire of T cells capable
of recognizing most of the pathogens we will ever encounter. This tremendous diversity
is due to the extreme variability of the TCR expressed by each T cell. Each TCR chain
consists of a variable (V) gene segment, a joining (J) region, a diversity (D) region in the β
chain only, and a constant (C) region [27]. In the thymus, the different TCR α and β
chains are generated randomly by germline rearrangements which bring together one
of many Vα genes with one of many Jα regions for the TCRα chain or one of many Vβ
genes, one of the two Dβ regions, and one of the thirteen Jβ regions for the TCRβ chain
[28, 29]. The numerous arrangements of elements in each TCR chain together with the
combinations of α and β chain pairing contribute to some of the TCR diversity observed
in nature [7]. However, the majority of the diversity in TCRs expressed by mature T cell
results from the addition and deletion of bases at the Vα-Jα, Vβ-Dβ, and, Dβ-Jβ junctions
(known as N-region substitutions) which occurs during TCR gene rearrangement [7].
This hypervariable region of the TCR α chain or TCR β chain is the third complementarity
determining region (CDR3). The TCR α and β chain CDR3s are considered to be the most
important regions of the TCR for antigen recognition due to their length and sequence
diversity. This combinatorial rearrangement of the TCR gene segments combined with
N-region substitutions provides a theoretical estimate for 10 15 different αβ TCRs in the T
cell repertoire [27].
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The random TCR rearrangements that lead to such a large potential TCR
repertoire suggests we should have T cell immunity against most pathogenic peptides
presented by MHC as well as self and nonself peptides presented by allo-MHC. Positive
selection enables developing thymocytes expressing TCRs capable of binding
antigen/self-MHC molecules in the thymus with the “correct” affinity to be protected
from programmed cell death (positive selection). These positively selected T cells then
complete T cell development resulting in a pool of mature T cells restricted only by selfMHC. In contrast, thymocytes expressing TCRs whose affinity for the host pMHC is too
low (death by neglect) or too high (negative selection) are not protected from
programmed cell death and do not complete T cell development, eliminating them from
the pool of mature T cells [30]. The net effect of thymic selection is to save
“immunologic space” for T cells that are beneficial to the host by eliminating T cells that
are not self-MHC restricted and those that have the potential for autoimmunity. These
are important factors to consider for TCR gene transfer studies given that most human
tumor reactive T cells recognize normal, non-mutated self-antigens [31-33].
Given the extreme TCR diversity, two critical questions initially raised by the field
are: (1) do we have a choice in TCRs that target a single pMHC, and (2) if we have a
choice, does it matter which TCR we select to use for a given target. Early studies aimed
to address these questions focused on the diversity of the TCR repertoire against a
single target pMHC by testing the concept of restricted TCR V gene usage [34-39].
Because of clonal selection theory, it would make sense that our immune system would
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select for one or a limited number of TCR rearrangements that “best” recognize a given
peptide [40]. Using TCRs reactive against melanoma antigen MART-1 as a model,
multiple studies found that the TCR diversity among MART-1 reactive T cell clones to be
very high [35, 36]. More importantly, individual MART-1-reactive T cells clones
recognized different subsets a panel of peptides with homology to the MART-1 peptide
[41]. Furthermore, peptides recognized commonly by the different MART-1 reactive T
cell clones were recognized by each clone with different efficiencies [41]. Diversity of
TCR V gene usage is not a property unique to MART-1-reactive T cells [42]. Such findings
indicate that each TCR can recognize a single antigen differently. Ultimately, how a T cell
recognizes its target might make a difference in the effectiveness and the safety (crossreactivity) of the resulting TCR gene-modified T cells in vivo.
TCR Affinity
TCR affinity has been traditionally thought to play a significant, if not the most
important, role in determining the sensitivity of a T cell to antigen recognition[1] .
Generally, the affinity of TCR for pMHC is lower than antibody/antigen interactions and
generally occur between 1-100 µM [11, 30, 43]. As discussed earlier, TCRs have different
affinities for the pMHC, the range of which is tightly regulated by thymic selection.
There are several important facts to consider regarding the relationship between TCR
affinity and T cell function. Contrary to the predictions of thymic selection, T cells
reactive with self-antigens are not always deleted in the thymus since many are found in
the periphery. In both animal and human systems, self-reactive T cells can be induced
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to mediate tumor rejection and in some cases, autoimmunity. These T cells are
generally CD8-dependent meaning they express TCRs with relatively low affinity for
pMHC. Their anti-self-reactivity is generally limited until their physiology or the host
environment is altered. Another key observation is that T cells derived from a single T
cell clone can have varied T cell function [44]. Under certain circumstances, T cells can
be very antigen reactive whereas in other circumstances they are weakly antigen
reactive [44, 45]. Therefore, it is likely that the biology of a given T cell can dictate
function and TCR affinity plays a less important role than previously thought.
There are several mechanisms, which can explain how the function of a T cell is
influenced by its environment, regardless of the affinity of the TCR-pMHC interaction. It
is well known that T cells become refractory to immune function resulting from the level
of immune suppression in the tumor-bearing host [46-52]. Furthermore, reactive
oxygen and nitrogen species in the tumor-bearing host can promote T cell death [5358]. Interesting, none of these suppressive mechanisms require changes in TCR affinity
to reduce immune function of a T cell. However, there are examples of immune
suppression mechanisms that do seem to impact on TCR affinity. We know that one key
role of CD8 is to stabilize the TCR-pMHC complex. It has been observed that the spatial
relationship of the TCR and CD8 on the surface of a T cell can vary leading to differences
in the relative stability of the TCR-pMHC complex [59]. Similarly, the ratio of the high
affinity form of CD8 (CD8αβ) versus the low affinity form of CD8 (CD8αα) can vary on
each T cell expressing the same TCR [60]. CD8αβ induces a higher functional avidity
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than CD8αα, which translates to higher anti-tumor activity. Finally, myeloid-derived
suppressor cells (MDSCs) have been shown to modify the TCR proteins by nitration of
tyrosine residues leading to weaker binding to pMHC [61]. In all these suppressive
mechanisms, the function of a T cell expressing a high affinity TCR could be as easily
overcome as the function of a T cell expressing a low affinity TCR. The studies described
in this dissertation aim to help shed light on this inconsistency.
T Cell Signaling and Function
As mentioned earlier, engagement of the TCR/CD3 complex with its pMHC ligand
at the immunological synapse initiates a radiating and branching network of signaling
cascades leading to T cell activation and function [62]. Precisely how the engagement of
the TCR with its pMHC target tips the signaling balance in favor of T cell activation is still
a matter of debate. Traditionally, TCR engagement is thought to promote lck-dependent
phosphorylation of ITAMs of CD3ζ chains, resulting in recruitment and activation of ζchain associated protein 70 (ZAP70), which induces the assembly of the signal
diversification and regulation components [63] (Fig. 1). Subsequent signaling events
facilitate the hallmarks of T cell activation, including Ca2+ release, actin polymerization,
integrin activation, proliferation, mobilization of transcription factors, cytokine
secretion, and degranulation [62].
Ultimately, signal propagation results in a functional response, which can vary
depending on the subset of T cell activated. When a naïve T cell is activated by an
antigen presenting cell (APC), they acquire effector functions while differentiating into
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various subtypes. Differentiation is often influenced by the cocktail of cytokines present
in the milieu during antigen presentation [64]. These T cell subsets are subsequently
identified by cell surface markers, transcription factors, and cytokine secretion profiles.
A well-characterized example of this is the Th1/Th2 dichotomy, where these
CD4+ T helper cell subpopulations are distinguished by their cytokine profiles. Th1 cells
express transcription factor T-bet, produce mainly IFNγ, IL-2, and TNFα, and have
functional importance in pro-inflammatory cell-mediated immunity, delayed-type
hypersensitivity, and immune responses against certain protozoa. Conversely, Th2 cells
express transcription factor GATA-3, secrete IL-4, -5, -6, -10, and -13, and promote noninflammatory immediate immune responses and are essential in promoting B cellmediate immunity. It is thought that these developmental routes and cytokine profiles
of Th1 and Th2 are mutually antagonistic, giving rise to the model of polarization of the
immune response [64].
Interestingly, a growing spectrum of additional T cell subset lineages has been
defined by transcription factor expression and signature cytokine secretion. These
include, but are not limited to, Th17 (ROR-γt+; IL-17A and -22 secreting), Treg (Foxp3+; IL10 and TGF-β secreting), and Th9 (IL-9 secreting) subsets [64]. CD8+ cytotoxic
lymphocytes (Tc) are similarly categorized into subsets based on cytokine profiles (Tc1,
Tc2, Tc17, etc.). These CD8+ subsets are hallmarked by cell-mediated killing by
perforin/granzyme-mediated or Fas/Fas-ligand-mediated apoptosis. In this way, the
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field generally accepts that T cells are functionally restricted by the subset into which
they differentiate [64].
The impact of TCR-pMHC affinity on TCR signaling remains debated. One
argument, the kinetic proofreading model [65], proposes that the TCR signaling cascade
serves as a biochemical clock. This models predicts that very slight discrepancies in
ligand engagement can cause time delays between successive steps of activation,
resulting in a distinct kinetic attenuation. Because of the intricate radiation and
branching of downstream pathways in TCR signaling, kinetic attenuation can produce
different ratios of downstream signaling molecules, leading to substantially different
cellular functions. Factors that influence this biochemical clock (unique to a given TCRpMHC interaction) are thought to include TCR-pMHC dissociation rates, TCR clustering,
and co-receptor accumulation in the immunological synapse [65, 66].
Overall, TCRs exhibit an enormous breadth of diversity, allowing for immune
surveillance over countless self and nonself targets. Antigen recognition dictated by TCR
specificity to its pMHC ligand initiates a complex, and not entirely understood, signaling
pathway resulting in a host of cellular responses. Although TCR affinity plays a major
role in dictating its specificity, the effect of slight alterations in TCR-pMHC interactions is
not always reconciled with changes in T cell reactivity. An enhanced understanding of
basic T cell biology will ultimately help improve the design of TCR-based therapeutics.
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Adoptive Cell Therapy
In light of T cell-mediated immune surveillance, unfortunately most viruses and
tumors have developed various mechanisms to evade the host immune system. Immune
evasion can lead to weak or ineffective immune responses, resulting in chronic
infections or malignancies. To address ineffective immune responses towards cancer,
many therapeutic approaches are aimed at optimizing the anti-tumor potential of T
cells. Immune-modulating strategies include directly promoting a T cell immune
response by administration of IL-2 which is used in treatment against melanoma and
renal cell carcinoma [67]. Conversely, other therapies lift restraints on T cell activation,
known as checkpoint blockade. These tactics include targeting inhibitory receptors
CTLA-4 or PD-1 with antagonist antibodies ipilimumab [68-70] and pembrolizumab [71,
72], respectively, which are currently approved to treat melanoma. Despite their recent
success, cytokine administration and checkpoint blockade are not 100% effective; thus,
combinatorial or novel therapeutic strategies need to be evaluated to improve cancer
and viral immunotherapies.
One such novel immunotherapy known as adoptive cell transfer (ACT) involves
the transfer of ex vivo activated and expanded antigen-reactive T cells or genetic
modification to redirect their specificity prior to transfer. ACT gained its first success
using lymphokine activated killer (LAK) cells [73] and later tumor infiltrating
lymphocytes (TIL) [74, 75] or antigen stimulated autologous peripheral blood
lymphocytes (PBL) [76-79]. The most promising of these early approaches utilized TIL

13

following harvest from tumor and short term ex vivo expansion and were pioneered by
the Rosenberg group at the Surgery Branch of the National Cancer Institute. Animal
models and studies in patients with melanoma demonstrated that TIL maintained tumor
reactivity in vitro, having the capability to lyse tumor cells and secrete cytokines, such as
IL-2, IFNγ, and TNFα [80, 81]. These cells also mediated objective clinical responses
when grown ex vivo and infused back into patients [82].
Despite these promising but preliminary clinical results, for a variety of reasons
TIL has not been a universal approach for ACT. For example, TIL production is a
logistically and technically demanding process. Oftentimes primary tumors harboring TIL
are previously resected as part of cancer treatment or are inaccessible depending on the
tumor type and location. Additionally, the time it takes or the inability to expand
available TIL to therapeutic numbers calls for an alternative cell-based approach for
treating cancer or chronic viral infections [83, 84].
Recent technological advances have facilitated efficient expression of transgenes
in T cells allowing for normal circulating PBL to be redirected targeting desired antigens.
Genetically engineering T cells with chimeric antigen receptors (CARs), TCRs, and other
receptor types have been shown to successfully redirect the specificity of T cells [85].
However, the ability to redirect a T cell to recognize a specific antigen is not enough to
guarantee an effective immunotherapy. Antigen recognition needs to be coupled with
efforts to ensure a T cell’s functionality is specific, limiting off-target or off-tumor
recognition. T cells should also be able to functionally persist long-term and be able to
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traffic to and accumulate at the target site. Additionally, optimal gene-modified T cells
should exhibit robust, multi-functional immune responses and resist mechanisms of
anergy, exhaustion and immunosuppression. They should also be amenable to deletion
on demand to diminish potential toxicity issues. While T cell engineering strategies show
promise at the bench and have shown some clinical success at the bedside, many
aspects of this type of therapy must be resolved before these effectors are safe and
effective enough to become the standard of care.
CAR Gene Therapy
CAR design. CARs, the first class of antigen receptors we will discuss, have been
widely examined for the use of redirecting T cell specificity. A CAR is simply described as
combining the antigen binding capability of an antibody with the intracellular signalingassociated component of a TCR (Fig. 2). This unique juxtaposition allows for high affinity,
three-dimensional epitope recognition by an immunoglobulin to be linked to the helper
or effector responses of a T cell [86]. Specifically, the extracellular antigen-recognizing
domain is generally derived from the antigen-binding fragment (Fab) of mouse
monoclonal antibodies (mAbs) that have high affinity for specific antigens. Unlike the
normal structure of the Fab fragment of a mAb, the Fab fragment in a CAR exists as a
single-chain variable fragment (scFv) [86]. The scFv is linked via hinge and
transmembrane domains to an intracellular signaling domain. This couples antigen
recognition to immune cell signal transduction by phosphorylation of immunoreceptor
tyrosine-based activation motifs (ITAMs). The first CAR, described by Eshhar and
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Figure 2. CAR-mediated target cell recognition. Structure of a 2nd generation CAR
interacting with a tumor cell. A CAR consists of a single-chain variable fragment (scFv)
composed of variable light (VL) and heavy (VH) chains linked via hinge, transmembrane
domains, and intracellular signaling domains containing at least the γ chain of the FcR or
the ζ chain of the TCR/CD3 complex. Specificity of the scFv region dictates MHCindependent recognition of a surface antigen. ITAMs of CD3ζ are denoted in blue
octagons.
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colleagues, linked the scFv to the signaling components of the FcRγ chain [87].
Subsequent CARs, however, have replaced FcRγ with ζ chain of the TCR/CD3 complex
[88] to enhance signaling potential as the CD3ζ signaling domain contains three ITAMs
as opposed to FcRγ’s single ITAM. Overall, CARs’ structural configuration allows for
essentially any mAb to be engineered into a CAR. For targets where generating
conventional antibodies in mice or other species is difficult, other techniques, including
phage display, have been useful in generating the antigen-binding portion of the CAR
[89, 90].
The use of a mAb as a ligand receptor facilitates recognition of intact proteins,
carbohydrates, and lipids, alleviating the need for target antigens to be processed and
presented by MHC molecules [86]. This would allow for CAR-mediated target
recognition despite HLA downregulation or aberrant antigen processing mechanisms.
Non-MHC-restriction also allows CAR to be used in patients of all HLA types [91]. This
provides a distinct advantage compared to TCR-engineered T cells, which will be
discussed in a later section. CAR function is also independent of many of the signaling
molecules or co-receptors required for TCR signaling and do not require association with
the CD3 complex for T cell activation and function [92]. As such, CARs contain all the
minimal elements necessary to bind antigen and activate the T cell. Additionally, as a
single chain construct, CAR are compact in relatively small vectors allowing it easy to
make high titer virus for transduction. Furthermore, single chain CARs are not subject to
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chain pairing competition or mispairing, unlike when introducing exogenous TCRs,
described later [93].
However, there are some limitations using CAR-engineered T cells [94]. For
example, CARs target surface antigens, rendering them ineffective against any
intracellular target that would otherwise be processed and presented by MHC. Also, the
mAb-antigen interaction is much stronger than a TCR-antigen interaction, which may
negatively impact T cell function [95]. Additionally, used of murine-derived scFv cause
concern for potential immunogenicity of these chimeric receptors [96], although efforts
to reduce immunogenicity have been used by humanizing murine-derived scFv or
generating scFv from human scFv phage display libraries [97]. Overall, CARs offer a
unique approach to re-direct the specificity of T cells combining the antigen recognition
capabilities of an antibody with T cell signaling components.
Generations of CARs. Over time, the design of CARs has been refined to provide
better antigen recognition and a more efficient transfer of cellular signaling for T cell
function and persistence. As mentioned previously, the signaling domain of FcRγ was
swapped with that of CD3ζ because CD3ζ included a greater number of ITAMs (Fig. 3)
leading to enhanced T cell function [88]. Additionally, the single chain antibody can be
substituted for other receptors or a ligand of a receptor expressed on tumor cells. Such
approaches include substituting the scFv region of a CAR for heregluin (a ligand for Her3
or Her4 receptors) [98], VEGF (anti-VEGFR2) [99], NKp30 (targeting B7-H6) [100] or the

18

Figure 3. Generations of CARs. Comparison of co-stimulatory domains included in first
(left), second (middle), or third (right) generation of CARs. ITAMs are denoted as colored
octagons.
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NKG2D receptor [101-103]. Moreover, multiple signaling domains have been added to
the CD3ζ or FcRγ domains to augment activation and co-stimulation mimicking
immunologic signal 2 during physiologic T cell activation [104]. Addition of costimulatory domains has led to subsequent “generations” of CARs.
“Second generation” CARs (Fig. 3) utilize one additional cytoplasmic domain of a
co-stimulatory receptor, such as CD28, 4-1BB, DAP10, OX40, or ICOS, providing greater
strength of signaling and persistence to the T cells [51, 105-117]. For example, one study
investigating the requirements of CAR signaling cassettes found that in a mouse CEA+
colorectal tumor xenograft model, CEA CAR-engineered T cells containing both CD3ζ and
CD28 enhanced proliferation and IFNγ secretion compared to CD3ζ-only containing
CARs [106]. The presence of CD28 was also required for efficient IL-2 secretion.
Additionally, one group found that CD19-specific CARs containing CD3ζ and costimulatory cassette 4-1BB provided enhanced anti-leukemic efficacy and prolonged
survival in tumor bearing mice compared to CD3ζ- or CD3ζ/CD28-containing CARs [113].
Together, these data suggest that the addition of co-stimulatory cassettes, including
CD28 and 4-1BB, is required for complete T cell activation and that second generation
CARs may provide enhanced therapeutic benefit.
A third generation of CARs (Fig. 3) were also developed using two co-stimulatory
domains with an activating domain, conferring an even greater potency to redirected T
cells [51, 115, 117-121]. For example, use of an ERBB2 CAR containing 4-1BB, CD28, and
CD3ζ signaling moieties exhibited greater transgene persistence, increased cytokine
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secretion, and enhanced lytic activity in vitro compared to ERBB2 CARs containing only
CD3ζ and CD28 signaling cassettes [117]. Moreover, the third generation CAR better
suppressed tumor growth in a xenogeneic mouse model compared to the second
generation CAR. In light of enhanced performance by third generation CARs, it is unclear
whether such strong co-stimulation would always be advantageous. One clinical report
highlighting this point used a third generation trastuzumab-based CAR containing CD3ζ,
CD28, and 4-1BB signaling moieties. Administration of anti-Her-2 third generation CARtransduced autologous T cells was lethal in one patient after cytokine storm and fatal
respiratory distress due to recognition of low levels of Her-2 on lung epithelia [122].
Thus, optimization of how many and which types of signaling domains included in CARs
are necessary. Only then can we determine which combination is best for augmenting
activation, sustained function and survival while minimizing anergy, premature death,
and rapid exhaustion. Additionally, further efforts examining how antigen location and
density, as well as CAR binding moiety, affinity, and sensitivity affect it T cell function
may also optimize CAR design.
CAR targets. The first clinical trials using CARs targeted folate binding protein
(FBP) for patients with ovarian cancer [123] and carbonic anhydrase IX (CAIX) for
patients with renal cell carcinoma (RCC) [124]. Both CARs were first generation
containing the FcRγ signaling domain. In both of these trials, no objective clinical
responses were seen, nor were the gene-modified T cells able to persist long term.
However, the potential for adverse events using CAR therapy was first recorded. In the
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trial targeting CAIX+ RCC, the phenomenon described as on-target/off-tumor effects was
clearly evident. Patients treated with the CAIX CAR gene-modified T cells experienced
grade 2-4 liver toxicity because the transduced cells recognized CAIX antigen expressed
on the epithelial cells of the bile duct [124]. These results indicated administration of
CAR T cells was feasible but could have unwanted off-tumor effects.
As subsequent generations of CARs were developed and more specific CAR
targets were identified, we observed greater clinical success using CARs. Efforts
targeting the pan-B cell antigen CD19 are the best examples of the proof-of-concept for
CAR therapy. Initial trials targeting CD19-associated with relapsed indolent nonHodgkin’s lymphomas (NHL) and chronic lymphocytic leukemia (CLL) [125-131]
demonstrated the safety of CAR T cells and modest clinical benefit. Later, patients with
B cell acute lymphoblastic leukemia (B-ALL) receiving CD19-targeted CAR T cell
treatment resulted in positive clinical outcomes with robust anti-tumor efficacy in two
independent trials [132, 133].
The success of CD19-targeting CARs has relied on CD19’s near universal
expression on B cell malignancies and its limited expression on B cells. Its absence on
bone marrow stem cells also limits off-target potential. Outcomes from this CD19 model
additionally provided the practical limitations of initial CAR design and fostered the
development of subsequent generations of CARs. Recently, a clinical trial using a second
generation CD19-reactive CAR treated both children and young adults with
chemotherapy-resistant B-precursor acute lymphoblastic leukemia [134]. In this trial,
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CD19 CARs exhibited potent anti-leukemic activity and all grade 3 and 4 toxicities were
reversible, suggesting second generation CARs can be relatively safe and effective. Other
studies, however, have seen serious neurotoxicity associated with administration of
CD19 CAR T cells [135], highlighting the remaining challenges in maximizing both the
efficacy and safety with the use of CARs.
Although less serious than aforementioned on-target/off-tumor events, another
drawback of the highly effective CD19 CAR campaign targeting B cell malignancies is the
prolonged elimination of normal B lymphocytes and, thus, impairment of humoral
immunity [125, 128, 130]. Although this can be mitigated by intravenous administration
of gammaglobulin, B cell aplasia and hypogammaglobulinemia should still be recognized
as on-target adverse events.
While CD19-targeted B cell malignancies have been the poster child advocating
for CAR therapy, it is important to acknowledge another CAR target that has exhibited
mixed clinical results. As mentioned earlier, the use of a third generation CAR based on
the widely used mAb trastuzumab targeting Her-2 induced respiratory distress resulting
in death in one treated patient with metastatic colon cancer [122]. It was discovered
that low level Her-2 expression on normal lung epithelia caused this fatal side effect,
characterized as a much more serious on-target/off-tumor adverse event than B cell
aplasia. With this is mind, a modified CAR-based approach targeting Her-2 led to a more
successful recent trial [136]. In this report, a dose-escalation study using a secondgeneration Her-2-specific CAR with a different scFv was used in patients with
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recurrent/refractory Her-2+ sarcomas. This study also differed in that it did not use coadministration of high-dose IL-2 or lymphodepleting chemotherapy prior to transfusion.
Transduced cells persisted for 6 weeks and trafficked to tumor sites without any evident
toxicities. Some patients even exhibited stable disease or partial response. The stark
contrast between these two trials highlights the importance of mAb and co-stimulatory
cassette selection, target distribution, and host conditioning can have on the positive
and negative outcomes in CAR clinical trials.
A wide variety of other CARs have been designed to target an array of antigens
showing promise as potential cancer immunotherapies. Other targets evaluated in vitro
and in vivo include but are not limited to EGFRvIII [137] for glioblastoma, GD2 [138, 139]
for neuroblastoma, GD3 [140, 141], MAGE-1 [142], and HMW-MAA [143] for melanoma
, CD20 [115, 119, 144-147], CD23 [148], CD30 [149-151] and others for hematologic
malignancies, PSMA [107, 152] for prostate cancer, MUC-1 [120], Her-2 [19, 153], and
CEA [154-156] for breast cancer, EGP-40 [157] for colorectal cancer, VEGF-R2 [99, 158]
and KDR [159] for tumor neovasculature, and MUC16 [160] for ovarian cancer. Table 1
lists a sampling of active clinical trials using CARs and their respective targets.
CAR summary. Overall, CARs provide MHC-independent recognition of a variety
of extracellular target types with a compact, single chain construct containing all the
minimal elements necessary for T cell activation. For better or for worse, the design of
CARs prevents any chance of receptor mispairing but circumvents the natural processes
of T cell activation and dysregulation. While documentation of on-target/off-tumor
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Table 1. Active clinical trials using CAR-engineered T cells.
Target
Antigen
CD19
CD133

Associated
Malignancy

CAR
Generation

Acute lymphoblastic
leukemia
Various malignancies

rd

3 (CD28:4-1BB)
1

st

nd

CD171

Neuroblastoma

CEA

CEA adenocarcinomas

EGFR

EGFR solid tumors

NCT02186860
NCT02541370

rd

2 (4-1BB) and 3 (CD28:
4-1BB); transgene includes
truncated EGFR

+

+

Clinical
Trial ID#

nd

2 (CD28)
st

nd

1 and 2 (4-1BB)

NCT02311621
NCT01723306
NCT01869166

rd

GD2

Neuroblastoma

3 (CD28:OX40);
transgene includes iC9
rd

GD2

GD2 sarcomas

3 (CD28-OX40);
transgene includes iC9

Her-2

Breast cancer

2 (CD28)

Her-2
Mesothelin

+

Glioblasoma multiforme
Pancreatic, ovarian, and
mesothelioma

NCT02439788

nd
nd

2 (CD28)
nd

2 (4-1BB)

NCT01953900
NCT02547961
NCT01109095
NCT02159716
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effects is well noted, off-target effects are not as readily seen because the antigen
binding regions of CARs are generally derived from well-characterized monoclonal
antibodies. However, several groups conducting clinical trials with CARs have recorded
other serious adverse events including tumor lysis syndrome [130] and cytokine storm
[128, 161, 162]. Overall, the majority of CAR studies have shown much promise for their
clinical use. Continuing efforts are ongoing to improve clinical outcomes while
minimizing adverse events.
TCR Gene Therapy
As the focus of these dissertation studies, we now introduce the concept,
success, and limitations of TCR-gene modified T cells. These discussions serve as a
prelude to identify what approaches can help us better understand antigen recognition
by a T cell in order to improve TCR-based ACT. A schematic of TCR engineering of T cells
for ACT (detailed in the following sections) is provided in Figure 4. Over the past 20
years, a myriad of TCRs have been cloned and characterized that recognize antigens,
including but not limited to, EBV [163], gp100 [44, 164], HCV [165, 166], HPV [167],
MART-1 [15, 34, 168], tyrosinase [169, 170], and unknown antigen reactivity [171]. To
date, TCRs investigated for ACT have been limited to mostly MHC-I-restricted
candidates. Although, more recent identification of direct tumor-recognizing MHC-IIrestricted CD4+ T cells [172] have provided the opportunity to generated MHC-IIrestricted TCR-transduced T cells [173]. The sections below describe the design, use,
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Figure 4. Adoptive cell transfer using TCR gene-modified T cells. Viral or cancer antigenreactive T cell clones are isolated and expanded from TIL or peripheral blood to identify
a therapeutic TCR candidate. TCR genes are identified and cloned into retroviral vectors.
Packing and producer cell lines are engineered with this retroviral construct to produce
high titer retrovirus used to transduce activated PBMC from an HLA-matched antigen
positive patient. Transduced cells are expanded ex vivo with cytokine support and
infused back into the patient. These autologous T cells with re-directed specificity
provide new anti-viral or anti-tumor immunity.
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success, and limitations of TCR-engineered T cells used in ACT. They provide a
foundation for the biologic questions addressed in this dissertation.
TCR design. An important factor influencing the effectiveness of
immunotherapeutic use of TCRs is the relationship between TCR-pMHC affinity and T
cell function [1]. Antigen recognition depends on a productive interaction between a
TCR and pMHC, and lower affinity interactions generally require the presence of the CD8
co-receptor to facilitate antigen recognition [2]. Thus, it might be predicted that T cells
engineered with high affinity TCRs are better effectors than T cells engineered with
lower affinity TCRs [15, 168, 169]. Various CD8-independent TCRs have been
characterized that can transfer antigen recognition to CD4+ cells in an MHC-I-restricted
manner, providing helper cytokine support and enhanced tumor regression [165, 166,
169, 170, 174-181]. Naturally occurring high affinity, CD8-independent TCRs are
relatively rare, however, and thus difficult to find. Rather than screening for such high
affinity TCRs, various methods have been developed to affinity-enhance already
characterized TCRs. These approaches are discussed in a later section. It is important to
recognize, however, that T cells harboring higher affinity TCRs are more likely to
undergo activation induced cell death (AICD) upon antigen encounter [182, 183], or
induce off-tumor/on-target and off-tumor/off-target reactivity [184-186],
counterproductive to their therapeutic intention.
It is also important to acknowledge that MHC-restriction of TCRs limits the
number of patients that can be treated using a single TCR, and engineered T cells would
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need to be HLA matched to patients. HLA class I expression has a tendency to be
downregulated on tumor cells [187, 188], however, which may also serve as a barrier to
effective therapy. Additionally, because TCRs require interaction with the CD3 complex,
a TCR’s expression and functionality is limited by available CD3 complex components.
Competition for the CD3 complex with endogenous TCR limits functional transgene
expression, although strategies discussed below may allow for improved association
with CD3 by the introduced TCR.
TCR chain pairing. Because TCRs exist as heterodimers, TCR gene-modified T
cells require two different genes, or chains, to be expressed to redirect specificity.
Because expression of two individual genes may result in non-uniform chain expression,
various approaches have been developed to address this. For example, the addition of
viral 2A self-cleavage peptide sequences between the α and β chains within retroviral
constructs allows for more uniform chain expression [189-191]. Additionally, codon
optimization of the construct facilitates increased TCR expression [192, 193]. Both these
approaches help augment introduced TCR expression without altering the TCR sequence
itself.
Additionally, the presence of an endogenous TCR can induce chain mispairing
between endogenous and introduced α and β chains. These interactions reduce the
level of expression of functional introduced TCR [168, 194] and could lead to novel and
unpredictable self-reactive TCRs (false pairing) with serious adverse events. Such offtarget/off-tumor adverse events have been reported as a result of high affinity TCRs
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recognizing unanticipated epitopes or as a result of TCR chain mispairing. Two recent
studies demonstrate undesirable reactivity propagated from TCR mispairing between
endogenous and introduced TCR α and β chains. One study recorded graft-versus-hostdisease (GVHD) in a mouse model in five different TCR systems [195]. Another
demonstrated the ability of engineered human T cells to develop MHC class I and IIrestricted allo- and auto-reactivity through TCR chain mispairing [196]. However, to
date, no evidence of GVHD has been seen in over 100 patients treated with this gene
therapy approach [197].
A handful of approaches have been developed to address potential for TCR chain
mispairing. One main strategic effort involves a host of modifications to the TCR
construct, summarized in Figure 5. As mentioned previously, codon optimization of the
TCR α and β genes can help promote efficient translation and surface assembly of the
introduced receptor without altering the TCR sequence itself [192, 193]. Introduction of
cysteine residues in the α and β constant regions has been shown to promote interchain disulfide bridge formation to limit mispairing [176]. Other approaches to help
improve pairing, expression, and function of the introduced TCRs include the addition of
leucine zippers at the end of the intracellular tails [174] and altering the glycosylation of
the TCR [177]. Substituting human constant regions with portions of or the entire mouse
constant regions also promotes proper pairing and enhanced surface expression [170,
198-202]. Specifically, elements of the murine constant regions do not efficiently
interact with the human constant regions [200]. Additionally, the murine constant
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Figure 5. TCR modifications to limit mispairing and improve cell surface expression and
function. Modifications of WT TCR structure (far left) include codon optimization,
introduction of a disulfide bridge, addition of leucine zipper, modification of
glycosylated residues, substitution with murine constant regions, or use of single chain
Vα-Vβ-Cβ with a Cα chain. WT, wildtype; V, variable; C, constant.
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region has a higher affinity for human CD3, which can favor the murinized receptor
associating with limited surface CD3 [198]. Receptors with murine constant regions
were also found to mediate higher levels of cytokine secretion in vitro [198, 199]. This
technique poses additional problems, however, including immunogenicity and clearance
of the engineered T cells as they express potentially antigenic domains in the transgene
[199].
Another novel approach to alleviate mispairing was demonstrated by recent
reports using single chain TCRs [200, 203]. One group engineered a recombinant TCR
consisting of a single chain Vα-Vβ-Cβ and a Cα chain, which only paired with each other
and not the endogenous TCR [200]. Another group used a stabilized Vα-Vβ single chain
TCR linked to intracellular signaling domains (lck, CD28), which elicited functional
activation of T cells in the absence of either the CD3 complex or co-receptors and
circumvented mispairing with endogenous TCRs [203]. Efforts to limit mispairing have
also focused on downregulating the endogenous TCR by via small interfering RNA
(siRNA) [204] or using designer zinc-finger nucleases [205]. All of these alternate
strategies share the same goal to reduce competition for the CD3 complex, allow for
stable pairing of the introduced TCR, and minimize adverse events due to false pairing.
TCR targets. More than 20 years after TCR gene-modified T cells were first used
to redirect T cell specificity in mice [206] this technology was first evaluated in humans
targeting melanoma-associated antigens. TCR engineered T cells’ first use in the clinic
targeted HLA-A2+/MART-1+ melanoma [207, 208]. These initial clinical studies
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demonstrated that TCR gene-modified T cells were generally safe, well tolerated, and
had the potential to be therapeutic in cancer patients. A later study targeting melanoma
antigens MART-1 and gp100 demonstrated further clinical benefit using TCR-transduced
T cells but highlighted the potential for adverse events [184]. Of note, the gp100reactive TCR in this study was high affinity and of mouse origin, and many patients
treated with this TCR exhibited toxicities in the eye and inner ear, displaying destruction
of normal melanocytes. This well-characterized example of on-target/off-tumor effects
first cautioned the use of high affinity TCRs. Fortunately, in this case such toxicities
resolved naturally or with administration of topical steroids in almost all patients. These
earliest studies suggested TCR gene-modified T cells were feasible with clinical benefit,
but that the choice of TCR may be important to limit toxicities.
Since these early studies, however, identification of numerous TCR genes
capable of recognizing tumor-associated antigens and improvements in TCR gene
transfer technology have allowed for specificity redirection to target of a variety of
other antigens and malignancies. These include, but not limited to, carcinoembryonic
antigen (CEA), cancer-testis antigen (CTA) family members, and viral protein family
members. Examples using TCR gene-modified T cells to target these families of antigens
are described below.
CEA is overexpressed in a many epithelial cancers, allowing CEA-reactive TCRs to
target a wide variety of malignancies. In fact, a recent clinical trial TCR gene-modified T
cells to target CEA+ colorectal cancer noted objective clinical response in a patient
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bearing metastatic disease [186]. However, on-target/off-tumor adverse events,
including inflammatory colitis, were documented in numerous patients as CEA has
shared expression on normal tissues, including the colon. This example highlights
therapeutic benefit as well as safety concerns using TCR-gene modified T cells targeting
CEA.
The CTA family of antigens, including NY-ESO-1 and MAGE, are expressed by the
normal testis and a host of human cancers including breast, bladder, colon, lung,
melanoma, head and neck, gastric, ovarian, thyroid, neuroblastoma, synovial cell
sarcoma, and prostate [209]. Clinical studies have shown T cells redirected to recognize
NY-ESO-1 provided objective clinical response in patients with synovial cell sarcoma and
melanoma without any evidence of previously reported adverse events [210]. A pair of
clinical trials targeting another widely expressed CTA, MAGE-A3, recorded much more
mixed results. The first clinical trial used a mouse-derived, high avidity TCR that was
further modified by site directed mutagenesis in its CDR3 [211]. Targeting MAGE-A3, it
cross-recognized MAGE-A9/A12. Although five out of nine patients experienced clinical
regression of their cancers, one third of the patients experienced neurological toxicity.
Two patients even died due to these adverse events. T cells cross-reactive against
unknown expression of MAGE-A12 in the brain are believed to have caused this toxicity.
Another clinical trial using an affinity-enhanced TCR targeting MAGE-A3 resulted in
cardiogenic shock and death of the first two patients treated [212, 213]. While no
MAGE-A3 expression was detected in cardiac tissue at autopsy, it was determined the
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TCR designed with affinity-enhancing mutations in α and β CDR2s exhibited an
unpredicted cross-reactivity to titin, a sarcomeric protein expressed in striated muscle.
Interestingly, the parental TCR from which the engineered TCR was derived from was
isolated from a patient without cardiac toxicity. This might attribute the adverse events
in the clinical trial to the intentionally induced CDR2 mutations. Taken together, these
studies are encouraging that TCR gene-modified T cells under the right circumstances
can provide clinical benefit but also highlight the importance of TCR and target selection
to minimize cross-reactivity by modified TCRs.
Viral proteins expressed on tumors compose a third family of antigens targeted
by TCR-engineered T cells. Several groups have TCR-engineered T cells to target
antigens, including CMV [214, 215], EBV [163, 216, 217], HIV [218-221], HCV [165, 166,
222], HPV [167, 223], and others. No clinical reports have yet been published testing
virus-reactive TCR-transduced T cells in humans, however. Table 2 lists some of the
active clinical trials using TCRs and their respective targets.
Use of high affinity TCRs in ACT. Discussed earlier, thymic selection generally
excludes high affinity TCRs against tumor (self) antigens to occur normally in the
periphery. But engineering T cells with high affinity TCRs circumvents normal thymic
limitation and can generate high avidity tumor-reactive T cells. There are clear
advantages to using a high affinity TCRs to engineer T cells for ACT. The ability to
generate tumor-reactive MHC class I-restricted CD4+ T cells is one major benefit using
high affinity TCRs [169]. CD4+ T cells’ ability to produce helper cytokines upon antigen
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Table 2. Active clinical trials using TCR-engineered T cells.
Target
Antigen

Associated
Malignancy

MHC
Restriction

Clinical
Trial ID#

gag
gp100

HIV
Melanoma
HPV-associated
cancers
Various
malignancies
Various
malignancies
Various
malignancies
Thyroid cancer
Melanoma
Myelodysplastic
syndrome, AML
Non-small cell
lung cancer,
mesothelioma

HLA-A2
HLA-A2

NCT00991224
NCT00509288

HLA-A2

NCT02280811

HLA-A1

NCT02153905

HLA-DP04

NCT02111850

HLA-A2

NCT02457650

HLA-A2
HLA-A2

NCT02390739
NCT01586403

HLA-A2

NCT02550535

HLA-A2

NCT02408016

HPV E6
MAGE-A3
MAGE-A3
NY-ESO-1
Thyroglobulin
Tyrosinase
WT1
WT-1
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stimulation offers the opportunity to provide MHC I-restricted T cell help at the tumor
site [169, 224, 225]. Therefore, TCR transduced CD4+ T cells might facilitate crosspriming or epitope spreading, leading to broad systemic anti-tumor immunity. Another
application for a high affinity TCR involves engineering CD4+ regulatory T cells [226].
Like helper T cells, MHC I-restricted regulatory T cells could help reduce the severity of
autoimmune diseases [226]. Thus, the ability to use high affinity TCRs to target novel
classes of MHC-I-restricted T cell subsets is a very attractive concept.
However, T cells expressing TCRs with extremely high affinity for pMHC can
undergo activation-induced cell death (AICD) upon antigen encounter. AICD could lead
to the destruction of the very effector cells that were intended to destroy a patient’s
cancer or virally infected cells [182, 183]. Additionally, high affinity TCRs are better at
detecting low levels of antigen [227], and have even exhibited cross-reactivity to related
antigens causing death in a clinical trial previously discussed [211]. T cells expressing
high affinity TCRs can also lead to autoimmunity as observed in one transgenic mouse
model [185] and two clinical trials [184, 186]. Given these observations, the proper use
of high affinity TCR sfor effective anti-tumor immunity remains unresolved. Approaches
used to design high affinity TCRs are discussed in a later section.
Other T cell Engineering Approaches
Other receptor types. While the use of CARs and TCRs to redirect the specificity
of a T cell have been well documented, ongoing efforts to design other receptor types
for gene modification hold therapeutic potential as well. For example, engineering T
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cells to express the NKG2D receptor allows T cells acquire the reactivity of natural killer
(NK) cells [101-103]. Another NK cell receptor that has been investigated for T cell
engineering is NKp30, which recognizes the tumor-prone antigen B7-H6. A recent study
combined the specificity of NKp30 and the signaling capability of CARs, designing a novel
NKp30-based CAR replacing the scFv domain with the ligand-binding domain of NKp30
[100]. Adoptive transfer of the NKp30-CAR T cells allowed for non-MHC-restricted
recognition of B7-H6 expressing RMA, a murine lymphoma, in vivo. Interestingly, NKp30CARs T cells provided protection against subsequent challenge with wildtype (WT) RMA
tumor cells. Similar efforts are examining the feasibility of replacing the scFV domain of
CARs with other ligands or ligand-binding receptors described earlier. Exploring other
approaches to engineer T cells with novel antigen receptors may help optimize the use
of gene-modified T cells for ACT.
Another unique approach under investigation is dual-receptor-engineering of T
cells. This strategy engineers T cells to co-express complementary CARs, TCRs or other
receptors, each specific to a distinct target. This approach is thought to optimize T cell
homing and tumor specificity while reducing toxic potential. Dual-specificity may also
provide synergistic signaling as well as a means to combat downregulation or mutation
of antigens in immune escape. One study validated this tactic by generating T cells coexpressing CARs reactive to MUC1 and ERBB2 targeting breast cancer cells in vitro [228].
They found that dual-targeted T cells killed ERBB2+ targets efficiently, but T cell
proliferation required engagement with both MUC1 and ERBB2 antigens because CARs
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contained either CD3ζ or CD28 for ERBB2 and MUC1 specificity, respectively.
Additionally, IL-2 production was modest in dual-CAR expressing cells compared to CAR
T cells engineered with a single second generation CAR containing both CD3ζ and CD28.
These data suggest generating dual-receptor engineered T cells is feasible but requires
optimization to enhance T cell function.
Additionally, recent work has highlighted anti-specific inhibitory chimeric antigen
receptors (iCARs) linked to a powerful acute inhibitory signaling domain, such as CTLA-4
and PD-1 [229]. T cells engineered with these iCARs were selectively limited in cytokine
secretion, cytotoxicity, and proliferation compared to those engineered with an
activating CAR targeting the same antigen. This dual-receptor approach provides an
attractive opportunity to limit unwanted off-target responses.
Cytokine production. Another approach to modify or enhance the potency of
receptor-engineered T cells is to further genetically modify T cells to secrete proinflammatory or pro-proliferative cytokines. This approach not only provides autocrine
support to enhance T cell function, proliferation, and/or persistence, but also favorably
alters the tumor microenvironment. This would enhance innate and cognate immune
effector recruitment while limiting the systemic toxicity of exogenously delivered
cytokines. For example, engineering melanoma-reactive T cells to express IL-2 resulted
in continued cell growth in the absence of exogenous IL-2, which may a viable approach
to help T cell persistence post-adoptive transfer [230]. A similar tactic demonstrated T
cells modified to express IL-12 exhibited enhanced anti-tumor function and were better
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able to resist immunosuppression by regulatory T cells [231, 232]. Similarly, engineering
T cells to secrete IL-12 transformed myeloid cell within tumors from immunosuppressive
to immunosupportive [233]. This strategy was even used in a recent phase I clinical trial
where IL-12 secreting MUC-16 (ecto)-targeting CAR T cells were infused into patients
with recurrent ovarian cancer [234]. In summary, the ability to additionally modify
receptor-engineered T cells to provide cytokine support is an attractive approach that
still needs more clinical validation to become mainstream.
Chemokine recognition. In addition to cytokine-engineered T cells, modifying
them to express chemokine receptors can aid in migration patterns, increasing the
efficiency of trafficking to and infiltration of tumors. Transferring genes encoding CCR4,
CCR2B, or CXCR2, enabled T cells to home towards CCL17, CXCL1, and macrophage
chemoattractant proteins [149, 235, 236]. Also, VEGFR-2-engineered T cells allowed T
cells to find tumor-associated neovasculature in one study [237]. Additional efforts to
improve T cell homing may include engineering T cells with certain integrins or their
ligands [238] or by blocking inhibitors of migration like endothelin [239]. Further
investigation is necessary, however, to prove clinical benefit.
Ways to Optimize Gene-Modified T cells.
Host conditioning. Lymphodepletion prior to ACT has been a point of interest to
improve long-term persistence and function of transferred T cells. This host preconditioning strategy is thought to create space for the transferred T cells and eliminate
competition for cytokines [240], remove competition at the surfaces of antigen
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presenting cells [241, 242], and withdraw immunosuppressive regulatory T cells [243].
This evidence came from preliminary mouse studies that were followed up in the clinic
by the Rosenberg group. They first noted that persistence and antitumor activity of
transferred T cells in vivo was greatly increased with non-myeloablative
lymphodepleting treatment using cyclophosphamide and fludarabine before adoptive
transfer [244]. It is believed these changes in the host may lead to induction of a
memory phenotype and enhance effector function. Systemic administration of
cytokines, such as IL-2, post-ACT has also enhanced transferred T cell function and
persistence [245, 246]. Post-conditioning with other cytokines including IL-15 or
immunomodulatory therapies such as PD-1 and CTLA-4 blockade should also be
considered.
Suicide switch. In light of on- or off-target toxicities, tumor lysis syndrome, and
cytokine storm documented with the use of engineered T cells, it would be beneficial to
preserve the ability to eradicate the transferred T cells, if needed. Such strategies aim
at turning off antigen receptor expression or eliminating the engineered cells posttransfer by incorporating certain “suicide genes” into the transgene. A long-studied
approach utilizes the herpes simplex virus-thymidine kinase (HSV-tk) gene. Its
incorporation into the transgene vector makes engineered T cells susceptible to
gancyclovir treatment [247, 248]. However, because HSV-tk is potentially immunogenic,
its expression may create unwanted immune-mediated destruction of transferred T cells
and decreased persistence [249, 250]. Another common approach and non-
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immunogenic technique incorporates caspase 9 under an inducible promoter (iC9) to
initiate apoptosis of transduced cells [251-254]. Additionally, studies incorporating CD20
[255] or EGFR [256] in transgene vectors generated transduced T cells susceptible to
rituximab and cetuximab treatment, respectively. In short, incorporation of suicide
switch mechanisms allow for novel ways to enhance the safety of engineered T cells by
allowing simple means to specifically eliminate them in vivo.
Affinity maturation. As discussed earlier, TCR affinity is known to play a
significant role in determining sensitivity of a T cell to antigen recognition. Therefore, it
is logical to predict that higher affinity TCRs may provide better therapeutic candidates
for reasons previously discussed. For example, the use of high affinity TCRs may better
equip engineered T cells to combat immune suppression mechanisms that alter T cell
function including MDSC-mediated nitration of TCR tyrosine residues, which can weaken
TCR-pMHC binding [61]. Additionally gene transfer of high affinity TCRs can generate
tumor-reactive MHC class I-restricted CD4+ T cells, creating a novel population of T cell
help at the tumor site [169, 224, 225]. Moreover, a population of reactive-CD4+ T cells
may facilitate cross-priming or epitope spreading allowing for a broad systemic antitumor response. For reasons discussed, however, identifying naturally occurring, high
affinity tumor-reactive TCRs is feasible but challenging due the principles behind thymic
selection [30].
One way to identify and clone high affinity TCRs is screening for CD8independence against human MHC-restricted antigens in mice. It is documented that
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mouse CD8 does not bind to the α3 domain of human MHC class I molecules [198, 257].
Thus, in a vaccinated HLA-A2 transgenic mouse model, isolated T cell clones reactive
against human tumors in vitro would likely express high affinity TCRs. This approach has
been used successfully to identify high affinity TCRs targeting CEA [258] and p53 [259].
Additionally, a recent approach has generated allo-restricted T cells using autologous
dendritic cells (DCs). DCs are co-transfected with in vitro transcribed RNA encoding an
allogeneic MHC molecule and a selected antigen [260], providing allo-stimulation. This
procedure allows for novel allo-pMHC ligands to activate high avidity, allo-restricted,
peptide-specific T cells as a source for high affinity TCRs. Together, these approaches
provide great flexibility for obtaining high affinity and high avidity T cells as potential
sources of TCRs for ACT.
While CD8-independent tumor cell recognition by a T cell clone should be a
hallmark of a high affinity TCR, this has not always been true. One such example
involved a gp100 reactive T cell clone designated T4H2 that was a CD4-/CD8- T cell that
efficiently recognized HLA-A2+ gp100+ human melanoma cells in vitro [44, 164].
However, when the T4H2 TCR was cloned and expressed in human T cells, it surprisingly
required CD8 expression for tumor cell recognition [44]. Therefore, each TCR must be
evaluated individually to ensure that a CD8-independent/high affinity TCR has been
cloned.
More recently, TCRs have been genetically modified to improve their biophysical
properties [210, 261-267]. Using yeast and phage display, TCRs have undergone
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“evolution” to select for high affinity binding to pMHC [3, 4, 265, 268, 269] a technique
also used in CAR design [89, 90]. Although it might be predicted that changes to the
CDR3 would lead to the highest affinity TCRs, amino acid alterations in any of the three
CDRs can contribute to enhanced TCR-pMHC affinities [262]. This was surprising because
the CDR3 is responsible for the majority of TCR diversity and specificity.
What is troublesome about these affinity enhancement strategies is the
randomness of introduced mutations. Yeast and phage display rely on purely random
generations of high volumes of different clones, followed by screening for the highest
biophysical interactions. Thus, there is no informed decision behind the selection of the
TCR ultimately used. Such a “blind” approach is concerning when trying to predict
therapeutic efficacy and safety in terms of potential on- or off-target toxicities. More
appropriate may be a rational structure-guided design of high affinity TCRs. A relatively
new concept, this approach allows for more control and understanding of the
mechanism of TCR affinity improvement with the potential to consciously avoid adverse
events related to off-target toxicities [266, 270]. Taken together, in vitro and in vivo
studies with high affinity TCRs, described earlier, indicate that TCR affinity can make a
difference in target recognition by TCR transduced T cells. But the overall effectiveness
and safety of high affinity TCRs in patients remains unresolved. As such, each TCR may
need to be carefully and individually evaluated for how its properties impact a T cell.
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Genomic Instability and Cross-Reactive TCRs
Genomic instability plays a central role in allowing viruses and malignancies to
escape immune surveillance [271, 272]. Mutated antigens enhance virulence by
escaping HLA-restricted immune responses in viral infections including HBV [273-275],
HCV [274, 276-279], HIV [280-282], EBV [283, 284], and choriomeningitis [285].
Similarly, a wide variety of cancers have displayed various mechanisms of immune
escape including downregulation of MHC-I expression [187, 188], mutated or
downregulated antigen processing proteins [286-288], and antigen loss or mutation
[271, 289, 290]. These mechanisms pose a fundamental problem for antigen-specific
TCR-engineered T cells that rely on proper processing and presentation of antigens by
MHC for target recognition.
Immune escape is not only responsible for ineffective host immune responses,
but also cause impaired development of preventative and therapeutic vaccines, and
inherent or acquired resistance to novel treatment strategies including
immunotherapies. Additionally, immunotherapies designed to elicit potent anti-tumor
or anti-viral T cell responses like ACT, checkpoint blockade, and cytokine support all
have potential to fail in light of these immune escape mechanisms. It is imperative to
investigate novel therapeutic approaches designed to combat genomic instability.
One potential strategy, highlighted in this dissertation, utilizes cross-reactive TCR
gene-modified T cells. Traditionally thought to have a lock-and-key specificity, the clonal
selection theory proposed that individual lymphocytes are specific for a single pMHC,
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and that alternative ligand recognition is unlikely [291, 292]. This “one-clonotype—onespecificity” paradigm has been challenged over the years. Based on sheer numbers, the
notion of >1015 potential foreign peptides (not including self) would require 10 15
different mono-specific TCRs [293, 294]. This does not seem feasible in terms of
immunologic space or sheer cellular mass. Additionally, the HLA locus is one of the most
polymorphic and fastest evolving regions of the human genome, currently encoding
more than 7,000 allelic variants [295]. Such HLA diversity is estimated to increase the
variety of peptides displayed. Recent studies have suggested that there are less than 108
distinct TCRs in the human naïve T cell pool [296]. It is argued that the vast diversity of
peptides and MHC alleles dwarfs that of TCR sequences, requiring TCRs to be able
provide flexible immune coverage [294].
Elegant studies have since demonstrated a varied T cell repertoire can be
selected by a single peptide [297] and that resulting T cells can be activated by
unrelated peptide sequences [298]. The use of combinatorial peptide libraries also
demonstrated cross-reactivity of individual T cell clones recognizing over a million
different individual peptides presented by a single MHC molecule [299-301]. Though
TCR cross-reactivity is no longer a novel concept, its mechanism, the control of antigen
sensitivity, the biophysics of TCR-pMHC engagement, and its functional consequences
are not yet fully understood.
A deeper understanding of what dictates the cross-reactive nature of a TCR (both
structurally and functionally) will allow for a more informed approach to designing
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therapeutics meant to combat mutating antigens and to limit cross-reactivity against
self-antigens. Thus, engineering T cells with promiscuous TCRs serves not only as a
potential therapeutic, but a tool to better understand and rationally design TCRs. In this
way, immune effectors could be equipped with the ability to accommodate recognition
of mutant antigens associated with immune escape.
Concluding Remarks
While the field of TCR gene transfer is still quite new, the use of TCR-transduced
T cells represents a promising new approach for treating patients with cancer, viral
infections, and their associated sequelae. TCR gene transfer also circumvents the
hurdles of obtaining tumor reactive T cells associated with TIL therapy and other forms
of adoptive T cell transfer. The use of viral vectors to engineer T cells with TCR genes
enables us to generate populations of autologous T cells with limitless specificities. It is
also clear that the TCR gene transfer approach is feasible and that the TCR transduced T
cells can be delivered safely; and objective clinical responses in treated patients indicate
that these genetically engineered T cells can be effective.
In light of recent clinical success, however, there remain many issues in
optimizing the efficacy and safety of this type of immunotherapy. Ultimately, extensive
studies are needed to determine if TCR-engineered T cells can deliver improvements in
progression-free and overall survival when compared to the other therapies.
Dependency on co-receptors, pairing competition, and predominantly low affinities of
physiologic TCRs call for efforts to optimize their use in ACT. But strategies that “blindly”
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affinity-enhance TCRs are worrisome because they lack the structural understanding
required to anticipate efficacy and unwanted cross-reactivity. Generation of more
efficient and safer TCRs warrants a more complete understanding of the basic biology of
a TCR gene-modified T cell and what factors are truly important in defining antigen
recognition and T cell function.
The goal of this dissertation is to better understand structure-function
relationships between a high affinity, HCV-cross-reactive TCR (HCV1406 TCR) and
naturally occurring mutant HCV pMHC ligands. We will compare changes in the kinetic,
cellular, and structural components of TCR-pMHC interactions with the polyfunctional
output by HCV1406 TCR gene-modified T cells. Taken together, these studies provide us
with fundamental information to build a more suitable model to confront diseases with
genomic instability and to better understand what factors govern antigen recognition by
a T cell. As we learn more about how TCR behavior influences T cell function, we will be
able to design more effective and safer TCR gene-modified T cells for ACT.

CHAPTER TWO
MATERIALS AND METHODS
Cell Lines and Media
All cell lines were obtained from the American Type Culture Collection (Rockford,
MD), unless otherwise noted. All media were obtained from Corning Life Sciences
(Corning, NY) unless otherwise noted. HEK293GP (human embryonic kidney packaging
cell line expressing retroviral gag and polymerase proteins), COS (monkey kidney tumor,
HLA-A2-), HepG2 (human hepatocellular carcinoma, HLA-A2+), and Huh-7 (human
hepatocellular carcinoma, HLA-A2-) cells lines were maintained in DMEM supplemented
with 10% fetal bovine serum (FBS; Tissue Culture Biologics, Long Beach, CA). PG13 cells
(stable viral producer cell line) were maintained in IMEM supplemented with 10% FBS.
T2 (HLA-A2+, TAP-deficient antigen presenting cell), Jurkat (CD4-CD8- T cell lymphoma),
and Jurkat76 (CD4-CD8-TCR- T cell lymphoma) cell lines were maintained in RPMI 1640
medium supplemented with 10%. Jurkat76 cells were kindly provided by Dr. Miriam
Heemskerk (Leiden University Medical Center, Leiden, Netherlands).
T Cells
All PBMC samples used for T cell transductions were obtained as apheresis
products purchased from Key Biologics (Memphis, TN). Ficoll-Hypaque (Sigma-Aldrich,
St. Louis, MO) density gradient centrifugation was used to isolate PBL-derived T cells
48
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from PBMC of normal healthy donors. T cell clones isolated from HCV-infected
individuals were generated from PBL samples collected from IRB-approved protocols at
the University of Colorado Denver.
T cells were maintained in complete T cell medium consisting of AIM-V medium
(Life Technologies, Grand Island, NY) supplemented with 5% heat-inactivated pooled
human AB serum (hAB; Valley Biomedical, Inc., Winchester, VA), 300 IU/mL recombinant
human IL-2 (rhIL-2; Novartis Pharmaceuticals Corporation, East Hanover, NJ) and 100
ng/mL recombinant human IL-15 (rhIL-15; Biological Resources Branch, National Cancer
Institute, Bethesda, MD) at 37oC in a humidified 5% CO2 incubator. Prior to retroviral
transduction, primary T cells were OKT3-activated for 3 days using 50 ng/mL anti-CD3
mAb (Miltenyi Biotec, Bergisch Gladbach, Germany), in complete T cell medium.
Cloning of HCV-Reactive T Cells from HCV+ Patients.
As mentioned above, HCV-reactive T cell clones were isolated from PBMC
samples from chronically infected patients or those with spontaneously resolved
infection collected under University of Colorado Denver IRB-approved protocols. HCVreactive T cell clones were obtained from the Rosen Lab at the University of Colorado
Denver. Briefly, T cells were Ficoll-Hypaque separated as described above and stained
with PE-labeled HLA-A*0201 tetramer folded around HCV NS3:1406-1415 (KLVALGINAV)
peptide (Beckman Coulter, Marseille, France). Cells were then sorted by flow cytometry
on a FACSVantage (BD Biosciences, San Jose, CA), and cloned via limited dilution cloning
as previously described [302]. Briefly, tetramer positive cells were plated at limiting
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dilution (5, 10, and 100 cells/well) and cultured with 8x104 and 1.6x104 irradiated
allogeneic PBMC and lymphoblastoid cell line (LCL), respectively in 250 µl/well of AIM-V
medium supplemented with 5% hAB serum, 100 IU/mL rhIL-2, and 0.03 µg/mL purified
anti-CD3 mAb (Miltenyi Biotec) in 96 well plates and incubated for 2 wk at 37 oC and 5%
CO2. After 14-21 days, wells exhibiting growth were transferred to T-25 flasks and restimulated with 25x106 and 5x106 irradiated allogeneic PBMC and LCL, respectively, in
30 mL of AIM-V medium supplemented with 5% hAB serum, 100 IU/mL rhIL-2, and 0.03
anti-CD3 mAb. Cultures were analyzed by FACS 14 days later and used in functional
assays.
Vectors
HCV NS3 Site Directed Mutagenesis
The WT HCV NS3 gene fused to GFP by a T2A self-cleaving viral sequence was
synthesized by Genscript (Piscataway NJ) and provided in a pcDNAIII vector. To generate
each variant HCV NS3:1406-1415 epitope within full length NS3, site directed
mutagenesis (GeneArt Site Directed Mutagenesis System, Invitrogen, Grand Island, NY)
was performed in the pcDNAIII vector using a series of primers (Table 3) synthesized by
Integrated DNA Technologies (Coralville, IA). Variants 8S/9G/12L and 8S/9S/12L/14S
required three and four rounds of site directed mutagenesis, respectively. Methylation,
mutagenesis, and recombination were performed according to manufacturer’s
protocols. Methylation and PCR amplification was performed on a C1000 Thermal Cycler
(Bio-Rad, Hercules, CA) under the following conditions: 20 min at 37oC (one cycle),
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Table 3. Primers used for site-directed mutagenesis of HCV NS3 pCDNAIII vector
variants.
Epitope

Forward primer(s): 5’3’

Reverse primer(s): 5’3’

V1408L

CTCGCCGCAAAGCTGCTCGCGTTGGGCATCA

TGATGCCCAACGCGAGCAGCTTTGCGGCGAG

A1409T

GCCGCAAAGCTGGTCACGTTGGGCATCAATG

CATTGATGCCCAACGTGACCAGCTTTGCGGC

I1412L

CTGGTCGCGTTGGGCCTCAATGCCGTGGCGT

ACGCCACGGCATTGAGGCCCAACGCGACCAG

I1412V

CTGGTCGCGTTGGGCGTCAATGCCGTGGCGT

ACGCCACGGCATTGACGCCCAACGCGACCAG

I1412N

TGGTCGCGTTGGGCAACAATGCCGTGGCGTA

TACGCCACGGCATTGTTGCCCAACGCGACCA

V1408S/

CTCGCCGCAAAGCTGAGCGCGTTGGGCATCAA

TTGATGCCCAACGCGCTCAGCTTTGCGGCGAG

A1409G/

CCGCAAAGCTGAGCGGGTTGGGCATCAATGC

GCATTGATGCCCAACCCGCTCAGCTTTGCGG

I1412L

CTGAGCGGGTTGGGCCTCAATGCCGTGGCGT

ACGCCACGGCATTGAGGCCCAACCCGCTCAG

V1408T

CTCGCCGCAAAGCTGACCGCGTTGGGCATCAA

TTGATGCCCAACGCGGTCAGCTTTGCGGCGAG

V1408S/

CTCGCCGCAAAGCTGAGCGCGTTGGGCATCAA

TTGATGCCCAACGCGCTCAGCTTTGCGGCGAG

A1409S/

GCCGCAAAGCTGAGCTCGTTGGGCATCAATG

CATTGATGCCCAACGAGCTCAGCTTTGCGGC

I1412L/

CTGAGCTCGTTGGGCCTCAATGCCGTGGCGT

ACGCCACGGCATTGAGGCCCAACGAGCTCAG

A1414S

TCGTTGGGCCTCAATTCCGTGGCGTACTACC

GGTAGTACGCCACGGAATTGAGGCCCAACGA
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followed by 2 min at 94oC (one cycle), followed by 20 sec at 94oC, 30 sec at 57oC, and 5
min at 68oC (18 cycles), followed by 5 min at 68oC (one cycle).
Mutated vectors were transformed into Escherichia coli DH5α-T1R competent
cells (Invitrogen) on LB ampicillin plates (25 g LB agar (Fisher, Hampton, NH) in 1 L deionized water supplemented with 100 µg/mL ampicillin (Sigma-Aldrich), and colonies
were expanded in superbroth (32 g Tryptone (Fisher), 20 g yeast extract (Fisher), and 5
grams NaCl (Fisher) in 1 L de-ionized water) supplemented with 100 µg/mL ampicillin
(Sigma-Aldrich). Plasmid DNA from recombinant clones was isolated using a Miniprep
Plasmid Isolation Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol
and sequenced (Genewiz, South Plainfield, NJ) to confirm that correct mutation had
been made and no other errors had occurred during the mutagenesis process. Final
products were used to transfect COS/A2 cells or subcloned into a modified SAMEN
retroviral vector (described below).
HCV TCR Retroviral Vectors
The original SAMEN retroviral vector described by Treisman and colleagues [303]
has been modified from its original components in stepwise fashion to include TCR chain
genes [170] and later a CD34t selection marker [304] for our TCR cloning purposes. Our
modified SAMEN retroviral vectors contains the TCR α chain, P2A self-cleaving linker,
TCR β chain, T2A self-cleaving-linker, and truncated CD34 molecule (CD34t) as a
transgene expression marker (Fig 6a). Each HCV1406 TCR and HCV1073 TCR containing
SAMEN retroviral vector was used to generate high titer produced cell lines used to
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Figure 6. Structures of retroviral vectors used for gene transfer. A modified SAMEN
retroviral backbone was used for transferring TCR, HLA-A2, HCV NS3, and CD8 genes to
alternate effectors and targets. pMFG retroviral vectors were used to transduce HCV
NS3:1406-1415 and CMVpp65:495-503 minigenes into tumor cell lines. (a) TCR retroviral
vector containing the HCV1406 TCR or HCV1073 TCR  and  chain genes fused by a P2A
self-cleaving peptide linker. A truncated version of the CD34 molecule (CD34t), which
serves as a marker for transduction, was fused to the 3’ end of the TCR  chain via a T2A
self-cleaving peptide. (b) HLA-A2 encoding retroviral vector. (c) Full length HCV NS3
fused to GFP by T2A. (d) Full length CD8αβ genes or (e) truncated CD8α’β’ lacking the
intracellular lck-binding domain fused to an mCherry expression marker separated by
P2A and T2A self-cleaving linkers, respectively. Vectors containing either (f) HCV
NS3:1406-1415 epitope or (g) CMVpp65:495-503 minigenes in pMFG both fused to GFP
by a T2A. LTR = long terminal repeat; + = packaging signal; SD = splice donor; SA = splice
acceptor.
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harvest retroviral supernatants to transduce Jurkat cells and PBL-derived T cells
(described in a later section).
Subsequent Retroviral Vector Construction Scheme
The structure of our modified SAMEN backbone offered the opportunity to swap
in/out various other genes used for retroviral transduction-mediated delivery. NotI and
BamHI restriction sites flank the 5’ end of the TCR α chain and the 3’ end of the CD34t
cassette, respectively. This allowed for simple replacement of TCRα/TCRβ/CD34t with
other genes/transduction makers with traditional cloning techniques using 5’NotI/BamHI-3’ compatible ends. The HLA-A2 gene was synthesized by GenScript and
provided in the pUC57 vector engineered with 5’ NotI and 3’ BamHI restriction sites.
HLA-A2 was subcloned out of the pUC57 vector into the modified SAMEN retroviral
vector. Briefly, vector DNA was transformed into Escherichia coli TOP10 competent cells
(Invitrogen) on LB ampicillin plates, and colonies were expanded in superbroth
(supplemented with 100 µg/mL ampicillin (Sigma-Aldrich). Plasmid DNA from
recombinant clones was isolated using a Miniprep Plasmid Isolation Kit (Qiagen)
according to manufacturer’s protocol and screened for the presence of each gene of
interest by restriction enzyme digest analysis. Genes were digested with NotI and BamHI
restriction enzymes (Thermo Scientific, Grand Island, NY) and products were separated
on a 1% agarose gel. DNA bands corresponding to the correct length of HLA-A2 were
excised from the gel and purified (Qiagen) according to manufacturer’s protocol.
Subsequently, gel-purified DNA was subcloned into the modified SAMEN retroviral
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vector with compatible restriction sites. A ligation reaction containing T4 DNA ligase
(New England Biolabs, Ipswich, MA) and T4 DNA ligase buffer (New England Biolabs)
with vector DNA and insert DNA in a 1:5 vector:insert ratio was incubated overnight at
16oC. Ligation products were transformed into competent E. coli and DNA was isolated
(Qiagen). The final product was sequenced (Genewiz, South Plainfield, NJ) to ensure no
errors had occurred during the cloning process.
Additionally, a pCR2.1 “shuttle vector” containing the sequence 5’NotI/EcoRI/T2A/transduction marker/BamHI-3’ was used to easily interchange genes
with various transduction markers (CD34t, GFP, or mCherry) to be subcloned into
SAMEN. CD8αβ, and CD8α’β’ genes to be inserted into retroviral backbones were
synthesized by GenScript provided in the pUC57 vector engineered with 5’ NotI and 3’
EcoRI restriction sites. Truncated CD8α’β’ gene sequences have been previously
described [305]. These genes were subcloned out of the pUC57 vector into pC2.1 shuttle
vector containing mCherry with NotI and EcoRI restriction sites using methods described
above. The resulting CD8-T2A-mCherry fragments were then excised from pCR2.1 and
subcloned into the SAMEN vector using NotI and BamHI restriction sites using the same
methodology. Final products were sequenced (Genewiz) to ensure no errors had
occurred during the cloning process.
HCV NS3 retroviral vector. WT HCV NS3 gene fused to GFP by a T2A linker was
synthesized by Genscript and provided in a pcDNAIII vector. Site directed mutagenesis
was performed to generate variant 1406-1415 epitopes (described earlier). Each of
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these subsequent sequences was subcloned from pcDNAIII into SAMEN in the same
manner as pUC57 vectors described above.
Final SAMEN retroviral products included HLA-A2 fused to GFP by a T2A linker
(Fig. 6b), HCV NS3 fused to GFP by a T2A linker (Fig. 6c), CD8α fused to CD8β fused to
mCherry by P2A and T2A linkers, respectively (Fig. 6d), and CD8α’ fused to CD8β’ fused
to mCherry by P2A and T2A linkers, respectively (Fig. 6e).
HCV and CMV minigene retroviral vectors. pMFG retroviral vectors containing
CMVpp65:495-503 as well as WT and variant HCV NS3:1406-1415 minigenes fused to
GFP by a T2A linker (also containing an additional neor cassette) were kindly provided
by Zhang Yi in the Nishimura Lab (Fig. 6f-g). All above retroviral vectors were used to
generate high titer producer cell lines used to transduce PBL-derived T cells, Jurkat cells,
and multiple tumor cell lines.
Generation of High Titer Producer Cell Lines
Generation of stable producer PG13 cell lines was accomplished as follows. For
each retroviral vector, 3 million 293GP cells were seeded in a 10 cm poly-D-Lysine
coated tissue culture plate (Thermo Scientific). Cells were co-transfected with 20 µg
retroviral vector DNA and 5 µg of a plasmid containing the vesicular stomatitis virus
envelope gene in 50 µl Lipofectamine 2000 (Life Technologies). Media was replaced 6
hours post-transfection and viral supernatant was collected and 0.45 µm filtered after a
48 hr incubation at 37oC in 5% CO2. 2 million PG13 cells seeded in a 10 cm tissue culture
plate were transduced over 72 hours using this fresh viral supernatant at 37 oC in 5%
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CO2. Transduction efficiency was analyzed by measuring CD34, GFP, or mCherry
expression depending on the retroviral vector used. CD34, GFP, or mCherry positive cells
were sorted for high and uniform expression using a FACSAria IIIu cell sorter (BD
BioSciences), and the resulting high-tighter producer cell lines were maintained in IMEM
supplemented with 10% FBS.
Preparation of retrovirus for transductions was accomplished by treating PG13
stable producer cell lines seeded overnight at 8x106 cells/T-175 flask with sodium
butyrate media (IMEM supplemented with 10% FBS, 1mM sodium butyrate (SigmaAldrich) and 10mM HEPES (Corning Life Sciences) for 8-10 hours. Media was replaced
with IMEM supplemented with 10% FBS and fresh viral supernatants were harvested
and 0.45 µm filtered the next day. Virus was used fresh or stored at -80oC for later use.
Gene Delivery
HCV TCR Retroviral Transduction
T cells, Jurkat cells, and Jurkat76 cell lines were transduced by spinoculation as
previously described [15, 305]. T cells derived from healthy donors were activated for 3
days prior to spinoculation using 50 ng/mL anti-CD3 monoclonal antibody (Miltenyi
Biotec) in complete medium. 24-well flat-bottom non-tissue culture-treated plates
(Thermo Fisher Scientific) were treated with 0.5 mL/well 30 µg/mL retronectin (Takara
Bio, Otsu, Shiga, Japan) overnight at 4o-C. Plates were blocked with 0.5 mL/well 2% PBSA
(bovine serum albumin (BSA; Fisher Scientific, Fair Lawn, NJ) in phosphate buffered
saline (PBS; Corning Life Sciences)) for 30 min at room temperature (RT) and washed
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with 2 mL/well PBS. 2 mL of fresh or frozen retroviral supernatant was added to each
well and the plates were spun for 2 hr at 2,000xg at 32oC and aspirated. 2 million
activated T cells or Jurkat cell lines were gently added to the viral-coated plates in 1 mL
of AIM-V/5% hAb, 600 IU/mL rhIL-2, and 200 ng/mL rhIL-15 and mixed with 1 mL filtered
retroviral supernatant. The plates were spun again for 2 hr at 2,000xg at 32 oC and
incubated overnight at 37oC in 5%CO2. After 24 hours, the transduced T cells were
transferred to tissue-culture treated flasks. Three days later, transduction efficiency
was determined by flow cytometry staining for CD34 using anti-CD34-APC mAb
(Biolegend). Cultures were enriched for TCR-transduced T cells or Jurkat cells by positive
selection using immunomagnetic beads labeled with anti-CD34 (Miltenyi Biotec) and
maintained in complete medium. T cells may also have been selectively sorted for CD4 +
or CD8+ transduced T cells using anti-CD4 or anti-CD8 immunomagnetic beads,
respectively (Miltenyi Biotec). Purity of selection was confirmed by FACS analysis.
After immunomagnetic selection, TCR-transduced T cells were further expanded
using a Rapid Expansion Protocol (REP). Briefly, 1x106 T cells were cultured in an upright
T-175 cell culture flask with 200x106 irradiated (5000 rads) allogeneic PBMC in 150 mL of
complete T cell medium supplemented with 30 ng/mL anti-CD3 mAb (Miltenyi Biotec).
Cells were incubated at 37oC in 5%CO2 for 5 days and harvested for use in functional
assays.
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CD8αβ and CD8α’β’ Retroviral Transduction
Jurkat and Jurkat76 cells were also transduced via spinoculation (methods
described above) with a modified SAMEN retroviral vector containing human CD8αβmCherry or CD8α’β’-mCherry (Figs. 6d-e). CD8+ cells were sorted for high and uniform
expression by FACS using anti-CD8-PerCP/Cy5.5 mAb (Biolegend) and maintained in
RPMI1640 supplemented with 10% FBS.
HLA-A2 Retroviral Transduction
A modified SAMEN retroviral vector containing HLA-A2 (Fig 6b) was used to
transduce Huh-7 and COS cell lines. Huh-7 and COS cells were seeded in a 24-well tissue
culture plate to yield 70-80% confluency. Two mL of 0.45 µm-filtered retroviral
supernatants were applied to each well and incubated for 48 hr at 37oC in 5% CO2. Flow
cytometry was used to confirm expression of HLA-A2 using an anti-HLA-A2-APC mAb
(Biolegend, San Diego, CA). Positive cells were sorted for high and uniform expression of
HLA-A2, and the resulting cell lines were maintained in DMEM supplemented with 10%
FBS.
HCV NS3:1406-1415 Ninigene Retroviral Transduction
pFMG retroviral vectors containing WT or variant HCV NS3:1406-1415 minigenes
(or the CMVpp65:495-503 epitope as a negative control) (Figs. 6f-g) were used to
transduce HepG2 and Huh-7 in the same manner described above. HepG2 and Huh-7
cells were seeded in a 24-well tissue culture plate to yield 70-80% confluency. Two mL
of 0.45 µm-filtered retroviral supernatants were applied to each well and incubated for
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48 hr at 37oC in 5% CO2. Flow cytometry was used to confirm expression of minigenes by
measuring GFP expression. Positive cells were sorted for high and uniform expression of
GFP, and the resulting cell lines were maintained in DMEM supplemented with 10% FBS
and 500 µg/mL G418 (Geneticin; Research Products International, Mount Prospect, IL).
Full length HCV NS3 DNA Transfection
COS and COS/A2 cells were transiently transfected to express the full length HCV
NS3 protein with WT or variant 1406-1415 epitopes using pcDNAIII vectors encoding
HCV NS3 linked to GFP by the self-cleaving viral sequence P2A. Cells were plated in a 24well tissue culture plate to yield 70-80% confluency and were transfected with 3 µg DNA
and 6 µl of Lipofectamine 2000 (Life Technologies) over 48 hours. Flow cytometry was
used to confirm expression of full length HCV NS3 by measuring intracellular GFP levels.
Full length HCV NS3 Retroviral Transduction
Because HepG2 cells were resistant to lipid-based transfection, a modified
SAMEN retroviral vector encoding HCV NS3-P2A-GFP was used to transduce HepG2 cells
(Fig 6c). Cells were plated in a 24-well tissue culture plate to yield 70-80% confluency.
Two mL of 0.45 µm-filtered retroviral supernatants were applied to each well and
incubated for 48 hr at 37oC in 5% CO2. Flow cytometry was used to confirm expression
of NS3 by measuring GFP expression. Positive cells were sorted for high and uniform
expression of GFP, and the resulting cell lines were maintained in DMEM supplemented
with 10% FBS.
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Peptides
All peptides used in functional assays were purchased from Synthetic
Biomolecules (San Diego, CA) at 95% purity. Peptides were stored in 100% dimethyl
sulfoxide (DMSO; Sigma-Aldrich) at -80oC at a concentration of 5 µg/µL. A complete list
of all peptides used, their sequences, and their abbreviations as referred to in the text
can be found in Table 4.
Alanine substituted peptides were used as stimulators against T cell clones
isolated from infected HCV+ patients (Chapter 4) as well as PBL-derived T cells and Jurkat
cell lines transduced to express the HCV1406 TCR (Appendix). An alanine scanner set for
the HCV NS3:1406-1415 peptide, was generated by substituting an alanine at each
residue position (1 through 10) except where an alanine natively occurs. In these cases
(positions 4 and 9) an isoleucine was substituted for an alanine.
Naturally occurring mutant sequences for HCV NS3:1406-1415 and HCV
NS3:1073-1081 epitopes were identified by searching the GenBank
(http://www.ncbi.nlm.nih.gov/genbank/) using the WT nucleotide sequences. Sequence
AAGCTGGTCGCGTTGGGCATCAATGCCGTG was used for HCV NS3:1406-1415, while
sequence TGCATCAATGGGGTGTGCTGGACTGTC was used for HCV NS3:1073-1081. Of
the 1,000+ sequences recovered for each, silent mutations were eliminated and 8
naturally occurring mutant epitopes were chosen for each that allowed for a spectrum
of amino acid changes in position and class. These peptides (also listed in Table 4) were
used for functional studies discussed in Chapters Four, Five, and Six.
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Table 4. Peptide names, abbreviations, and sequences used for functional studies.
Peptide Name

Abbreviation

Sequence

Tyrosinase:368-376
CMVpp65:495-503

Tyro
CMV

YMDGTMSQV
NLVPMVATV

HCV NS3:1406-1415
HCV NS3:V1408L
HCV NS3:A1409T
HCV NS3:I1412L
HCV NS3:I1412V
HCV NS3:I1412N
HCV NS3:V1408S/A1409G/I1412L
NS3:V1408T
HCV NS3:V1408S/A1409S/I1412L/A1414S

HCV1406wt
V1408L
A1409T
I1412L
I1412V
I1412N
8S/9G/12L
V1408T
8S/9S/12L/14S

KLVALGINAV
KLLALGINAV
KLVTLGINAV
KLVALGLNAV
KLVALGVNAV
KLVALGNNAV
KLSGLGLNAV
KLTALGINAV
KLSSLGLNSV

HCV NS3:K1406A
HCV NS3:L1407A
HCV NS3:V1408A
HCV NS3:A1409I
HCV NS3:L1410A
HCV NS3:G1411A
HCV NS3:I1412A
HCV NS3:N1413A
HCV NS3:A1414I
HCV NS3:V1415A

K1406A
L1407A
V1408A
A1409I
L1410A
G1411A
I1412A
N1413A
A1414I
V1415A

ALVALGINAV
KAVALGINAV
KLAALGINAV
KLVILGINAV
KLVAAGINAV
KLVALAINAV
KLVALGANAV
KLVALGIAAV
KLVALGINIV
KLVALGINAA

HCV1073wt
HCV NS3:1073-1081
CINGVCWTV
I1074V
HCV NS3:I1074V
CVNGVCWTV
I1073A
HCV NS3:I1074L
CLNGVCWTV
V1077A
HCV NS3:V1077A
CINGACWTV
C1078F
HCV NS3:C1078F
CINGVFWTV
V1081N
HCV NS3:V1081N
CINGVCWTN
T1080S
HCV NS3:T1080S
CINGVCWSV
V1081A
HCV NS3:V1081A
CINGVCWTA
80S/81I
HCV NS3:T1080S/V1081I
CINGVCWSI
*All peptides were acquired at 95% purity from Synthetic Biomolecules (San Diego, CA).
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Proteins
MHC class I protein was kindly generated by members of the Baker Lab at the
University of Notre Dame. Recombinant MHC-I was used for peptide-MHC thermal
denaturation studies as well as TCR-pMHC binding affinity measurements. Briefly,
recombinant HLA-A*0201 heavy chain and β-2 microglobulin were expressed as
inclusion bodies in Escherichia coli [306]. Expression of HCV1406 TCR was performed
similarly. TCR and MHC folding and assembly from inclusion bodies was performed
according to standard procedures [307]. Protein was purified using ion exchange
followed by size-exclusion chromatography.
Cytokine Release Assay
Antigen reactivity by HCV1406 TCR or HCV1073 TCR transduced T cells and Jurkat
cell lines was measured in cytokine release assays as previously described [168]. Briefly,
HCV+ tumor cells or peptide-loaded T2 cells were routinely used as stimulators. T2 cells
were pulsed with 10 µg/mL peptide for 2 hrs prior to co-culture. Titration of HCV1406
TCR reactivity used peptide concentrations ranging from 10 – 0.00001 µg/mL. 1x105
responder and stimulator cells were co-cultured in a 1:1 ratio in 96-well U-bottom tissue
culture plates in 200 µL complete medium. Ten ng/mL phorbol 12-myristate 13-acetate
(PMA; Sigma-Aldrich) was added to Jurkat cell co-cultures to enhance sensitivity to
stimulation. Co-cultures were incubated at 37oC for 20 hrs and supernatants were
harvested. The amount of IFNγ or IL-2 released by 105 T cells or Jurkat cells, respectively,
was measured via ELISA (R&D Systems, Minneapolis, MN).
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Immunofluorescence Staining Reagents
A table summarizing all immunofluorescence staining reagents can be found in
Table 5. Sections below describe the applications for various reagents used.
Immunofluorescence Antibodies
Fluorochrome-conjugated antibodies were used to detect T cell surface markers
(CD3, CD4, CD8), transduced or endogenous TCRs, and CD34 as a marker for
transduction. Additionally, TCR-transduced T cells were analyzed for activation markers
CD25 and CD69 and inhibitory markers PD-1 and TIM-3 to characterize a representative
population of TCR-transduced PBL-derived T cells. In functional assays, TCR-transduced T
cells were also stained for lytic marker CD107a and intracellular cytokines IFNγ, TNFα, IL2, IL-4, IL-17A, and IL-22. Pairing of fluorochromes to antibodies was determined by
established staining profiles of each antibody to allow for detection of bright, dim, and
negative populations. Spectral overlap between fluorescent dyes was also considered.A
summary of antibodies, selected fluorochormes, and their manufacturers are listed in
Table 5.
Dextramers and Tetramers
APC-labeled HLA-A*0201 dextamer folded around WT HCV NS3:1406-1415
(KLVALGINAV) (Immundex, Copenhagen, Denmark) was used as a surrogate for TCR
expression as commercially available antibodies do not bind HCV1406 TCR very well. The
NIH Tetramer Core Facility at Emory University (Atlanta, GA) kindly provided a panel of
monomers and tetramers used for tetramer binding experiments. The core provided
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Table 5. Reagents and manufacturers used for immunofluorescence.
Use

Reagent

Clone

Conjugated
Fluorochrome

anti-CD3
SK7
APC/Cy7
anti-CD4
161A1
FITC
anti-CD8
SK1
AF† 700
anti-CD34
581
PerCP/Cy5.5
Transduced T
anti-CD25
BC96
BV‡ 711
Cell Culture
anti-CD69
FN50
PE/Cy7
Characterization
anti-PD-1
EH12.2H7
BV 421
(Chapter Three)
anti-TIM-3
F38-2E2
BV 605
KLVALGINAV/HLAN/A
APC
A*0201 Dextramer
anti-TCR Vβ13.6
N/A
PE

Manufacturer
Biolegend§
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Biolegend
Immudex¶
Beckman Coulter||

T Cell Surface
Markers
(Remaining
Chapters)

anti-CD3
anti-CD4
anti-CD34
anti-CD107a

UCHT1
RPA-T4
561
H4A3

APC/Cy7
PE/Cy7
PE
BV 510

Biolegend
Biolegend
Biolegend
Biolegend

Polyfunctionality
Assay-Specific
Surface Markers

anti-CD3
anti-CD4
anti-CD8
anti-CD34
anti-CD107a

UCHT1
RPA-T4
SK1
581
H4A3

APC/Cy7
PE/Cy7
FITC
AF 700
BV 510

Biolegend
Biolegend
Biolegend
Biolegend
Biolegend

anti-IFNγ
anti-TNFα

4S.B3
Mab11
MQ117H12
8D4-8
BL168
BG/IL22

BV 421
BV 711

Biolegend
Biolegend

PerCP/Cy5.5

Biolegend

AF 647
BV 570
PE

Biolegend
Biolegend
Biolegend

Intracellular
Cytokines

†

anti-IL-2
anti-IL-4
anti-IL-17A
anti-IL-22

AF, Alexa Fluor ‡BV, Brilliant Violet; §Biolegend, San Diego, CA; ¶Immudex,
Copenhangen, Denmark; ||Beckman Coulter, Marseille, France
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Table 5. Reagents and manufacturers used for immunofluorescence (cont’d).
Use

Reagent

Clone

Conjugated
Fluorochrome

Manufacturer

KLVALGINAV/
APC (supplied
NIH Tetramer Core
N/A
HLA-A*0201
as a monomer)
Facility#
KLLALGINAV/
N/A
APC
NIH Tetramer Core Facility
HLA-A*0201
KLVTLGINAV/
N/A
APC
NIH Tetramer Core Facility
HLA-A*0201
KLVALGLNAV/
N/A
APC
NIH Tetramer Core Facility
HLA-A*0201
KLVALGVNAV/
N/A
APC
NIH Tetramer Core Facility
Tetramer
HLA-A*0201
Staining and
KLVALGNNAV/
N/A
APC
NIH Tetramer Core Facility
Dissociation
HLA-A*0201
Experiments
KLSGLGLNAV/
N/A
APC
NIH Tetramer Core Facility
HLA-A*0201
KLTALGINAV/
N/A
APC
NIH Tetramer Core Facility
HLA-A*0201
KLSSLGLNSV/
N/A
APC
NIH Tetramer Core Facility
HLA-A*0201
YMDGTMSQV/
N/A
APC
NIH Tetramer Core Facility
HLA-A*0201
Streptavidin
N/A
APC
Prozyme**
#
NIH Tetramer Core Facility at Emory University, Atlanta, Georgia; **Prozyme, Hayward,
CA
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HLA-A*0201 monomers folded around WT HCV NS3:1406-1415 (KLVALGINAV) or
tyrosinase:368-376 (TMDGTMSQV) at 2.0 mg/mL. They also provided APC-labeled HLAA*0201 tetramers folded around WT and variant HCV NS3:1406-1415 peptides at 1.5
mg/mL. A full description of tetramers and monomers provided is listed in Table 5.
Monomer Tetramerization
HLA-A*0201 monomers (folded around HCV NS3:1406-1415 and tyrosinase:368376) supplied at 2.0 mg/mL were tetramerized by adding 13.9 μL of 2.1 mg/mL
streptavidin-APC (Prozyme, Hayward, CA) at RT 10 times in 10 minute intervals. At the
end of 10 additions of streptavidin-APC, monomers were fully tetramerized with a slight
excess of streptavidin-APC.
Tetramer Binding Experiments
Saturating concentrations of WT and variant HCV NS3:1406-1415 tetramers were
evaluated for HCV1406 TCR transduced Jurkat or Jurkat76 cells and HCV1406 TCRtransduced Jurkat as well as Jurkat76 cells engineered to co-express full length CD8αβ.
Cell lines were incubated with each tetramer, concentrations ranging from 1x10-7 to
1x10-12, and either anti-CD34/AF700 (Biolegend) (for Jurkat cells) or anti-CD3-APC/Cy
(Biolegend) (for Jurkat76 cells) in 2% PBSA/0.2% sodium azide (Sigma-Alrich) on ice for
at least 2 hr in the dark. Because it has been shown the presence of anti-CD8 antibodies
can alter tetramer binding [308-310], cells were not co-stained for CD8. Rather, the
presence of CD8 was measured by transgene marker mCherry. Cells were washed and
resuspended in ice-cold 2% PBSA/0.2% sodium azide, and analyzed for bound

68
fluorescent tetramers using an LSRFortessa flow cytometer (BD Biosceinces).
Fluorescence of the non-TCR-transduced cells was used for background subtraction to
determine specific binding to TCR-transduced cells. Specific tetramer binding for each
concentration of tetramer was calculated for each cell line as follows:
CD8+ Jurkat: %Tetramer+CD34+mCherry+ – %Tetramer+CD34-mCherry +
CD8- Jurkat: %Tetramer+CD34+mCherry - – %Tetramer+CD34-mCherry CD8+ Jurkat76: %Tetramer+CD3+mCherry + – %Tetramer+CD3-mCherry +
CD8- Jurkat76: %Tetramer+CD3+mCherry - – %Tetramer+CD3-mCherry Bi-Functional T cell Reactivity Assay
Percentages of IFNγ producing and/or lytic HCV1406 TCR -transduced T cells was
measured in an intracellular IFNγ/surface CD107a-detection assay. 3x105 responder and
3x105 stimulator cells were co-cultured in a 1:1 ratio in 96-well U-bottom tissue culture
plates in 200 µL complete medium. Five µL anti-CD107a mAb, 5.0 ng/mL brefeldin-A,
and 2.0 nM monensin (all Biolegend) were added at the start of co-culture. Co-cultures
were incubated at 37oC for 5 hours, and cells were stained for immunofluorescence
against cell surface antigens for 20 minutes at RT. Subsequently, cells were fixed in
Fixation Buffer (Biolegend) for 20 min, washed 3 times in Permeabilization and Wash
Buffer (Biolegend), and counterstained for intracellular IFNγ for 20 min at RT. Data were
acquired using an LSRFortessa flow cytometer (BD Biosciences). CD34+ events
(transduced T cells) were gated into CD4+CD8- or CD4-CD8+ populations using FlowJo vX
(TreeStar, Ashland, OR). Percentages of CD107a+IFNγ- (lytic only), CD107a+IFNγ+ (lytic
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and cytokine-secreting), CD107a-IFNγ+ (cytokine-secreting only), or CD107a-IFNγ- (nonreactive) cells were calculated for both CD34+CD4+CD8- and CD34+CD4+CD8- T cell
populations and frequencies were converted into pie charts.
Polyfunctional T Cell Lysis and Multi-Intracellular Cytokine Assay
In similar methods described above, HCV+ tumor cells or peptide-loaded T2 cells
were put into co-culture with HCV1406 TCR-transduced PBL-derived T cells. 3x105
responder and 3x105 stimulator cells were mixed in a 1:1 ratio in 96-well U-bottom
tissue culture plates in 200 µL complete medium. Five µL anti-CD107a mAb, 5.0 ng/mL
brefeldin-A, and 2.0 nM monensin (all Biolegend, San Diego, CA) were added at the
beginning of the co-culture. Co-cultures were incubated at 37oC for 5 hours, and cells
were stained for cell surface antigens for 20 minutes at RT. Subsequently, cells were
incubated in Fixation Buffer (Biolegend) for 20 min, washed 3 times in Permeabilization
and Wash Buffer (Biolegend), and stained for intracellular cytokines for 20 min at RT.
Cells were washed, resuspended in Cell Staining Buffer (Biolegend), and analyzed by
flow cytometry. Samples were acquired using a LSRFortessa flow cytometer (BD
Biosciences). Staining profiles were gated and analyzed using FlowJoX software
(TreeStar, Ashland, OR).
Multi-Dimensional Flow Cytometry Data Analysis
Seven-parameter functional analysis by flow cytometry yields datasets far too
complex to analyze in traditional flow cytometry analysis software such as FlowJo. We
evaluated a series of software packages in their ability to visualize and interpret our
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complex, high dimensional data assessing T cell polyfunctionality. Some of the
requirements of these tools are to be able to represent rare and high frequency
populations, visualize the data at a single cell level, preserve the relationships and
geometry of the data, and provide an interpretable view of the data for publication or
presentation. The programs available ranged from all manual gating to unsupervised
gating, and analysis algorithms contained clustering, dimension reduction, hierarchy
extraction and/or t-Distributed Stochastic Neighbor Embedding (tSNE).
In order to uniformly evaluate the different analysis methods, the same set of
polyfunctional T cell stimulation data was analyzed in each approach. Below we present
detailed methods, highlighting representative graphical output for each tool evaluated.
We also provide commentary on the general benefits and drawbacks and the feasibility
of (or lack thereof) in generating meaningful interpretation of changes in T cell
polyfunctionality. For consistency, we use the same experimental dataset for the
comparison of each tool, and for simplicity, we illustrate only comparisons of negatively
(tyrosinase:368-376) or positively (WT HCV NS3:1406-1415) peptide-stimulated HCV
TCR-transduced CD8+ T cells. It is pointed out where additional comparisons between
CD8+ and CD4+ T cells as well across variant peptide or tumor stimulation conditions
would be easily interpreted in subsequent analytical approaches or would make the
data more complicated to discern a biological message. In summary, the goal of these
comparative evaluations was to generate simple and meaningful graphical output
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evaluating changes in HCV1406 TCR-transduced T cell polyfunctional phenotypes in
response to variant HCV NS3:1406-1415 peptide and tumor stimulations.
Gating Strategy
Lymphocyte populations were discerned by FSC vs. SSC comparison, and events
were gated on CD4+CD8- or CD4-CD8+ populations. CD4+ or CD8+ T cells were then gated
on CD34+ expression to define our transduced cell populations. These CD4+CD8-CD34+ or
CD4-CD8+CD34+ were subsequently used as starting points for subsequent analysis using
the remaining software strategies. Functional parameters included CD107a, IFNγ, TNFα,
IL-2, IL-4, IL-17A, and IL-22.
GemStone
GemStone, available through Verity Software House (Topsham, ME), uses
probability state modeling (PSM) to represent a set of cellular progressions or “Cell
Types”, originally engineered to analyze and visualize multidimensional cellular
populations [311]. The basis of PSM is creating a model consisting of different Cell
Types, which are defined by the user. Using the information available for each of the
Cell Types, parameter profiles are then created, and these Cell Types are used as
progression steps in the model. Relationships between parameters may be discovered
and transitional cell types may also be defined. As a model is built, complexity may be
added and then tested with the data to be analyzed.
Major benefits of PSM analysis include accounting for population overlap, simple
clustering routines, and identifying populations without giving biological
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interrelationships. Additionally, gates are not drawn using GemStone so there is neither
subjectivity nor operator variability. While gating defines positive and negative,
GemStone allows for transitional populations and can allow for up- and down-regulation
of markers. One disadvantage, however, is that design of templates used for analysis
requires knowledge of some biology of the system.
A TriCOM is a tool contained within GemStone that is used to show different
phenotypes and activation states (Fig. 7). TriCOM analysis displays concentric pie charts
for each level of co-expressed parameters. Multiple parameters in a single cell
population are represented by multiple colors within a single wedge.
For our purposes, the TriCOMs showed a distinct visualization of cytokines
present at each order of staining, but the concentric pie charts became much harder to
read when analyzing higher orders of staining (≥3 parameters). For example, the
proportions of cells expressing only one cytokine each are relatively easily interpreted
(Fig. 7, bottom pie chart). It becomes less clear, however, when trying to resolve
populations greater than three parameters or looking at two parameter positive cells
that occur in low frequencies. Overall, while TriCOMs are useful tools that clearly
visualize phenotypes, they can become difficult to read at greater than three
parameters or for low frequency populations. Additionally, making comparisons across
multiple treatment groups would require a large number of TriCOMs with so many
functional parameters evaluated.
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Figure 7. GemStone TriCOM analysis. TriCOMs display percentage of CD8+ HCV1406
TCR-transduced T cells positive for combinations of functional markers in concentric pie
charts. The bottom pie chart represents frequency of cells positive for only 1 marker,
and each pie chart above it represents an additional level of staining up to 7
simultaneous markers (top pie chart). Functional phenotypes are represented by a
single wedge with multiple colors. Frequency of cells in each category is shown to the
right of each pie chart. Phenotypes at each level are coded by the colors that make up
each wedge. Purple=CD107a, Blue-IFNγ, Turquoise=TNFα, Green=IL-2, Gray=IL-4,
Pink=IL-17A, Gold=IL-22.

74
Spanning-Tree Progression Analysis of Density-Normalized Events
Spanning-tree Progression Analysis of Density-Normalized Events (SPADE) was
created to aid in visualization and analysis of multi-parameter data. This algorithm,
available through Cytobank (Mountain View, CA; http://www.cytobank.org), is designed
to extract a hierarchy from high-dimensional cytometry data in an unsupervised
manner. This enables multiple cell types to be visualized in a branched tree structure
[312]. SPADE contains 4 modules: i) Density-dependent down-sampling, which allows
rare as well as abundant populations to be represented equally; ii) Agglomerative
clustering, which separates the down-sampled data into groups containing cells with
similar phenotypes; because the rare cells are represented equally, a node for these
cells can be created; iii) A minimum spanning tree is created which connects all of the
clusters with a minimal edge length; iv) Each data file is up-sampled, with the cells being
mapped to the appropriate cluster. The clusters are then organized and displayed as a
two dimensional tree. SPADE has been most useful for studies looking at cell
populations with mixed lineages or tracking distinct cellular progressions [312-315].
Clusters form nicely when certain markers are mutually exclusive from others or if there
is a clear progression of cellular phenotypes. After spanning-trees are generated, other
markers can be analyzed for their intensity within these nodes, but only one a time.
The major benefits of SPADE are that the user does not need to know a
hierarchical order before analysis and that rare cell types are identifiable. It is also
scalable with increasing numbers of parameters. As such, investigators can infer likely
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cellular processes and hierarchies without needing predetermined hierarchies. The
spanning tree is only limited by choice of markers used in an experiment and the
subsets used for building a tree. The major limitation of SPADE, however, is that data
are represented as clusters rather than individual cells so single cell resolutions is lost.
And if spanning trees fail to cluster, few useful conclusions can be made.
For our purposes, a SPADE-derived spanning-tree was not optimal in determining
a cellular progression of T cell polyfunctionality. Cytokine phenotypes did not cluster,
and instead of a tree, a web-like pattern was generated. Although it is clear there are
visual differences between spanning-trees of tyrosinase versus WT NS3:140601415
peptide-stimulated TCR-transduced T cells (Fig. 8), SPADE-generated spanning-trees
were not useful in easily determining phenotypes of each individual node. Addition of
parameters that would cluster naive, memory, activating, or inhibitory T cell markers
would create more nodal or mutually exclusive populations but would limit our ability to
evaluate as many cytokines.
Self-Organizing Maps of Visualizing and Interpretation of Cytometry Data
Self-Organizing Maps of Visualizing and Interpretation of Cytometry Data
(FlowSOM) also focuses on clustering as well as being a visualization aid [316]. An Rbased program available through BioConductor (Seattle, WA), this algorithm consists of
four steps. First, the data is read. Data can be compensated, transformed and gated and
then exported by FlowJo, or these functions may be performed using FlowSOM itself
within R. Second, a self-organizing map is built which is an artificial neural network,
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a)

b)

Figure 8. Graphical output provided by clustering tool SPADE. SPADE-generated
spanning trees represent phenotypic clustering of CD8+ HCV1406 TCR-transduced T cells
after co-culture stimulation (a) tyrosinase:368-376 or (b) WT HCV NS3:1406-1415
peptides. Colored nodes refer to cell density. Cytokine profiles of each node are unable
to be graphically displayed.
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containing a grid of nodes. These nodes represent a single point in multidimensional
space. Cells are then classified to the nearest node, and the grid places nodes that
closely resemble each spatially proportionally. Third, a minimal spanning tree is built
connecting the nodes that are most similar to each other in minimal branches. Lastly,
metaclustering calculates the expected number of nodes if there is a much larger
amount of clusters than the expected number of cell types. After this process, the data
may be visualized either as a minimal spanning tree, similar to SPADE, or as a grid. Each
node is coded as a pie chart with information about the phenotype of cells in that node.
The benefits of using FlowSOM is that even though this is an R-based program,
using the provided documentation only a minimal understanding of R will allow you to
successfully use this program. The program also does not tax the memory usage of a
desktop computer, and the output is very detailed. Each node of the minimal spanning
tree contains colored wedges corresponding to the measured functional parameters.
Similar to our analysis in SPADE, there are clear visual differences between
NS3:1406-1415 peptide stimulation compared to negative control tryosinase (Fig. 9).
However, the identification of nodal phenotypes was difficult to interpret. Overall,
clustering tools can be very useful for when tracking distinct cellular progressions or
measuring changes in mixed cell populations with distinct lineages. But when looking at
a subset of T cells without mutually exclusive markers present, clustering tools are not
optimal to make these multi-dimensional analyses.
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a)

b)

IL-2
IFNγ
CD107a
IL-17A
TNFα
IL-4
IL-22

Figure 9. Graphical output provided by clustering tool FlowSOM. FlowSOM-generated
minimal spanning trees represent phenotypic clustering of CD8 + HCV TCR-transduced T
cells after co-culture stimulation with (a) tyrosinase:368-376 or (b) WT HCV NS3:14061415. Size of each node corresponds to cell density. Colored pie wedges refers to
cytokine(s) produced by each nodal population.

79
viSNE
viSNE, also available through Cytobank, is a tool for the visualization of highdimensional single-cell data. Analysis places a cell in a two-dimensional map but
preserves the separation between types. This mapping takes advantage of the inherent
structure of the data where different types are in separate regions in high-dimensional
space. viSNE uses a nonlinear dimensionality reduction algorithm which is based on tDistributed Stochastic Neighbor Embedding (t-SNE) [317]. t-SNE calculates a distance
matrix in high dimensional space, which is transformed into a similarity matrix. Low
dimensional similarities are calculated using Student’s t-distribution. viSNE generates a
representation of this data that is similar to a biaxial plot and retains the geometry of
the populations. The data is represented as cells in high-dimensional data space and
does so without relying on traditional gating strategies. viSNE can also discretely and
automatically separate cells based on subtype, provided they exist. The cyt feature
allows for coloring of cells based on selected expression markers. The data appears as a
cloud biaxial plot with a specific geometry. Differences in populations can be seen as
changes in the geometry, and events may be colored to determine which parameter or
parameters have changed.
A major benefit with using viSNE is that comparisons are made in high
dimensional space. When there are populations that do not resolve when examined in 2
or 3 dimensions, viSNE can overcome that obstacle. viSNE is also unsupervised and does
not require in depth knowledge of the system being investigated. A limitation of viSNE is
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that low-dimensional mapping cannot represent all of the information in high
dimensional space as viSNE only captures the most dominant structures. Additionally,
plots become too crowded when more than 30,000 cells are shown.
For our purposes, viSNE was able to detect distinct changes in our populations
when examining cytokines or CD107a singly (Fig. 10), but determination of
polyfunctional populations required cumbersome mental overlap of the plots. For
example, while it is evident that IFNγ+ cells reside in the top right corner of its
corresponding cyt map, it is logical to conclude that TNFα directly overlays much of this
area. IL-2 also seemingly occupies much of the cyt map where TNFα is positive as well,
but that IL-4 but is limited in its overlap with IFNγ. While these observations support
what FlowJo-generated dotplots suggest, making conclusive arguments by mentally
overlapping multiple plots is difficult. This would be even more challenging when
comparing multiple T cell subsets or across multiple stimulation conditions. While
others have shown a cyt plots with color gradients coding for the number of cytokines
present using t-SNE within R [318], viSNE is currently unable to spatially compare
multiple cytokines in the same plot for our analysis.
FLOw Clustering without K
FLOw Clustering without K (FLOCK) is an unsupervised algorithm analysis
publically available through Immunology Database and Analysis Portal (ImmPort;
http://www.immport.org), sponsored by the NIAID, for open use by the immunology
research community. FLOCK computationally determines the number of unique
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Figure 10. viSNE-generated cyt maps. cyt maps displaying collected events in a
tyrosinase peptide stimulation (top left panel) or HCV peptide stimulation (remaining
panels) for expression of CD107a, IFNγ, TNFα, IL-2, and IL-4. Scale (blue to red)
corresponds to strength of parameter fluorescence (low to high, respectively).
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populations in high dimensional flow data using a rapid binning approach and maps
across independent samples [319]. Relying on predetermined gating of populations of
interest, it color-codes various populations within a matrix of biaxial plots. FLOCK can
calculate many useful summary statistics through cross-sample analysis to compare
differences across treatment groups, and is a model-independent approach to multiparameter analysis.
There are 5 steps in this analysis algorithm. i) Data preprocessing: Compensated
FCS files were converted to tab-delimited text files using a FlowJo export function. The
data consisted of a table of rows and columns defined by cells and measured
parameters, respectively. The columns are normalized so that the balance of each
parameter is normalized. ii) Grid-based density clustering: Data is portioned into equally
sized bins, and partitioning is applied to all dimensions in the dataset simultaneously.
Each dimension is portioned into the same number of bins, resulting in partitions of ndimensional space called hyperregions. Each hyperregion is assessed to determine the
number of events in the region. If events exceed a specific threshold, the hyperregion is
called dense. iii) Centroid generation: Hyperregions are grouped together if they are
adjacent to each other in n-dimensional space, each called a dense hyperregion group.
The centroids representing all events in each dense hyperregion group are then
determined. iv) Event assignment: After centroids are determined, each event is
assigned to its closest centroid. The centroids are updated based on the newly assigned
events, and the cluster membership is computed again with the new centroids. This

83
procedure, after a few iterations, is regarded as a modified K-means determination.
FLOCK quickly converges to a stable result during the centroid recalculation, and unique
populations are identified. The visualization module of FLOCK contains two-dimensional
dot plots with each population colored uniquely. Expression profiles of a population are
presented to indicate the approximate expression level of each marker of a population
as negative, low, or high.
Major advantages of FLOCK are that any up-front gating can be performed using
FlowJo, which is a familiar tool, and FLOCK’s ease of use. Data can be easily uploaded,
and after answering a few questions an analysis is requested with a subsequent
notification after it has been completed.
For our purposes, FLOCK was able to identify distinct populations based on
intensity of staining for each pair-wise comparison of functional parameters (Fig. 11).
For example, the red population (Pop. 1) corresponds to the third most prevalent
population consisting of IL-2 low, IFNγ negative, CD107a low, IL-17A low, TNFα negative,
IL-4 low, and IL-22 low expressing CD8+ T cells. In this way, FLOCK adds greater
resolution to individual polyfunctional populations but at the expense of graphical
clarity. To be able to track changes in polyfunctional populations across variant epitope
stimulations would require eight additional matrices per T cell subset analyzed. Overall,
the ability to visualize each population with corresponding quantitative data is a very
nice and useful aspect of FLOCK. But large-scale comparative analysis requires too many
plots for clear evaluations.
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Figure 11. Quantitative multidimensional dotplots generated in FLOCK. FLOCK analysis displays pairwise comparisons using a
matrix of dotplots to display the relationship of expression among the 7 functional parameters. Color-coded populations for various
combinations of markers are accompanied with frequency percentages and description of staining intensity. 1=negative
fluorescence; 2=low fluorescence; 3=positive fluorescence; 4=high fluorescence.
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Simplified Presentation of Incredibly Complex Evaluations
Simplified Presentation of Incredibly Complex Evaluations (SPICE) uses large
FlowJo datasets to graphically normalize data. Preprocessing of the data is performed
using both FlowJo and Pestle. After sequential gating in FlowJo, Pestle offers data
formatting and background subtraction of multivariate datasets, which are import into
SPICE for graphical and statistical analyses. While background subtraction can result in
below zero values, SPICE has a threshold approach which will minimize systematic bias
and can maximize the amount of information that can be gained from positive
measurements [320]. SPICE also offers the ability to statistically compare the
distributions for all parameters. A χ2 measurement uses a nonparametric partial
permutation (Monte Carlo simulation) to determine the differences between samples.
Visualization of data includes pie charts, bar graphs, and cool plots, a type of heat map.
The major benefits of using Pestle/SPICE are the ease of use, readily available
software and its range of simple visualization of data. A major drawback of SPICE
analysis, however, is that the data is initially manipulated in FlowJo, which means a
significant amount of subjectivity is present. Another potential drawback is the software
is currently only offered for Apple MacTM usage.For our purposes, tandem analysis in
Pestle/SPICE most clearly displayed polyfunctional phenotypes of TCR-transduced T
cells. A complete interpretation of SPICE-generated data is provided in Chapter Six.
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Hierarchical Clustering Analysis
This approach was made popular in the era of gene expression microarray data
analysis where both tissue samples and genes would be clustered to identify genes that
could distinguish between tissue subtypes. The frequencies of the 128 possible
combinations of seven parameters (generated in FlowJo) are formed into a 128xk matrix
where k is the number of different conditions to be compared (e.g. k = 7 if there are 7
different peptide conditions included). The row corresponding to the frequency of cells
with no parameters is removed, leaving a matrix of 127xk. Next, the correlation matrix
of the 127 patterns is calculated, creating a 127x127 matrix representing the similarity
of patterns across the cells under the different peptides. The correlation matrix is then
used to perform agglomerative (“bottom up”) hierarchical clustering in which patterns
that are most similar to each other (i.e. have the highest correlation) are put into one
cluster, and clusters that are similar are merged. There are many references that
provide details of the algorithm and specify the different options the user is required to
choose (i.e., similarity metric, and distance metric between clusters (called the
“linkage”), agglomerative vs. divisive clustering) to fully generate the dendrogram (i.e.,
the tree-structure) [321]. For our purposes, we used correlation as our similarity metric,
average linkage, and agglomerative clustering. Graphical representations are included
with discussion of the data in Chapter Six. A comparison of all multi-dimensional flow
cytometry data analysis strategies evaluated for T cell polyfunctionality is summarized in
Table 6.
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Table 6. Summary of approaches used to analyze antigen-specific polyfunctional T cell responses.
Software

Analysis Strategy

Advantages

Disadvantages

Popular, widely used
Limited in scope for analyzing
Basic flow cytometry software
software; output can be
>2 dimensions. Time
FlowJo package; Manual, sequential
imported into other
consuming and subjective
gating
multidimensional software
gating
tools
Accounts for population
Templates require knowledge
overlap and simple clustering of some biology of the system;
Probability state modeling;
GemStone
routines; lack of gating
TriCOMs visually hard to
template driven analysis
eliminates subjectivity and
interpret and compare ≥3
operator variability
parameters
“Spanning-tree Progression
No prior knowledge of
Represents data as clusters
Analysis of Density-Normalized hierarchical order needed;
rather than individual cells;
SPADE
Events”; unsupervised
scalable; better for mutually does not appropriately analyze
clustering extracts cellular exclusive markers and mixed if data does not lend itself to
hierarchy
lineage populations
clustering
“Self-Organizing Maps of
Similar to SPADE; while RSimilar to SPADE; difficultly
Visualizing and Interpretation based, only requires minimal detailed data to compare
FlowSOM
of Cytometry Data”; R-based
understanding of R to
across multiple treatment
clustering tool
effectively use
groups
*(P) = software for purchase; (F) = freeware; (F/P) = freeware with additional purchasable options

Graphical
Display

Available
Through:*

Histograms
and dot
plots

TreeStar (P)

TriCOMs

Verity
Software
House (P)

Spanning
trees

Cytobank
(F/P)

Minimal
spanning
trees or
grids

Bioconductor
(F)
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Table 6. Summary of approaches used to analyze antigen-specific polyfunctional T cell responses (cont’d)
Software

Analysis Strategy

Advantages

Disadvantages

Graphical
Display

Available
Through:*

Low-dimensional mapping
Nonlinear dimensionality
Unsupervised and does not
cannot represent all the
reduction algorithm based on require in depth knowledge of
information in high
Cytobank
viSNE
t-Distributed Stochastic
the system; preserves cell
dimensional space; cyt
cyt maps
(F/P)
separation and retains prior
maps require visual
Neighbor Embedding
gating information
overlay to make multi(t-SNE)
dimensional comparisons
Up-front gating relies on
Difficult to demonstrate
familiar FlowJo; delineates
“FLOw Clustering without K”;
differences between Color-coded
FLOCK
populations based intensity of
ImmPort (F)
unsupervised rapid binning
populations with very
dot plots
expression profiles; crosscomplex matrices
sample statistical analysis
Uses FlowJo generated
Hierarchical
Agglomerative “bottom up”
population frequencies; can
Subjective gating
Dendogram
Clustering
R (F)
clustering tool
show response relatability
generates bias;
/ heat map
Analysis
across treatment groups
“Simplified Presentation of
Ease of use and clear
Incredibly Complex Data”;
visualization of complex
manual gating within
Pie charts,
quantitatively compares
SPICE
datasets; offers background FlowJo affords significant bar graphs,
NIAID (F)
discrete phenotypic profiles in
subtraction and permutation
amount of subjectivity “cool plots”
a mixture; uses FlowJo output
statistical analysis
with formatting tool Pestle
*(P) = software for purchase; (F) = freeware; (F/P) = freeware with additional purchasable options
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In Vivo Xenograft Model
Prior to tumor challenge, scid/beige mice (n=5 per treatment group) were given
2Gy total body irradiation. 107 HCV NS3:1406-1415 minigene+ or HCV- HepG2 cells
were injected subcutaneously in 0.1 cc saline. Generally, palpable tumors formed
within 7 days after tumor challenge. Once palpable tumors formed, mice were
adoptively transferred 106 or 107 HCV1406 TCR-transduced T cells, 107 tyrosinasereactive TIL 1383I TCR-transduced T cells, or no T cells. Tumor volume was measured
every three days through day 70 post tumor challenge. A Wilcoxon rank sum test was
used to determine significant difference in tumor burden between treatment groups.
Circular Dichroism Spectroscopy
Thermal denaturation of peptide/MHC complexes was performed by Yuan Wang
in the Baker Lab at the University of Notre Dame as described previously [322, 323].
Briefly, proteins were dissolved in 20 mM phosphate, 75 mM NaCl, pH 7.4 at a
concentration of 10 µM. Circular dichroism (CD) spectroscopy was performed on a Jasco
J815 instrument (Jasco, Inc., Easton, MD). Temperature was increased from 10 °C to 100
°C at an increment of approximately 1 °C/min, monitoring at a wavelength of 218 nm.
Data analysis was performed in OriginPro 9.0. Because unfolding is irreversible, the
resulting derivative curve was processed with a single peak fitting algorithm to fit the
peak to a Gaussian function to determine the Tm and its standard error.
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Surface Plasmon Resonance
TCR-pMHC binding affinity between HCV1406 TCR and WT or mutant HCV
NS3:1406-1415/HLA*0201 was measured by the Baker Lab at the University of Notre
Dame via surface plasmon resonance (SPR). SPR was performed using a Biacore 3000
instrument (GE Healthcare) in 10 mM HEPES, 150 mM NaCl, 3 mM EDTA and 0.005%
surfactant P20 (pH 7.4). The TCR was covalently coupled to a CM5 sensor chip via
standard amine coupling. Equilibrium experiments were performed by injecting 70 µl of
multiple concentrations of the pMHC complex at a flow of 5 µl/min. Injected
concentrations ranged from 0.5 µM to 200 µM. The responses at equilibrium were
determined by averaging the signal over the final 10 s of the injection and subtracting
the responses from identical injections over a mock surface. Experiments were
performed at 25oC. All injections were repeated three times. Fitting was performed with
Biaevaluation 3.0.1 using a 1:1 binding model.
Modeling of TCR-pMHC Complexes
Computational modeling experiments were performed by Timothy Riley in the
Baker lab at the University of Notre Dame. TCR-pMHC structural models were
constructed using a template-based approach described recently [324].

Briefly,

sequences for the HCV1406 and HCV1073 TCRs were aligned and compared to a panel
of HLA-A2 restricted TCRs with known TCR-pMHC structures to serve as model
templates. A template TCR was selected if the TCR alignment indicated strong sequence
similarity and/or minor loop length changes. The DMF5-MART-1/HLA-A2 TCR-pMHC
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complex [325] was selected as the template for the HCV1406 complex and the B7Tax/HLA-A2 complex [326] was chosen for HCV1073. Using PyRosetta, a python toolkit
for the Rosetta protein design suite [327, 328], the given TCR sequences and peptides
were mapped onto the three-dimensional coordinates of the template TCRs and
peptides in the TCR-pMHC complexes. Repacking the amino acid sidechains and an
energetic minimization of the CDR loops/peptides generated initial models of the target
TCRs.
Further design work performed in Rosetta followed a steepest descent design
where many independent decoy structures were generated for each modeling stage.
Each model underwent one stage for low resolution docking, one stage for high
resolution docking, and multiple stages for CDR loop modeling. Using the energy
scoring function Talaris2013 [329], the lowest scoring decoys from each stage were
chosen for the next step. Following generation of an initial TCR-pMHC model, 10,000
decoys were generated with fully randomized pMHC and TCR docking orientations
coupled with a low resolution rigid body energy minimization move. Since many decoys
generated in this stage were low scoring, preference was given to structures with
docking angles similar to the template. After the low resolution docking stage, loop
randomization and modeling was performed as previously described with generation of
100 decoys for each CDR loop [330]. The first round of loop modeling was followed by
generation of 10,000 decoys with 3 Å, 8 rigid body perturbations and docked in high
resolution. The final stages consisted of sequentially modeling each modified CDR loop
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until Rosetta scores were no longer decreasing between stages. The final model of
HCV1406 required 19 stages and HCV1073 required only 12 stages due to a high
template similarity (See Appendix). Structural analysis was performed with PyMol and
Discovery Studio.
Determination of HCV1406 TCR— NS3:1406-1415/HLA-A*0201 Crystal Structure
Crystal structure determination was performed by Yuan Wang in the Baker Lab
at the University of Notre Dame. Crystals of the HCV1406 TCR—WT HCV NS3:14061415/HLA-A2 complex were grown in 13% (v/v) PEG 3350, 0.1M Sodium cacodylate, pH
6.1, 0.2M ammonia sulfate and 3% (w/v) 1,5-diaminopentane dihydrochloride at a
protein concentration of 6mg/mL at 20°C. Crystallization was performed by hanging
drop vapor diffusion. For cryoprotection, crystals were transferred into 20%
glycerol/80% mother liquor for 30s and immediately frozen in liquid nitrogen.
Diffraction data were collected at 22ID (SER-CAT) beamlines at the Advanced Photon
Source, Argonne National Laboratories, Argonne, IL. Rigid body refinement followed by
TLS refinement was performed with program Phenix [331] and Refmac5 [332].
Evaluation of models and fitting to map were performed with program COOT [333]. The
model was checked in WHATIF and MolProbity to evaluate the structure during the
refinement. Atomic positioning was verified with a simulated annealing composite OMIT
map calculated in Phenix. The structure has been deposited into Protein Data Bank (PDB
ID 4ZEZ).
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Ethics Statement
All recombinant DNA and retroviral transduction work was done under approved
Medical University of South Carolina, University of Chicago, University of Colorado
Denver, University of Notre Dame, and Loyola University of Chicago Institutional
Biosafety Committee (IBC) protocols. All applicable international, national, and/or
institutional guidelines for the care and use animals were followed. All animal studies
were conducted under approved Medical University of South Carolina (MUSC)
Institutional Animal Care and Use Committee (IACUC) protocols. The University of
Colorado Denver institutional review board (IRB) approved the study for the collection
of PBMC samples to generate HCV-reactive T cells clones, as described above. All adult
subjects were provided written informed consent. All other human materials used were
either established, de-identified tumor cell lines or PBMC purchased from commercial
sources.

CHAPTER THREE
TCR GENE-MODIFIED T CELLS CAN EFFICIENTLY TREAT ESTABLISHED HEPATITIS CASSOCIATED HEPATOCELLULAR CARCINOMA: A PROOF OF CONCEPT
Rationale
As described earlier, many groups have reported that retroviral vectors
containing TCR genes can be used to redirect the specificity of PBL-derived T cells to
recognize tumor cells [15, 34, 165, 168, 169, 259, 334, 335]. Recent clinical success with
TCR gene-modified T cells to treat malignancies such as melanoma encourages the
investigation of using this approach to treat other malignancies and viral infections [210,
211, 336]. Available technology to TCR-gene modify T cells allows for the generation of
therapeutic autologous T cells with new anti-viral and anti-tumor immunity, provided an
effective TCR against a viral/tumor antigen has been identified and target cells can be
recognized.
While the bulk of the studies in this dissertation focus on TCR cross-reactivity
against mutagenic HCV epitopes, it is both prudent and logical to first firmly characterize
basic T cell reactivity against its wildtype (WT) cognate ligand. Such fundamental
information would also be imperative when evaluating the therapeutic potential of any
TCR. In this chapter, we discuss the rationale behind the original selection of this TCR
and how its gene transfer into PBL-derived T cell facilitates recognition of HCV+ tumor
targets in vitro and in vivo, providing potential therapeutic benefit.
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As with any candidate for TCR gene therapy, there needs to be a rationale
behind both the target and receptor selection. HCV is a model target for exploring the
potential use of such adoptive transfer techniques to treat virally-infected cells and
tumor cells. HCV infects approximately 130-150 million people globally [337] and
chronic infection can lead to associated liver diseases including cirrhosis and
hepatocellular carcinoma (HCC). These diseases are a leading cause of liver
transplantation in the United States and Europe [338, 339]. Although standard
combined therapy of pegylated-IFNα and ribavirin (RBV) have had some success, there
has been much greater clinical responses when treating HCV+ patients with newly FDAapproved NS3/4A protease inhibitors boceprevir, telaprevir, and simeprevir [340-342].
Despite this recent success, the rapidly mutating HCV genome can generate drug
resistant variants, which might lead to virologic breakthrough or relapse [343-345].
Moreover, many patients who may be cured of HCV infection by these novel drugs may
have already developed associated disease or malignancies that cannot be treated
effectively by these anti-viral agents. These issues combined with hindered preventative
and therapeutic vaccine development [346, 347] warrants exploration of other novel
methods to treat HCV infection and its associated disease such as HCC.
The TCR we have selected as a candidate to treat HCV-associated HCC recognizes
HCV NS3:1406-1415, a highly antigenic and mutagenic epitope of the helicase/protease
NS3, restricted by HLA-A2, and is referred to here as HCV1406 TCR. We have previously
shown that this HCV1406 TCR was isolated from a T cell clone found in an HCV+ HLA-A2-
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patient who received an HLA-A2+ liver allograft [302] and that we can genetically
engineer Jurkat cells with HCV1406 TCR to recognize HCV+ targets [165]. In the sections
described below, we demonstrate that transduced PBL-derived T cells can recognize
naturally processed HCV NS3 protein in HCC cell lines in vitro and can inhibit the growth
of established HCV+ tumors in vivo. These results indicate that HCV1406 TCR-engineered
T cells may serve as a potential immunotherapy to treat HCV-associated HCC. Moreover,
these studies provide the basis of WT ligand reactivity and provide a foundation of
cross-reactive antigen recognition studies in subsequent chapters.
HCV1406 TCR-Transduced T Cells Can Recognize Naturally Processed HCV NS3
Although we have shown that TCR-transduced Jurkat cells can recognize HCV
NS3:1406-1415 peptide-loaded T2 cells and minigene-expressing tumor cells [165], it is
critical to establish that TCR gene-modified primary T cells can recognize both peptideloaded targets and HCV+ tumors to validate its potential use in ACT and provide a
foundation for WT antigen reactivity.
The best system to assess TCR-transduced T cell recognition of HCV antigen
would be to use HCV-infected primary liver cells or liver tumor cells, but human liver
containing HCC cells infected with HCV were not available for our experiments. As an
alternative, we engineered HepG2 cells to express HCV NS3:1406-1415 as a minigene.
Anti-CD3-activated PBL-derived T cells transduced with HCV1406 TCR for in vitro
experiments were enriched for TCR transgene expression using anti-CD34
immunomagnetic beads. The enriched populations are routinely ≥95% CD34+ post
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magnetic sort. Both CD4+ and CD8+ TCR-transduced T cell populations (CD3+CD34+) post
immunomagnetic selection are highly activated (CD25+CD69+) with low levels of
exhaustion markers PD-1 and TIM-3. Due to poor staining with available V11
antibodies, dextramer binding is shown to measure expression of the introduced TCR.
Dextramer staining also allows us to identify properly paired introduced TCR.
Representative immunofluorescence analysis for experimental HCV1406 TCRtransduced T cells is shown in Figure 12a. T cells transduced to express HCV1406 TCR
secreted large amounts of IFNγ when stimulated by HepG2 cells (HLA-A2+) either pulsed
with HCV NS3:1406-1415 peptide or expressing the HCV minigene (Fig. 12b). Similarly,
TCR-transduced T cells recognized Huh-7 cells (HLA-A2-) only when transfected to
express the HCV minigene and HLA-A2. Thus, we have shown for the first time that
HCV1406 TCR-transduced PBL-derived T cells can recognize HCV+ tumor targets.
Because HCV antigen expression as a minigene is not naturally processed for
presentation, we wanted to test HLA-A2-restricted recognition of naturally processed
and presented HCV NS3:1406-1415 derived from a larger protein (full length NS3) to
more accurately reflect physiologic conditions. COS/A2 cells were transiently
transfected with a pcDNAIII vector encoding the full length HCV protein NS3 linked to
GFP. Typical transfections yielded 40-60% GFP expression (Figure 13a). These HCV TCRtransduced T cells were capable of recognizing the naturally processed HCV NS3 in an
HLA-A2-dependent manner (Fig. 13b). Robust IFNγ secretion was observed when
stimulated with COS/A2/NS3 but not any other cell lines. Additionally, HepG2 cells
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a)

b)

Figure 12 HCV1406 TCR-transduced T cell recognition of HCV+ hepatocellular
carcinoma cells. PBL from three normal donors were transduced with the HCV1406 TCR
retroviral vector and enriched for CD34t expressing cells using anti-CD34
immunomagnetic beads. (a) Representative populations of CD34-enriched TCRtransduced T cells. TCR-transduced T cells were analyzed for HCV NS3:1406-1415
dextramer binding and markers of activation (CD25, CD69) or exhaustion (PD-1, TIM-3).
(b) HCV1406 TCR-transduced T cells from three representative normal donors (Donor A
(white bars), Donor B (black bars), Donor C (striped bars)) were co-cultured with various
stimulators. (left panel) T2 cells alone or loaded with NS3:1406-1415 peptide or control
CMVpp65 peptide; (middle panel) HepG2 cells (HLA-A2+) alone, pulsed with HCV peptide
or expressing the HCV minigene; (right panel) Huh-7 cells (HLA-A2-) alone or expressing
the HCV minigene±HLA-A2. IFNγ secretion was assessed as a single-point ELISA by Yi
Zhang (University of Chicago).
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a)

c)

b)

d)

Figure 13. HCV1406 TCR transduced T cells can recognize naturally processed HCV NS3:1406-1415 antigen. PBL from a normal
donor was transduced with the HCV1406 TCR retroviral vector and immunomagnetically enriched for CD34t expressing cells. (a) COS
and COS/A2 cells were transiently transfected with pcDNAIII expression vector harboring HCV NS3-GFP and analyzed for transfection
efficiency. (b) HepG2 cells were transduced with a retroviral vector encoding HCV NS3-GFP and were analyzed for transfection
efficiency. Transduced T cells were stimulated with T2 cells loaded with HCV NS3:1406-1415 or tyrosinase:368-376 peptides and
(c) COS±HLA-A2 cells or (d) HepG2 cells engineered to express full length HCV NS3 protein. The amount of IFNγ released (average ±
standard deviation of triplicate wells) was measured by ELISA.
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transduced to express NS3 (Fig. 13c) also stimulated substantial IFNγ secretion by
HCV1406 TCR-transduced T cells (Fig. 13d). These data indicate that HCV1406 TCR genemodified T cells can recognize naturally processed HCV NS3 antigen, meaning they may
have therapeutic potential against HCV-associated HCC.
HCV NS3:1406-1415 Recognition by HCV1406 TCR-Transduced PBL Is CD8-Indpendent
To verify CD8-independent recognition of both peptide and tumor, we purified
TCR-transduced CD4+ and CD8+ T cells from a bulk culture and stimulated each T cell
subset with peptide-loaded and HCV+ tumor targets. Figure 14 demonstrates that CD8independent recognition is conserved against peptide-loaded or HCV+ tumor targets as
both purified CD4+ and CD8+ TCR-transduced T cells secreted robust amounts of IFNγ
when stimulated by HCV-loaded T2 cells and HCV+ HepG2 cells. Moreover, our HCV TCRtransduced T cells displayed lytic behavior as measured by CD107a surface expression
against peptide-loaded targets and HCV+ HepG2 cells (Fig. 15). Counterstaining for
intracellular IFNγ also revealed that reactive T cells can be lytic, IFNγ -producing, or
both. CD4+ and CD8+ T cells also exhibited distinct heterogeneous functional
phenotypes. Therefore, we are able to generate both CD8+ and CD4+ effectors,
potentially offering MHC class I-restricted helper function against this HCV antigen in
vivo.
HCV TCR-Transduced T cells Mediate the Regression of Established HCV+ HCC In Vivo
While our in vitro data firmly demonstrates that both CD4+ and CD8+ TCRtransduced T cells can be lytic and produce IFNγ, it is necessary to validate in vivo
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Figure 14. Recognition of HCV NS3:1406-1415 by HCV1406 TCR-transduced PBLderived T cells is CD8-independent.. HCV1406 TCR-transduced PBL were
immunomagnetically purified into CD4+ (black bars) or CD8+ (white bars) populations.
Stimulators included T2 cells pulsed with 10 µg/mL of HCV NS3:1406-1415 peptide or
control tyrosinase:368-376 peptide as well as HepG2 engineered to express the HCV
NS3:1406-1415 minigene. The amount of IFNγ release (average ± standard deviation of
triplicate wells) was measured by ELISA.
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Figure 15. Lytic and IFNγ-producing ability of HCV1406 TCR transduced T cells reactive
against HCV NS3:1406-1415. T2 cells pulsed with HCV NS3:1406-1415 or
tyrosinase:368-376 and HCV+ HepG2 cells were used as targets and co-cultured with
transduced PBL. Cells were immunofluoresnce stained for CD3, CD4, CD8, CD34,
CD107a, and intracellular IFNγ. Gating and data analysis was performed in FlowJo. Pie
charts reflect reactivity of TCR-transduced (CD34+) CD4+ (left) or CD8+ (right) T cells. Pie
chart percentages are represented as CD107a+IFNγ- (lytic only=blue), CD107a+IFNγ+ (lytic
and cytokine-secreting=red), CD107a-IFNγ+ (IFNγ -producinng only=green), or CD107aIFNγ- (non-reactive=gray).
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recognition of HCV+ tumors in a xenograft mouse model to establish therapeutic
potential. We established HCC tumors in scid/beige mice (n=5 per treatment group) by
subcutaneous injection of HCV+ or HCV- HepG2 cells. Once the tumors were palpable
(day 7 post injection), transduced T cells were adoptively transferred. HCV + tumorbearing mice exhibited reduced tumor growth after adoptive transfer of 10 7 HCV TCRtransduced T cells but not when treated with tyrosinase-reactive TIL 1383I TCRtransduced T cells or a lower dose (106) of HCV TCR-transduced T cells (Fig. 16). It is
important to note that in the experiment presented HCV+ HepG2 tumors in untreated
mice grew at a slower rate after day 30 than in other HCV+ tumor-bearing mice groups.
We attribute this to experimental variation since other experiments demonstrated more
uniform HCV+ tumor growth in other treatment groups (Zhang, unpublished).
Regardless, the change in tumor burden at day 70 between HCV TCR-transduced T celltreated HCV+ and HCV- HepG2-tumor bearing mice exhibited significance with a p-value
of 0.02 as determined by Wilcoxin Rank Sum Test. In at least one instance, HCV + tumors
harvested from 107 HCV TCR-transduced T cells exhibited antigen loss, which could
explain why tumors were not completely eliminated even though displaying a
statistically significant reduction in tumor burden (Zhang, unpublished). Taken together,
these data further support the HCV+ HCC recognition capability by HCV1406 TCRtransduced T cells and the potential for HCV1406 TCR-transduced T cells to be used in
patients.
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Figure 16. HCV1406 TCR-transduced T cells inhibit the growth of established HCV+
hepatocellular carcinoma tumors in vivo. Parental HepG2 (black) or HCV+ HepG2
(white) tumors were established in scid/beige mice (n=5 per treatment group). Mice
were given no T cells (diamonds), 107 TIL 1383I TCR-transduced T cells (circles), or 106
(x’s) or 107 (squares) HCV1406 TCR-transduced T cells on day 7 post tumor challenge.
Statistically significant differences in tumor growth over 70 days was determined using
the Wilcoxon rank sum test, p=0.02. These data were generated by Yi Zhang (University
of Chicago).
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Significance
HCV1406 TCR-transduced T cells demonstrated their ability to recognize HCV
NS3:1406-1415 peptide-loaded targets as well as naturally processed antigen presented
by HCV+ HCC cells. Furthermore, in our xenograft model, HCV+ tumor-bearing mice
exhibited tumor regression after adoptive transfer of HCV1406 TCR-engineered human T
cells. These data suggest that HCV1406 TCR-transduced T cells may provide therapeutic
benefit against HCV infection and/or its associated disease, such as HCC.
Of interest is the phenotypic heterogeneity observed in TCR-transduced T cells
reactive against peptide-loaded targets and naturally processed HCV+ tumors. While
both CD4+ and CD8+ T cells are capable of recognizing these targets, they expressed IFNγ
and CD107a in different proportions. While most reactive CD4+ T cells secreted IFNγ in
response to these targets, some cells exhibited cytolytic activity as indicated by CD107a
expression. Conversely, a greater number of CD8+ T cells exhibited a lytic phenotype;
those that secreted IFNγ were more likely to simultaneously express CD107a as well.
These data support other reports that CD4+ T cells can exhibit cytolytic activity [348-351]
and provide insight into the heterogeneous behavior of T cells expressing the same TCR.
Interestingly, not all CD34+ T cells produced IFNγ or expressed CD107a. As shown in
Figure 12, there is a range of CD34 expressed on TCR-transduced T cells, and only a
subset of CD34+ TCR-transduced T cells bound dextramer (indicating properly paired
HCV1406 TCR). Perhaps, there is a minimal amount of CD34+ (TCR transgene) expression
necessary to facilitate TCR engagement with pMHC, activating a functional response.
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This could explain why not all CD34+ T cells were reactive against HCV targets.
Additionally, IFNγ-CD107a-CD34+ T cells may be producing other cytokines not evaluated
in these experiments and are not actually “non-reactive”. The influence of TCR density
on antigen recognition as well as evaluating reactivity by other cytokines is addressed in
subsequent chapters.
Taken together, we have established a proof-of-principle that we can generate
HCV1406 TCR gene-modified CD4+ and CD8+ PBL-derived T cells capable of recognizing
and inhibiting the growth of HCV+ tumor targets. They may provide a useful tool to treat
patients with HCV-associated diseases, such as HCC. While important observations for a
potential immunotherapeutic candidate, these data also lay the groundwork for
subsequent cross-reactive characterization of this TCR in light of HCV’s genomic
instability.
Several groups have reported that mutations in the HCV genome can lead to
HCV antigen escape variants [279, 352-356]. In this way, it is speculated that HCV can
evade the immune response resulting in disease progression. Although it is not clear to
what extent antigen loss actually leads to disease progression, especially in HCC, TCR
gene transfer may provide an opportunity to treat patients with HCV antigen escape
variants should a TCR exhibit cross-reactive behavior against prevalent variants. The
next chapter describes cross-reactive behavior of TCRs against mutagenic HCV antigens,
serving as a model to combat diseases of genetic instability.

CHAPTER FOUR
HEPATITIS C VIRUS-CROSS-REACTIVE TCR GENE-MODIFIED T CELLS: A MODEL FOR
IMMUNOTHERAPY AGAINST DISEASES WITH GENOMIC INSTABILITY
Rationale
As described in Chapter One, the genomic instability of cancers and viruses can
serve as a mechanism for immune escape, leading to HLA downregulation, alterations in
antigen processing, antigen loss, and antigen mutation [187, 188, 271, 288, 289].
Contributing to poor host immune responses, such mechanisms of immune escape pose
barriers for the development of preventative and therapeutic vaccines and impair the
design of effective immunotherapies. Therefore, it is important to investigate novel
treatment approaches designed to combat genomic instability.
The HCV genome contains several regions that are genetically unstable and
mutate readily [357, 358], making HCV an excellent model for genomic instability.
Immune escape variants may be potential therapeutic targets for HCV infection and its
associated disease. Despite the recent clinical success of FDA-approved protease
inhibitors [359, 360], the very genomic instability that allows for immune escape could
generate acquired resistant variants to these novel drugs [361, 362]. Therefore the use
of cross-reactive TCRs targeting mutagenic epitopes may be advantageous in this
instance.
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We chose to use HCV as our TCR cross-reactivity model for a variety of reasons.
First, we have the available reagents to assess T cell reactivity against mutant HCV
epitopes. We have previously cloned multiple high-affinity HCV-reactive TCRs capable of
transferring reactivity to both CD4+ and CD8+ PBL-derived T cells [165, 166]. Additionally,
we have selected panels of naturally occurring and epidemiologically relevant
immunogenic epitopes to assess cross-reactivity of a pair of HCV-reactive TCRs. More
importantly, HCV is epidemiologically significant with a worldwide prevalence of 3%
[337]. Strong evidence suggests that the immune system plays a key role in mediating
viral clearance [357], but that weak or ineffective immune responses can lead to chronic
infections [363-365]. A hallmark of HCV, and most relevant to this study, is its high rate
of replication coupled with the lack of proofreading ability of its polymerase [366, 367].
This genomic instability is thought to lead to immune escape variants that evade T cell
recognition [274, 276-278, 357, 358]. However, T cells’ ability to cross-recognize
mutated epitopes has been previously associated with viral control [368, 369],
suggesting TCR cross-reactivity may be advantageous for viral clearance. Additionally,
while ineffective immune responses may be partially caused by low avidity T cells [365,
370], it has been suggested that high avidity T cells can also quell HCV immune escape
by selective pressure [365]. So in diseases with genomic instability, such as HCV, it
would optimal to generate T cells with both high avidity and cross-reactivity [365].
In this chapter, we examined whether T cells harboring cross-reactive TCRs might
offer a therapeutic solution in instances of genomic instability, using HCV as a model.
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We demonstrated cross-reactivity of two TCRs against immunogenic and mutagenic
NS3:1406-1415 and NS3:1073-1081 epitopes in TCR-gene-modified T cells. Our
approach includes: (1) functional studies demonstrating cross-reactive profiles; (2)
epidemiological data supporting the relevance of mutant epitopes targeted in these
studies; (3) TCR-pMHC structural modeling to rationalize how TCR structural properties
accommodate recognition of certain mutated epitopes; and lastly, we (4) provide
preliminary clinical evidence suggesting cross-reactive TCR may facilitate HCV viral
clearance. Together, this approach serves as a model to address diseases with genomic
instability and highlights the potential benefit of cross-reactive TCRs. A better
understanding of such TCRs’ promiscuous behavior may allow for exploitation of these
properties to develop novel adoptive T cell-based therapies.
HCV1406 TCR Is Cross-Reactive Against Naturally Occurring
HCV NS3:1406-1415 Mutant Epitopes
We have previously reported on an HLA-A2-restricted, HCV NS3:1406-1415reactive TCR from an allo-specific CD8+ T cell clone isolated from an HCV+ HLA-A2+
patient who received an HLA-A2- liver allograft [302]. In Chapter Three, we described
our ability to transfer CD8-independent reactivity against HCV peptide-targets and HCV+
HCC cells to both Jurkat cells and primary T cells [165, 371]. Because this TCR lacked any
selective pressure against A2-restricted antigens during development or in the
periphery, we wanted to test any potential diversity in recognition against altered but
physiologically relevant HCV ligands. In this manner, HCV1406 TCR served as an optimal
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candidate to assess cross-reactivity against diseases of genomic instability. We identified
a variety of naturally occurring mutant epitopes with a GenBank search using the
nucleotide sequence for the WT HCV NS3:1406-1415 epitope KLVALGINAV. Results were
filtered for silent mutations and a panel of selected mutant epitopes with amino acid
substitutions varying in both position and class is listed in Table 7. HCV1406 TCRtransduced PBL-derived T cells from three representative normal healthy donors were
generated as previously described [304], and enriched for transduced cells as described
in Chapters Two and Three.
Cross-recognition of naturally occurring mutant HCV NS3:1406-1415 epitopes
was tested by stimulating bulk cultures of HCV1406 TCR-transduced T cells with T2 cells
loaded with WT or mutant NS3:1406-1415 peptides in IFNγ release assays (Fig. 17). Of
the eight naturally occurring mutants tested, seven induced robust IFNγ production by
TCR-transduced T cells similar to or greater than that of WT peptide stimulation. We
generally classify “reactive” peptides as those that elicit at least 200 pg/mL and twice
above background IFNγ levels. Only T2 cells loaded with variant V1408S/A1409G/I1412L
(subsequently referred to as 8S/9G/12L) were not recognized by a bulk culture of all
three donors T cells. Of note, Donor B exhibited substantially less IFNγ secretion across
all peptide stimulation conditions and did not recognize mutants A1409T, I1412N, and
V1408S/A1409S/I1412L/A1414S (subsequently referred to as 8S/9S/12L/14S). A peptide
titration from 1 µg/mL – 0.00001 µg/mL suggested Donor B had an overall lower
functional avidity against the WT peptide (Fig. 18). Further analysis of Donor B’s
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Table 7. HCV NS3:1406-1415 and NS3:1073-1081 mutant epitope sequences and
epidemiological frequencies.
Epitope

Sequence

Genotype

Frequency (%)*

HCV NS3:1406-1415
V1408L
A1409T
I1412L
I1412V
I1412N
8S/9G/12L
V1408T
8S/9S/12L/14S

KLVALGINAV
KLLALGINAV
KLVTLGINAV
KLVALGLNAV
KLVALGVNAV
KLVALGNNAV
KLSGLGLNAV
KLTALGINAV
KLSSLGLNSV

1a
1b
1a
1a
1a/1b
N/A†
1a/1b
1a
1b

43.46
0.31
1.31
1.63
31.7/0.31
N/A
0.65/42.81
1.63
0.31

HCV NS3:1073-1081
I1074V
I1074L
V1077A
C1078F
V1081N
T1080S
V1081A
80S/81I

CINGVCWTV
CVNGVCWTV
CLNGVCWTV
CINGACWTV
CINGVFWTV
CINGVCWTN
CINGVCWSV
CINGVCWTA
CINGVCWSI

1a/1b
1a/1b
1b
1a
1a
N/A
1a
1a
1a

90.2/41.59
1.31/45.57
0.61
0.98
0.33
N/A
0.33
0.33
0.98

YMDGTMSQV
Tyrosinase:368-376
N/A
N/A
*Frequencies based on the 918 collected HCV genome sequences in the Los Alamos HCV
Sequence Database (http://hcv.lanl.gov/content/index). †N/A: Epitope not found in
database.

112

Figure 17. HCV1406 TCR-transduced PBL are cross-reactive against naturally occurring
HCV NS3:1406-1415 variants. HCV1406 TCR-transduced PBL from three representative
donors (A, black bars; B white bars; C gray bars) were co-cultured with T2 cells pulsed
with 10 µg/mL of WT or mutant HCV NS3:1406-1415 peptides or tyrosinase:368-376 as a
control. IFNγ secretion was measured by ELISA. Mean and standard deviation of
triplicate measurements are shown. All variants that qualified as reactive in the text
secreted at least 200 pg/mL IFNγ and twice above background. These data were
generated by Gretchen Lyons in the Nishimura Lab (University of Chicago).
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Figure 18. Relative avidity of HCV1406 donors A and B against WT HCV NS3:1406-1415.
HCV1406 TCR-transduced PBL were co-cultured with peptide-loaded T2 cells in
concentrations ranging from 1 - 0.00001 µg/mL. IFNγ secretion was measured by ELISA.
Mean and standard deviation of triplicate measurements are shown. Relative avidity
curves and estimated EC50 values of Donors A (solid, black triangles) B (dashed, white
circles), and C (dotted, gray diamonds) are shown. These data were generated by
Gretchen Lyons in the Nishimura Lab (University of Notre Dame).
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transduced T cells revealed 87% CD4+ with only 10% CD8+ T cells. Comparatively, Donors
A and C had much higher levels of CD8+ T cells compared to CD4+ T cells at 32% CD4+ /
61% CD8+ and 14% CD4+ / 72% CD8+, respectively (data not shown). Together, these
observations suggest that some mutant epitopes may require CD8 to be recognized,
even though we have previously shown recognition of the WT antigen is CD8independent.
Some but Not All NS3:1406-1415 Mutant Epitopes Require the CD8 Co-Receptor
The data described above suggest that T cells may require CD8 to crossrecognize some but not all HCV NS3:1406-1415 epitopes. To test this hypothesis, we
evaluated the cross-reactivity of HCV1406 TCR-transduced Jurkat cells (natively CD8[165, 305]) or Jurkat cells we engineered to express the α and β genes of CD8.
Transduced cells were stimulated with peptide-loaded T2 cells, and subsequent IL-2
release was measured by ELISA (Fig. 19). Transduced CD8- Jurkat cells recognized WT
NS3:1406-1415 and mutants V1408L, and I1412V with similar or greater IL-2 secretion
than CD8+ Jurkat cells. Interestingly, recognition of I1412L and V1408T was also CD8independent but CD8- Jurkat cells released only 25-50% as much IL-2 compared to CD8+
Jurkat cells. In contrast, IL-2 production after stimulation with T2 cells loaded with
mutants A1409T, I1412N, 8S/9S/12L/14S was restricted to CD8+ Jurkat cells. These
observations suggest that certain amino acid substitutions may lower the affinity of the
TCR-pMHC interaction enough to require stabilization by CD8 to facilitate recognition.
These data are supportive of transduced PBL cross-reactivity shown in Figure 18 where
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Figure 19. Recognition of some but not all mutant HCV NS3:1406-1415 peptides
require the CD8 co-receptor. Peptide-loaded T2 cells were co-cultured with HCV1406transduced Jurkat cells (CD8 negative, black bars; CD8 positive, white bars). IL-2
secretion was measured by ELISA. Mean and standard deviation of triplicate
measurements are shown. All variants that qualified as reactive in the text secreted at
least 200 pg/mL IL-2 and twice above background.
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Donor B (with only 10% CD8+ T cells) was very weakly/non-reactive against these same
three mutant peptides. Although Donor B still contains a low frequency a CD8 + T cells, it
may require a greater number to achieve detectable levels of secreted IFNγ above
background and comparable to that of other more strongly recognized variants.
Additionally, peptide titration experiments down to 0.0001 µg/mL demonstrated that
different mutations had differential impacts of functional avidity, but that avidity was
enhanced by presence of CD8 (Fig. 20). Yet, even at low levels of antigen (1-10 nM)
Jurkat cells were responsive to multiple antigens, which may be important for
maintaining enough cross-reactive immune pressure to help prevent immune escape.
It is important to consider that amino acid substitutions could disrupt peptide–
MHC binding, destabilizing the overall protein complex, which could alter antigen
recognition [372]. We determined that a lack of or weaker peptide binding to MHC
cannot account for an absent an attenuated response of any of the NS3:1406-1415
variants because all epitopes bound similarly to HLA-A2 as measured by their thermal
stability via CD spectroscopy (Table 8). Together, these data suggest that the HCV1406
TCR is cross-reactive against a variety of naturally occurring HCV NS3:1406-1415
variants, but some mutations require CD8 for recognition and/or maximum cytokine
response.
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Figure 20. Influence of the CD8 co-receptor on the functional avidity of HCV1406 TCRtransduced Jurkat cells against naturally occurring mutant HCV NS3:1406-1415
variants. HCV1406 TCR-transduced Jurkat cells were co-cultured with peptide-loaded T2
cells in concentrations ranging from 1 - 0.0001 µg/mL. IL-2 secretion was measured by
ELISA. Relative avidity curves values of CD8+ (solid, triangles) CD8- (dashed, squares)
Jurkat cells are shown. These data were generated by Gretchen Lyons in the Nishimura
Lab (University of Notre Dame).
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Table 8. The apparent Tm values of HCV NS3:1406-1415/HLA-A2 variants as measured
by circular dichroism spectroscopy.
Epitope

Tm (oC)*

WT
64. 9±0.1
V1408L
60.7±0.3
A1409T
64.6±0.1
I1412L
58.1±0.3
I1412V
58.4±0.3
I1412N
59.3±0.1
8S/9G/12L
62.0±0.1
V1408T
69.2±0.2
*Average of three independent experiments ± standard error. These measurements
were kindly provided by Yuan Wang in the Baker Lab (University of Notre Dame).
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Cross-Reactivity against Naturally Occurring Mutant
HCV Epitopes Is Not Limited to HCV1406 TCR
While we have clear evidence that the HCV1406 TCR demonstrates crossreactivity against mutant epitopes, it is possible that this is because this TCR is HLA-A2
restricted but was identified in an HLA-A2- host, and by definition cross-reactive [302].
To better generalize the phenomenon of TCR cross-reactivity, we assessed the crossreactivity of a second TCR reactive against a second immunodominant HCV epitope
NS3:1073-1081. This HLA-A2-restricted TCR was isolated from an HLA-A2+ host with
chronic HCV infection. We previously showed T cells transduced with the HCV1073 TCR
recognized both peptide-loaded targets and human HCC cells expressing the WT antigen
[166]. HCV1073 TCR is not allo-restricted, and thus, a complementary TCR used to
characterize cross-reactivity.
A panel of naturally occurring HCV NS3:1073-1081 mutant epitopes was
identified in the same manner described above (Table 7) and used to established crossreactivity of HCV1073 TCR-gene modified T cells. Remarkably, a strong cross-reactive
profile was seen in primary T cells from three healthy donors engineered to express the
HCV1073 TCR (Fig. 21). T2 cells loaded with utant peptides I1074V, I1074L, T1080S, and
T1080S/V1081I (subsequently referred to as 80S/81I) stimulated robust IFNγ release by
HCV1073 TCR-transduced T cells. Interestingly, mutant V1081A stimulated weak
cytokine release (just over our threshold of 200 pg/mL and twice background) in all
three donors, and V1081N was weakly reactive in two out of three donors. Mutant
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Figure 21. HCV1073 TCR is also cross-reactive against naturally occurring HCV
NS3:1073-1081 mutants. HCV1073 TCR-transduced PBL of three representative donors
(Donor D, black bars; Donor E, white bars; Donor F, gray bars) were co-cultured with T2
cells loaded with 10 µg/mL WT or mutant HCV NS3:1073-1081 peptides or
tyrosinase:368-376 peptide as a control. IFNγ secretion was measured by ELISA. Mean
and standard deviation of triplicate measurements are shown. Mean and standard
deviation of triplicate measurements are shown. All variants that qualified as reactive in
the text secreted at least 200 pg/mL IFNγ and twice above background.
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epitope C1078F, however, only stimulated very weak IFNγ release in one donor, and
mutant peptide V1077A was not recognized by any donors. In summary, we have
identified an additional HCV-reactive TCR isolated from a second host exhibiting broad
cross-reactivity against naturally occurring mutants of a second immunodominant HCV
epitope.
HCV NS3:1073-1081 Naturally Occurring Mutants Are Less CD8-Dependent
To test CD8-dependent recognition of mutant HCV NS3:1073-1081 peptides, we
engineered CD8- and CD8+ Jurkat cells with the HCV1073 TCR and stimulated them with
peptide-loaded T2 cells (Fig. 22). Both CD8- and CD8+ HCV1073 TCR-transduced cells
secreted similar or greater amounts of IL-2 to some but not all mutant peptides
compared to WT. CD8- Jurkat cells secreted substantial amounts of IL-2 against mutant
peptides I1074V, I1074L, V1070S, 80S/81I, and to a lesser extent mutant V1081A. This
suggests that the HCV1073 TCR may exhibit flexibility to accommodate changes in some
peptides without needing CD8 to stabilize the TCR-pMHC interaction. Interestingly, coexpression of CD8 does not seem to greatly enhance the reactive potential against these
five mutant epitopes. Additionally, CD8+ TCR-transduced Jurkat cells were also weakly
reactive against V1081N, suggesting that this peptide modification requires either CD8driven affinity-enhancement or augmented signaling to be recognized. In summary, we
have shown that HCV1073 TCR can facilitate CD8-independent recognition of multiple
naturally occurring mutant HCV NS3:1073-1081 mutant epitopes.
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Figure 22. HCV NS3:1073-1081 naturally occurring mutants are less CD8-dependent.
CD8- (black bars) or CD8+ (white bars) HCV1073 TCR-transduced Jurkat76 cells were cocultured overnight with peptide-loaded T2 cells. The average and standard deviation of
triplicate measurements of IL-2 release by ELISA is shown. All variants that qualified as
reactive in the text secreted at least 200 pg/mL IL-2 and twice above background.
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HCV NS3:1406-1415 and NS3:1073-1081 Mutant Epitopes
Are Epidemiologically Relevant
We know that the mutant HCV NS3:1406-1416 and NS3:1073-1081 epitopes
studied here are naturally occurring because they were identified in the GenBank.
However, our cross-reactive TCRs would only be clinically advantageous if the mutant
epitopes recognized were highly prevalent in infected individuals. To evaluate the
prevalence of these mutations, we searched the Los Alamos HCV Sequence Database,
which contains 918 HCV genome sequences recorded worldwide in a variety of known
viral genotypes. Using the QuickAlign search tool, we examined the database for
epitope frequency of both NS3:1406-1415 and NS3:1073-1081 using KLVALGINAV or
CINGVCWTV, respectively, as the reference peptide sequence. Frequencies of recorded
altered sequences were generated and sorted by known HCV genotype. Table 7
illustrates the predominant frequency and genotype(s) of these naturally occurring
mutant immunodominant epitopes.
In the United States, HCV genotypes 1a and 1b make up greater than 75% of
prevalent infections and the most common genotypes worldwide [373]. Interestingly,
for the NS3:1406-1415 epitope, the WT sequence KLVALGINAV makes up only 43.46% or
genotype 1a frequencies in this database, and mutant I1412V makes up an additional
31.7% of recorded genome sequences ranking as the second most common recorded
epitope sequence. Of note, both of these epitopes are recognized independently of CD8
expression, allowing for both CD4+ and CD8+ transduced T cells to recognize these
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HCV+ targets. While the nine total epitope sequences studied here account for 42.38%
of all recorded sequences in the Los Alamos HCV Sequence Database, they comprise
80.38% of the recorded genotype 1a sequences. Inclusion of these mutant epitopes
recognized by this TCR nearly doubles the amount of recorded sequences recognized by
CD8+ effectors from only 43.46%, representative of only the WT epitope. This suggests
HCV1406 TCR could provide enhanced coverage against observed HCV NS3:1406-1415
variants most applicable to the United States. However, this TCR does not recognize
variant 8S/9G/12L, which is the dominant epitope of genotype 1b at 42.81%, suggesting
the HCV1406 TCR may not be as effective in genotype 1b-infected individuals.
Comparing HCV1073 TCR cross-reactivity with epidemiological frequencies also
suggests that a second cross-reactive TCR may have clinical benefit. While genotype 1a
HCV NS3:1073-1081 epitope is well conserved with 90.2% of the recorded genomes
have the WT CINGVCWTV sequence, genotype 1b is dominated by the I1074V mutant
(45.57%); WT comprises only 41.59% of recorded sequences. In total, the various
epitope sequences studied here account for 64.28% of total sequences in the database,
but they provide coverage of 94.46% and 89.3% of genotypes 1a and 1b, respectively
(most relevant to the United States’ and Europe’s viral prevalence [373]). The ability for
HCV1073 TCR to mediate CD8-independent recognition includes upwards of 90% of the
recorded epitope sequences in both genotypes 1a and 1b instead of being limited to
41.59% of recorded cases in genotype 1b. Thus, our HCV model suggests there could be
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clinical benefit in using cross-reactive TCRs if mutant epitopes in the TCR recognition
patterns are highly prevalent.
Computational Modeling of TCR-pMHC Structures
Rationalizes Biological Outcomes
To generate structural hypotheses for the cross-reactivity of the HCV1073 and
HCV1406 TCRs, we generated models of the two TCR-pMHC complexes using a
template-based approach that combines loop and peptide modeling with low and high
resolution docking procedures. We previously demonstrated this modeling procedure
can reliably reproduce key structural features such as interface contacts and TCR
docking modes [324]. After identifying appropriate template structures, the TCRs and
peptides were computationally morphed and several rounds of structural and energetic
refinement were applied. The TCR-pMHC complexes were subsequently subjected to
multiple rounds of fully randomized low resolution docking, high resolution interface
refinement, and restrained high resolution docking (See Appendix). Both TCRs are
predicted to engage with binding modes typical for class I-restricted TCRs [374] (Fig.
23a). In the model of the HCV1406 TCR-pMHC complex, the NS3:1406-1415 peptide is
predicted to adopt a conformation similar to that in the known pMHC crystal structure
(Protein Databank (PDB) identification 3MRM) (Fig. 23b). Detailed interpretation of
structure-based assessment of each TCR’s cross-reactivity is described below.
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Figure 23. Computational models of the HCV1406 and HCV1073 TCR-pMHC complexes
rationalize receptor cross-reactivity. (a) Overview of the modeled complexes, showing
the traditional TCR binding mode. (b) The conformation of the peptide in the model of
the HCV1406 complex (grey) is predicted to be very similar to the conformation seen in
the unligated peptide/HLA-A2 complex (green). (c) V1408 of the NS3:1406-1415 peptide
occupies a large space near the HLA-A2 α1 helix, with no contacts predicted from the
TCR. (d) A1409 of NS3:1406-1415 is predicted to interact with Y31 of CDR1α. (e) I1412
of NS3:1406-1415 is predicted to interact with Y50 of CDR2α, as well as H70 of the HLAA2 α1 helix. (f) I1074 and V1081 of the NS3:1073-1081 peptide occupy the P2 and P9
pockets of HLA-A2 as expected. C1078 is predicted to face downward towards the base
of the peptide binding groove. T1080 is predicted to be fully exposed, with no contacts
to the TCR. (g) V1077 of NS3:1073-1081 is predicted to interact with L94 of CDR3α as
well as W1079 of the peptide. These data were kindly provided by Timothy Riley in the
Baker Lab (University of Notre Dame).
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Structure-Based Assessment of HCV1406 Cross-Reactivity
In the model of the HCV1406 TCR-pMHC complex, the NS3:1406-1415 peptide is
predicted to adopt a conformation very similar to that in the known pMHC crystal
structure (PDB 3MRM) (Fig. 23b). The side chain of V1408 is directed down towards the
base of the HLA-A2 1 helix, in a loosely-packed region with sufficient space to
accommodate other side chains (Fig. 23c). There are no TCR atoms in proximity to
contact the WT valine or a mutant leucine, serine, or threonine. The region is solvent
exposed, ensuring a serine or threonine would be able to satisfy hydrogen bonding
requirements. The model is thus consistent with the observation that the V1408L and
V1408T mutant peptides are recognized as equally well as the wild type epitope. In
contrast to V1408, A1409 is directed towards the TCR, contacting Y31 of CDR1 (Fig.
23d). Substitution with a threonine would require TCR and/or peptide rearrangements
to resolve atomic clashes and satisfy the threonine hydrogen bonding needs. This would
likely weaken TCR binding and could account for the weaker potency and loss of CD8
independence seen with the A1409T mutant peptide.
The side chain of I1412 of NS3:1406-1415 is directed towards the HLA-A2 1
helix, but interacts with Y50 of CDR2 as well as H70 of HLA-A2 (Fig. 23e). Substitution
with leucine would be predicted to retain these interactions, accounting for the high
level of reactivity with the I1412L peptide. The I1412V peptide, however, would lose
interactions with HLA-A2, likely resulting in weaker peptide binding and/or peptide
conformational changes. Some combination of either of these could account for the
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weaker potency of the I1421V peptide. Substitution with asparagine would require
more drastic structural alterations, accounting for the even weaker potency of the
I1412N mutant peptide.
For the NS3:1406-1415 V1408S/A1409G/I1412L triple mutant, as V1408S and
I1412L should be well-tolerated, the loss of activity may be attributable to the loss of
interactions Y31 stemming from the A1409G mutation (Fig. 23d). Additionally,
substitution of A1409 with glycine may render the peptide more dynamic, further
reducing TCR binding by raising the entropic penalty for binding [375]. The latter
explanation may explain the weakened but not eliminated potency of variant
8S/9S/12L/14S. Mutants V1048S, I1412L, and A1414S should all be tolerated as
described above. On the other hand, substitution of A1409 to serine rather than glycine
would be expected to impact interactions with Y31, but still retain peptide rigidity. A
summary of these structural interpretations of functional responses is listed in Table 9.
Structure-Based Assessment of HCV1073 Cross-Reactivity
The model of the HCV1073 complex provides for similar structural
interpretations as with the HCV1406 complex. The side chain of the P2 I1074 of the
NS3:1073-1081 peptide is predicted to occupy the HLA-A2 P2 pocket as is typical for a
peptide bound to HLA-A2 [376, 377], with sufficient room for a valine and leucine (Fig.
23f). Although some effect on peptide binding affinity is anticipated, the lack of any TCR
contacts to this position coupled with the relatively conserved mutations can explain the
strong activity of the I1074V and I1074L mutant peptides. A similar interpretation is
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Table 9. Summary of predicted structural consequences of the HCV NS3:1406-1415 and NS3:1073-1081 mutations.
Epitope
HCV NS3:1406-1415
V1408L
V1408T
A1409T
I1412L
I1412V
I1412N
8S/9G/12L
8S/9S/12L/14S

Structural Interpretation

Figure

Potency
–CD8

Potency
+CD8

No changes in TCR/MHC/peptide contacts
No changes in TCR/MHC/peptide contacts
Altered TCR contacts, rearrangements needed for
hydrogen bonding
No changes in TCR/MHC/peptide contacts
Loss of MHC contacts, altered peptide conformation
Loss of MHC contacts and introduction of polar group requiring
changes in peptide conformation
Loss in TCR contacts, greater peptide dynamics from
introduction of glycine
Loss in TCR contacts

23C
23C

++
++

++
++

23D

-

+

23E
23E

++
+

++
+

23E

-

+

23C-E

-

-

23C-E

-

+

23F
23F
23G
23F
23F
23F
23F
23F

++
++
++
+
++

++
++
+
++
+
++

HCV NS3:1073-1081
I1074V
Conservative P2 anchor substitution
I1074L
Conservative P2 anchor substitution
V1077A
Loss of and alteration in TCR contacts
C1078F
Altered MHC contacts and peptide conformation
V1081N
Substantially weaker peptide binding from inappropriate P9 anchor
T1080S
No changes in TCR/MHC/peptide contacts
V1081A
Weaker peptide binding from P9 anchor substitution
80S/81I
No change in TCR/MHC/peptide contacts
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possible for mutant V1081A, as the valine at P9 occupies the HLA-A2 PΩ pocket (Fig.
23f). Substitution of an alanine here is likely to have a greater effect on peptide binding,
explaining the reduced activity of the V1081A mutant.
The model shows the P6 cysteine of the NS3:1073-1081 peptide vectored down
towards the base of the HLA-A2 binding groove (Fig. 23f), as commonly seen with
peptides bound to class I MHC proteins [377]. Substitution to a bulky amino acid such as
phenylalanine is likely to substantially alter peptide conformation and likely weaken
peptide binding to HLA-A2, explaining the loss of activity of the C1078F peptide. The P8
threonine is predicted to be fully exposed (Fig. 23f), with no interactions with the TCR,
and hence a serine substitution here is expected to be well tolerated, explaining the full
potency of the conservative T1080S mutant. Similar explanations hold for the fully
active T1080S/V1081I double mutant.
The model shows the P5 valine of NS3:1073-1081 pointing directly up into the
TCR-pMHC interface, packing against L94 of CDR3 (Fig. 23g). This valine also packs
against the P7 tryptophan of the peptide, which interacts with multiple residues of the
TCR  chain. In addition to removing interactions with CDR3, replacement of the valine
with alanine could have knock-on effects on the position of the tryptophan, further
impacting TCR interactions with the peptide. A combination of these
effects may explain the loss of activity seen with mutant V1077A. A summary of these
structural interpretations is also reported in Table 9. Together, we can begin to
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rationalize how various amino acid substitutions can alter functional responses by
HCV1406 TCR- and HCV1073 TCR-transduced T cells.
HCV Cross-Reactive TCRs May Be Clinically Advantageous
to Help Prevent Chronic Infection
It has been suggested that a major cause of chronic HCV infection is the ability of
the virus to escape immune surveillance with a rapidly mutating genome [279, 352-356].
Therefore, it would be logical to predict that infected individuals with more crossreactive TCRs might facilitate clearance of HCV infection or prevent chronic infection
better than those with a more restricted repertoire of HCV-reactive TCRs. Such an
observation would also support the claim that cross-reactive TCRs may be
therapeutically beneficial in diseases exhibiting genomic instability. A very preliminary
set of experiments to detect any such clinical evidence of this theory examined
recognition capability of T cells isolated from chronically infected patients and from
those who spontaneously resolved infection. After raising HCV NS3:1406-1415 tetramer
positive T cell clones from both types of patients, reactivity of multiple clones was
tested against an alanine scanner set of the HCV NS3:1406-1415 peptide and a variety of
naturally occurring mutants. Based on a limited number clones evaluated, T cells
isolated from chronically infected patients tended to have a similar and limited crossreactive profile. Conversely, representative clones isolated from patients who
spontaneously resolved infection tended to have a much more varied and diverse
response against both alanine-substituted peptides and naturally occurring mutant
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epitopes. Reactivity profiles from two representative clones of each patient cohort are
shown in Figure 24. While not an exhaustive characterization or a conclusive study,
these observations support the hypothesis that cross-reactive TCRs may have play a
beneficial role in combating HCV and other diseases with genomic instability.
Significance
Immune evasion by viruses and cancer cells has been a critical barrier to
mounting effective host immune responses and has been problematic for the
development of successful immunotherapies including ACT. A combination of
viral/cancer genomic instability and immense selective pressure by successful immune
effectors can lead to these escape variants. Finding a way to harness the immune
system’s ability to selectively eliminate its targets while maintaining flexibility to combat
genomic instability, a driving force behind immune escape, is the ultimate therapeutic
goal for these diseases.
Overall, in our HCV model for genomic instability, we have characterized CD8independent recognition of multiple naturally occurring mutant epitopes for two HCVcross-reactive TCRs. The reported prevalence of mutant epitopes adds clinical relevance
to potential therapeutic use of either or both of these receptors in ACT. Furthermore,
preliminary experiments testing cross-reactivity of T cell clones raised from chronically
infected versus spontaneously resolved patients support the hypothesis that HCV-crossreactive TCRs could have an impact on clearance of HCV infection or its associated
disease. Our structural modeling also provides a context for altered T cell responses. An
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Figure 24. T cell clones raised from patients with spontaneously resolved HCV infection have a more diverse cross-reactivity than
those isolated from chronically infected HCV patients. HLA-A2*01/HCV NS3:1406-1415 tetramer positive T cell clones raised from
(a) chronically HCV-infected patients or (b) patients who spontaneously resolved HCV infection were co-cultured with T2 cells pulsed
with 10 µg/mL of WT HCV NS3:1406-1415 peptide (white bars), HCV NS3:1406-1415 peptides with alanine substitutions at positions
1 through 10 (black bars; left panels), a variety of naturally occurring mutant epitopes (black bars; right panels) or tyrosinase:368376 peptide as a control. Two representative clones from each cohort are shown. IFNγ secretion was measured by ELISA. Peptides:
1-V1408L, 2-V1408T, 3-A1409T, 4-A1409V, 5-I1412L, 6-I1412V, 7-8S/9G/12L, 8-8S/9S/12L, 9-8S/9S/12L/14S. These data were kindly
provided by the Rosen Lab (University of Colorado Denver).
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improved structural understanding of how amino acid substitutions impact the pMHC
topography and subsequently T cell function will be helpful. Nonetheless, our approach
serves as an important model for identifying and designing cross-reactive TCR-based
immunotherapies for diseases with genomic instability, including HCV. Studies aimed to
address what kinetic, biological, and structural factors influence antigen recognition,
TCR cross-reactivity, and T cell function are addressed in the following chapters.

CHAPTER FIVE
ASSESSING THE IMPORTANCE OF TCR-pMHC AFFINITY ON
ANTIGEN RECOGNITION BY HCV1406 TCR GENE-MODIFIED T CELLS
Rationale
In Chapter Four, we discussed how two TCRs exhibited cross-reactivity against
naturally occurring mutant HCV epitopes and how TCR cross-reactivity may be
advantageous for treating diseases with genomic instability. Additionally, structural
modeling of the TCR-pMHC interface helped rationalize altered antigen recognition (or
lack thereof). But modeling does not identify the mechanism(s) responsible for the
changes in the pMHC ligand that might alter T cell function. Although speculation
revolves around which parameters best explain a productive or non-productive TCRpMHC interaction, TCR-pMHC affinity is generally thought to play the most central role
[1].
A better understanding of how a TCR engages with the pMHC complex and how
that interaction activates a T cell could help manipulate TCR gene-modified T cells to
enhance therapeutic efficacy and limit off-target toxicities. Our HCV model allows us to
evaluate antigen recognition of a single TCR against a series of naturally occurring
mutant epitopes with varied TCR-pMHC affinities. In this chapter, we begin our
investigation into which parameters influence antigen recognition by comparing altered
TCR-pMHC binding affinities with functional responses. We also address how other
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factors, including the CD8 co-receptor, pMHC ligand density, and TCR density affect
recognition of altered pMHC ligands and TCR cross-reactivity.
We have chosen to focus the remainder of these structure-function studies on
the HCV1406 TCR. Structure-function studies using the HCV1073 TCR would not be
feasible because the HCV NS3:1073-1081 epitope contains two cysteine residues
(CINGVCWTV). This peptide and its mutants have the propensity for oxidization and
forming disulfide bridges. These properties make NS3:1073-1081 peptides extremely
challenging to generate reliable peptide-MHC and TCR-pMHC binding measurements
and would be troublesome for additional kinetic or structural evaluations. For these
reasons, the remaining kinetic, functional, and structural studies will focus on HCV1406
TCR.
TCR-pMHC Affinity Trends with but
Does Not Completely Dictate Antigen Recognition
Most investigators in the field believe that the critical feature of a TCR-pMHC
interaction is its affinity [1]. Our model using WT and naturally occurring mutant HCV
NS3:1406-1415 peptides enables us to examine how TCR-pMHC interactions with
varying affinities impact T cell function. By surface plasmon resonance (SPR), we
measured the equilibrium KD of HCV1406 TCR with all NS3:1406-1415 pMHC except
8S/9S/12L/14S—HLA-A2 (Table 10). We determined that HCV1406 TCR bound WT HCV
NS3:1406-1415/HLA-A2 at the highest affinity of all pMHC with an average of 16.8 μM.
Although functionally a high affinity TCR exhibiting CD8-independent target recognition,
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Table 10. TCR-pMHC binding affinities for HCV1406 TCR—HCV NS3:1406-1415/HLA-A2
variants as measured by surface plasmon resonance.
Epitope

KD (µM)*

WT
16.8±0.3
†
I1412L
32.4±0.7
†
V1408T
45.9±0.6
V1408L†
60.1±5.2
†
I1412V
63.4±3.0
‡
A1409T
119.7±9.2
‡
I1412N
168.0±17.6
8S/9G/12L‡
169.3±23.4
*average KD of three independent experiments ± standard error. These measurements
were kindly provided by Yuan Wang in the Baker Lab (University of Notre Dame).
†
“moderate affinity”
‡
“lower affinity”
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the affinity measurement of HCV1406 TCR-WT pMHC interaction falls short of a
traditional high affinity KD. Traditional high affinity interactions are classified in the nM
or <10 µM range and low affinity TCRs are generally >300 µM; but we are arbitrarily
categorizing the remaining TCR-pMHC interactions as “moderate” and “lower” as a
point of comparison to WT. TCR-pMHC interactions containing variants I1412L (32.4
μM), V1408T (45.9 μM), V1408L (60.1 μM), and I1412V (63.4 μM) exhibited relatively
similar measurable affinities (within a two-fold range). We categorized these variants in
a “moderate affinity” range compared to WT. TCR-pMHC interactions containing
variants A1409T, I1412N, and 8S/9G/12L were approximately one log fold higher KD than
the WT peptide, measuring in a similar range we called “lower affinities”: 120 μM, 168
μM, and 169 μM, respectively. Although the TCR- 8S/9S/12L/14S–MHC interaction could
not be measured by SPR, its amino acid substitutions would predict it to fall into the
“lower affinity” range. Taken together, we have established multiple ranges of
measurable affinities (comprised of various amino acid substitutions) to compare the
influence of TCR-pMHC affinity on T cell function.
We discussed in Chapter Four that recognition of some but not all mutant HCV
NS3:1406-1415 peptides required the CD8 co-receptor. Thus, we wanted to evaluate
whether changes in TCR-pMHC affinity correlate with CD8-dependence. Figure 25
demonstrates WT and variant HCV NS3:1406-1415 peptide recognition of PBL-derived
HCV1406 TCR-transduced CD4+ and CD8+ T cells ranked by affinity (decreasing left to
right). Recall, we normally define “reactive” T cells as producing >200 pg/mL IFNγ and at
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Figure 25. Reorganization of cross-reactivity by decreasing affinity reveals an inverse
trend. PBL from a normal donor were transduced with the HCV1406 TCR retroviral
vector. TCR-transduced cells were enriched using anti-CD34 immunomagnetic beads
and subsequently isolated into CD4+ and CD8+ populations. T cells were co-cultured with
T2 cells pulsed with 10 µg/mL of WT or mutant HCV NS3:1406-1415 peptides or
tyrosinase:368-376 as a control. IFNγ secretion was measured by ELISA. Mean and
standard deviation of triplicate measurements are shown. All variants that qualified as
reactive in the text secreted at least 200 pg/mL IFNγ and twice above background and at
least >5% of WT cytokine release. Affinities of TCR-pMHC interactions are shown in red.

140
least twice above background (tyrosinase stimulation). However, in the case of HCV1406
where TCR-transduced T cells and Jurkat cells can secrete cytokine > 40,000 ng/mL,
reactive ligands must also exceed 5% of WT cytokine response. Interestingly, the IFNγ
secretion patterns are distinctly different between CD4+ and CD8+ TCR-transduced T
cells. Both CD4+ and CD8+ TCR-transduced T cells were reactive against T2 cells loaded
with WT (17 μM) and the four variant ligands that fall into our “moderate affinity” range
(32-63 μM). CD8+ T cells routinely exhibited comparable averages of IFNγ secretion
against all five of these peptides. This suggests there may be an upper limit at which a
higher affinity no longer augments cytokine secretion. While CD4+ T cells responded
with similar magnitudes of IFNγ secretion against WT, I1412L, and V1408L, they
reproducibly secreted up to 50% less IFNγ against V1408T, and I1412L. This is surprising
because decreased function is not consistent with decreased affinity.
However, none of the “lower affinity” pMHC variants (A1409T, I1412N,
8S/9G/12L, and 8S/9S/12L/14S) were recognized by CD4+ T cells, suggesting that a
threshold for CD8-independece exists somewhere between 63 and 120 μM. However,
variant 8S/9G/12L was not recognized by either CD4+ or CD8+ T cells, despite having
virtually identical TCR-pMHC affinity as CD8-dependent mutant I1412N (169 μM
compared to 168 μM). While we observed antigen recognition trends with affinity,
these data do not support TCR-pMHC affinity as the defining characteristic dictating
antigen recognition. With that in mind, it is prudent to explore other potential factors
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including co-receptors, antigen density, or TCR density that may contribute to T cell
recognition of altered peptide ligands.
CD8-Dependent TCR Cross-Reactivity Relies on the Recruitment of Lck
Although we observed a relationship between CD8-dependence and TCR-pMHC
affinity, it was uncertain how CD8 was actually permitting or enhancing functional
recognition of some mutant peptides. One way the CD8 co-receptor facilitates antigen
recognition is through stabilization of the TCR-pMHC complex, thus enhancing the
affinity of the TCR-pMHC interaction [378]. TCR-pMHC stabilization by CD8 helps justify
differences in the recognition of mutant peptides between HCV1406 TCR-transduced
CD4+ and CD8+ T cells (segregated by “moderate” and “lower” affinities). However, CD8
can also bind the src kinase, lck [379]. Recruitment of lck to the TCR/CD3 complex helps
facilitate the initiation of the TCR signaling cascade [26]. It has previously been
suggested that a T cell’s sensitivity to antigen stimulation can be more dependent on
the signaling capacity of CD8 rather than its affinity-enhancement, especially among
high affinity TCRs [305]. To determine the influence of affinity-enhancement versus
signaling augmentation by CD8 on TCR cross-reactivity, we engineered Jurkat cells
(natively CD8-) to express full length CD8αβ, or a truncated form (CD8α’β’), lacking the
intracellular lck-binding domain. CD8-transduced cells were sorted to have roughly
equivalent expression of CD8 (Figure 26a). Examining the reactivity of these CD8engineered Jurkat cells against each of the mutant peptides allowed us to separate the
importance of affinity enhancement and signaling augmentation by CD8.
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Figure 26. CD8 co-receptor signaling components are required for reactivity against
CD8-dependent ligands. (a) Jurkat cells were transduced to express either full length
CD8αβ or truncated CD8α’β’ lacking the intracellular lck-binding domain. (b) Each group
was transduced with a retrovirus encoding the HCV1406 TCR. After anti-CD34
immunomagnetic enrichment, these cells were co-cultured with T2 cells loaded with
HCV NS3:1406-1415 (WT and variants) peptide or tyrosinase:368-376 peptide as a
negative control. IL-2 secretion by Jurkat cells was measured by ELISA. Mean and
standard deviation of triplicate measurements are shown. All variants that qualified as
reactive in the text secreted at least 200 pg/mL IL-2 and twice above background and
>5% of WT reactivity. Affinities of TCR-pMHC interactions are shown in red. These data
are representative of three independent experiments.
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HCV1406 TCR-transduced Jurkat cells stimulated with WT HCV NS3:1406-1415
peptide-loaded T2 cells reproducibly resulted in minimal differences in IL-2 secretion
among CD8 negative, CD8αβ, or CD8α’β’ cells (Fig. 26b). The previously characterized
CD8-independent ligands, I1412L, V1408T, V1408L, and I1412V stimulated robust IL-2
release from all three Jurkat cell lines. Of note, the presence of CD8 (full length or
truncated) did not seem to always augment cytokine release against all of these
“moderate affinity” variants. This observation contradicts what we and others have
found whereby the presence of CD8αβ can augment cytokine release in TCR-transduced
T cells [305]. Perhaps there is an upper limit to CD8 help if the TCR-pMHC interaction is
maximally efficient at inducing T cell activation. Jurkat cells lacking CD8 are again not
reactive (by our established criteria) against “lower affinity” ligands A1409T, I1412N,
8S/9G/12L, or 8S/9S/12L/14S. The introduction of full length CD8αβ, however, rescues
reactivity against all mutant peptides except 8S/9G/12L. Interestingly, Jurkat cells
expressing truncated CD8α’β’ were minimally or non-reactive reactive against these
“lower affinity” variants, suggesting that TCR-pMHC stabilization is not sufficient and
that the intracellular lck-binding domain is also required for T cell activation. These
results also support the claim that TCR-pMHC affinity is not necessarily the determining
factor in antigen recognition. We have also highlighted the important role of CD8
signaling on facilitating or enhancing antigen recognition of multiple mutant peptides.
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Antigen Density Influences Cross-Reactive Responses
Clinical reports of on-target/off-tumor or off-target effects by TCR-transduced T
cells used in ACT have been attributed to recognition of low levels of antigen by high
affinity TCRs [122, 184, 186]. We also acknowledge that evaluating reactivity against
peptide-loaded T2 cells is not necessarily a physiological representation of the antigen
density a T cell might encounter on a virally-infected cell or tumor. For these reasons,
the effect of antigen density on recognition of WT and naturally occurring mutant
peptides by a TCR is an important point to consider for anti-tumor responses and
potential cross-reactivity.
Therefore, we established multiple levels of antigen density arbitrarily defined as
highest, lowest, and intermediate (Fig. 27). T2 cells are TAP-deficient and incapable of
presenting endogenously processed antigen, which allows for saturating levels of
exogenously loaded peptide. Peptide-pulsed T2 cells serve as our highest ligand density
and have been used in reactivity assays thus far. To achieve an arbitrarily lower level of
antigen density, we engineered a panel of HepG2 cells expressing WT and variant HCV
NS3:1406-1415 epitopes each as a minigene fused to GFP by a 2A linker. Transduced
cells were sorted for high and uniform GFP expression (Fig. 28a). We define minigene+
HepG2 cells as lower antigen density because they require the internal expression of
epitopes with minimal antigen processing, but compete with endogenously processed
peptides for available MHC-I. To establish an intermediate density of antigen between
peptide-loaded T2 cells and antigen-expressing HepG2 cells, we exogenously loaded
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Figure 27. A model for pMHC ligand density. (a) T2 cells are TAP-deficient and
incapable of presenting endogenously processed antigens (green triangles, red stars,
purple rectangles). Exogenously loading with HCV NS3:1406-1415 peptide (white ovals)
saturates available surface MHC-I with antigen. (b) HepG2 cells are TAP+ and present
internally processed antigens on MHC-I. Exogenously loading with high concentrations
of HCV NS3:1406-1415 peptide can compete out endogenous antigen presented on
MHC-I, but are presented at a lower density than peptide-loaded T2 cells. (c) HepG2
cells engineered to express HCV NS3:1406-1415 epitopes as minigenes require internal
expression and minimal antigen processing and compete with endogenously processed
peptides for MHC-I. HCV minigene-expressing HepG2 cells present HCV NS3:1406-1415
peptide at the “lowest” density of our three systems. HCV1406 TCR-transduced T cells
were stimulated with each of these arbitrarily defined densities of pMHC ligand to
assess the impact of ligand density on antigen recognition and TCR cross-reactivity.
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HCV NS3:1406-1415 peptides on HepG2 cells. While peptides are not internally
expressed, the loaded antigen still has to compete out occupied surface MHC-I on TAP+
HepG2 cells for effective presentation to T cells. These three antigen expressionpresentation systems allow for an arbitrary evaluation of the influence of antigen
density on the cross-reactivity of a single TCR.
We previously showed that CD4+ TCR-transduced T cells recognized WT and all
“moderate affinity” mutants, while CD8+ TCR-transduced T cells recognized all but
mutant 8S/9G/12L. (Fig. 25) Changes in the amount of cytokine released by “reactive” T
cells reproducibly differed by no greater than two-fold when stimulated with variant
pMHC ligands. Interestingly, the antigen recognition pattern varied much more at a
lower density of antigen, consistent with the results of a peptide titration presented
earlier (Fig. 20). Not unexpected, peptide-loaded HepG2s were better recognized than
minigene-expressing HepG2 cells (Fig. 28b). WT peptide recognition did not differ
dramatically, but a decrease in antigen density had the greatest impact on “moderate”
and “lower affinity” interactions. HepG2 cells expressing I1412L, V1408T, and V1408L
minigenes stimulated nearly 20-fold less IFNγ secretion compared to peptide-loaded
HepG2 cells. Interestingly, despite nearly identical affinity to V1408L, expression of
I1412V as a minigene abrogated recognition by our defining criteria. Additionally, “lower
affinity” ligands A1409T, I1412N, and 8S/9S/12L/14S exogenously loaded onto HepG2
cells were non-reactive defined by our criteria (<5% WT reactivity response), but still
elicited hundreds more pg/mL IFNγ secretion compared to minigene-expressing cells.
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Figure 28. HCV1406 TCR cross-reactivity is substantially diminished in the context of
HCV+ tumor cells. (a) HepG2 cells were transduced with retroviral vectors encoding HCV
NS3:1406-1415 variants as minigenes fused to GFP by a T2A linker. Cells were sorted for
high and uniform expression of GFP. MFI are shown in parenthesis. (b) PBL from a
normal donor were transduced with the HCV1406 TCR retroviral vector and enriched for
CD34t expressing using anti-CD34 immunomagnetic beads. CD34+ T cells co-cultured for
18 hr with WT or mutant HCV NS3:1406-1415 peptide-loaded or minigene-expressing
HepG2 cells . IFNγ secretion was measured by ELISA. Mean and standard deviation of
triplicate measurements are shown. All variants that qualified as reactive in the text
secreted at least 200 pg/mL IFNγ and twice above background and at least >5% of WT
reactivity. SPR-measured affinities of TCR-pMHC interactions are shown below in red.
These data are representative of three independent experiments.
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These results suggest the density of antigen plays an important role in facilitating
antigen recognition and T cell activation.
To evaluate if the CD8 co-receptor impacts antigen recognition in light of
decreased antigen density, we stimulated HCV1406 TCR-transduced CD4+ or CD8+ T cells
with “intermediate density" peptide-loaded HepG2 cells (Fig. 29a) or “lower density”
minigene-expressing HepG2 cells (Fig. 29b). We found that CD4+ T cells were most
susceptible to changes in antigen density. For example, we previously demonstrated
that TCR-transduced CD4+ T cells were highly reactive against WT and all “moderate
affinity” antigen-loaded T2 cells. Differences in magnitude of IFNγ secretion were
reproducibly no more than 2-3 fold (Fig. 25). Interestingly, mutant peptides (V1408T and
I1412V) loaded on HepG2 cells (a lower density of antigen compared to T2) stimulated
less than 750 pg/mL of IFNγ, while WT and V1408L stimulated over 60,000 and 20,000
pg/mL of IFNγ, respectively. Additionally, the presence of the CD8 co-receptor
compensated for intermediate densities of “moderate affinity” ligands, but “lower
affinity” mutant ligands stimulated nearly 60-fold less IFNγ secretion. Only two-fold
differences were observed between “moderate” and “lower” affinity ligands in T2 cell
stimulations (Fig. 25). These observations suggest that even antigen densities between
peptide-loaded targets (tumor cells vs T2 cells) can have a profound effect on antigen
recognition. Also, differences in cytokine secretion are not always reconciled by
differences in TCR-pMHC affinity.
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Figure 29. HCV1406 TCR CD4+ T Cells are more susceptible to changes in ligand density.
(a) HepG2 cells exogenously loaded with 10 μg/mL WT or variant HCV NS3:1406-1415
peptides or HepG2 cells engineered to express WT and variant HCV NS3:1406-1415
minigenes were co-cultured with PBL-derived T cells transduced with the HCV1406 TCR
retroviral vector. (b) HCV1406 TCR-transduced PBL were immunomagnetically isolated
into CD4+ or CD8+ populations and co-cultured with HepG2 cells loaded with WT or
variant HCV NS3:1406-1415 peptides. IFNγ secretion after 18 hr co-culture was
measured by ELISA. Mean and standard deviation of triplicate measurements are
shown. All variants that qualified as reactive in the text secreted at least 200 pg/mL
IFNγ and twice above background and at least >5% of WT reactivity. SPR-measured
affinities of TCR-pMHC interactions are shown below in red. These data are
representative of three independent experiments.
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In our lowest antigen density system, minigene-expressing HepG2 cells elicited
reproducibly similar amounts of IFNγ release from both CD4+ and CD8+ TCR-transduced
T cells. However, only “moderate affinity” mutant pMHC could be recognized at lowest
densities and now required the presence of CD8. In summary, recognition of lower
affinity ligands seems to be affected more dramatically by changes in antigen density.
However, CD8 can facilitate recognition of higher affinity antigens at lower densities.
These data suggest that antigen density plays a critical role in antigen recognition of
altered ligands.
TCR Transgene Levels Influence IFNγ Production Independent of Affinity
Given that antigen density influences antigen recognition and TCR crossreactivity, it would be logical to predict that TCR density may also impact T cell
recognition of altered ligands. The composition of our retroviral vector used to genemodify T cells provides a useful tool to answer this question. As discussed previously,
our TCR retroviral vector contains a CD34t cassette as a marker of transduction
efficiency. While useful for enriching transduced T cell populations for in vitro studies
and clinical treatment, our CD34t marker also allows us to assess relative TCR expression
without staining for the TCR with an antibody or tetramer, which can influence the
outcome of functional assays [380-382].
We evaluated the impact of TCR density on antigen recognition and TCR crossreactivity by HCV1406 TCR-transduced PBL by relating intracellular IFNγ production with
TCR transgene levels. HCV1406 TCR-transduced T cells were stimulated with WT and
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mutant HCV NS3:1406-1415 peptide-loaded T2 cells and analyzed for intracellular IFNγ
production by flow cytometry. We also stained T cells for surface markers CD4 and CD8
and our transduction marker CD34t. We have previously shown that increased levels of
CD34 relate to increased tetramer binding (Foley unpublished, [304]), suggesting that
CD34 serves as a good correlate for TCR expression. This approach enabled us able to
relate the various levels of TCR transgene with intensity of cytokine production. Figure
30 displays representative CD34 vs IFNγ dotplots and our gating strategy used to assess
IFNγ production in High, Medium, and Low CD34-expressing CD4+ or CD8+ TCRtransduced T cells. Mean fluorescence intensity (MFI) of intracellular IFNγ was
calculated in each CD34 expression gate for both CD8+ (Fig. 31a) and CD4+ T cells (Fig.
31b).
In TCR-transduced CD8+ T cells, IFNγ production was positively associated with
TCR transgene expression. CD34 Hi-expressing CD8+ T cells exhibited the greatest
intensity of IFNγ, and all peptide but 8S/9G/12L stimulated similar levels of IFNγ staining
in the CD34 Med and CD34 Low populations. However, only CD34 Hi-expressing CD4+ T
cells produced high IFNγ levels above background against all CD8-independent peptides.
The WT epitope, as well as mutant peptides I1412L and V1408L, stimulated modest IFNγ
production in CD34 Med- and CD34 Low-expressing cells. Despite having similar
affinities to I1412L and V1408L, however, mutants V1408T and I1412V only stimulated
substantial amounts of IFNg production in CD34 Hi-expressing T cells. Together, these
data suggest that TCR transgene expression influences antigen recognition, but that the
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Figure 30. Gating strategy used to establish the relationship between TCR transgene
expression and IFNγ production. PBL from a normal donor were transduced to express
HCV1406 TCR and enriched for TCR-transduced cells using anti-CD34 immunomagnetic
beads. T cells were co-cultured with peptide-loaded T2 cells for 5 hr and IFNγ
production was assessed by intracellular cytokine staining. Representative
immunofluorescence and gating of surface CD34 vs intracellular IFNγ for (a) CD8+ and
(b) CD4+ TCR-transduced T cells. CD34+ populations were subgated to delineate CD34
high, medium, and low expressing populations. Mean fluorescence intensity (MFI) of
intracellular IFNγ was calculated for each CD34-expressing population.
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Figure 31. IFNγ production is positively associated with TCR transgene expression but
high expression is required for CD4+ T cells to produce IFNγ. PBL from a normal donor
were transduced to express HCV1406 TCR and enriched for transduced cells using antiCD34 immunomagnetic beads. T cells were co-cultured with peptide-loaded T2 cells for
5 hr and evaluated for IFNγ production by intracellular cytokine staining. Mean
fluorescence intensity (MFI) of IFNγ production in CD34 high (black), medium (gray), and
low (white) expression populations are shown in (a) CD8+ and (b) CD4+ TCR-transduced T
cells. These data are representative of three independent experiments with three
different donors each.
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relationships between TCR-pMHC affinity, TCR density, CD8, and the intensity of
cytokine production remain ill-defined.
Elimination of TCR Pairing Competition Enhances Cross-Reactivity
In an effort to better understand the interplay between TCR density, CD8 coreceptor function, and TCR cross-reactivity, we designed a panel of Jurkat cells equipped
to delineate these contributions. Jurkat cells, like PBL-derived T cells, express an
endogenous TCR. Consequently, TCR chains introduced into Jurkat cells have the
potential to mispair with the endogenous TCR chains and also compete for association
with CD3, limiting the density of functional introduced TCRs. Conversely, a variant Jurkat
cell line, Jurkat76, lacks an endogenous TCR [383] (Fig. 32a). Introduction of a TCR into
Jurkat76 cells eliminates the opportunity for both TCR chain mispairing and competition
for CD3. Therefore, Jurkat76 cells serve as a system with optimal density of the
introduced TCR. We also engineered Jurkat76 cells (natively CD8-) to express full length
CD8αβ, or truncated CD8α’β’ lacking the intracellular lck-binding domain (Figs. 32b-c).
Comparing functional responses between Jurkat and Jurkat76 cell lines may provide
better insight into the impact of both TCR density and CD8 on antigen recognition and
TCR cross-reactivity. A schematic of this model is provided in Figs 32d-e.
As described earlier, we observed CD8-dependence in Jurkat cells in light of TCR
pairing competition between endogenous and introduced TCRs (Fig. 33a). We evaluated
the effect of TCR chain pairing competition on cross-reactivity by peptide-stimulating
our engineered Jurkat76 cell lines (Fig. 33b). Jurkat76 cells with and without CD8
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Figure 32. A Jurkat model for TCR chain pairing and CD8 signaling. (a) Jurkat cells
express an endogenous TCR (measured by Vβ8 expression) while Jurkat76 cells lack an
endogenous TCR. Both (b) Jurkat and (c) Jurkat76 cells were engineered to express full
length CD8αβ or a truncated version (CD8α’β’) lacking the intracellular lck-binding
domain. (d) Introduced TCRs (red) can mispair with endogenous TCRs (green) and
compete to associate with CD3 (blue) in Jurkat cells. (e) TCR pairing competition is
absent in Jurkat76 cells. Introduction of full length CD8αβ stabilizes the TCR-pMHC
interaction and facilitates TCR/CD3 signaling by recruiting lck. Introduction of CD8α’β’
uncouples signaling from TCR-pMHC stabilization.
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Figure 33. Absence of TCR pairing competition alleviates CD8-dependence. (a) Jurkat
and (b) Jurkat76 cells (lacking an endogenous TCR) were transduced to express either
full length CD8αβ or truncated CD8α’β’. Each group was transduced with a retrovirus
encoding the HCV1406 TCR. After anti-CD3 immunomagnetic enrichment, Jurkat cells
were co-cultured with peptide-loaded T2 cells. IL-2 release by Jurkat cells was measured
by ELISA. Mean and standard deviation of triplicate measurements are shown. All
variants that qualified as reactive in the text secreted at least 200 pg/mL IFNγ and twice
above background and at least >5% of WT reactivity. SPR-measured affinities of TCRpMHC interactions are shown in red. These data are representative of three
independent experiments.
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variants demonstrated similar levels of IL-2 release against WT or “moderate affinity”
ligands. In contrast, mutants V1408T and I1412V, which exhibited a reproducibly lower
reactivity in TCR-transduced CD8- Jurkat cells, had comparable cytokine release to WT in
in all Jurkat76 cells. Overall, the lack of an endogenous TCR had minimal impact on
recognition of ligands with moderate affinities (17 µm – 64 µM). Surprisingly,
eliminating TCR pairing competition (enhancing TCR density) facilitated the recognition
of “lower affinity” ligands A1409T, I1412N, and 8S/9S/12L/14S by CD8- Jurkat76 cells.
CD8α’β’ Jurkat76 cells also recognized “lower affinity” mutant pMHC, with IL-2 secretion
levels falling between CD8- and CD8αβ Jurkat76 cells’. Together, these data suggest that
in the presence of TCR chain pairing competition, both the stabilization and signaling
functions of CD8 are required. However, increased TCR expression in the absence of TCR
chain pairing competition reduces the importance of the CD8 signaling component.
Most unexpectedly, we observed IL-2 secretion by CD8αβ Jurkat76 when
stimulated with variant 8S/9G/12L. Countless experiments in WT Jurkat cells, numerous
PBL donors, and even the parent T cell clone from which this TCR originated consistently
showed no reactivity (Figs. 17,19,25-26,28-31). While the lack of recognition of
8S/9G/12L by the parent T cell clone seems puzzling, the most plausible explanation is
that the parent clone underwent aberrant allelic exclusion during development and
expressed two productively rearranged TCR α chains [165]. Thus, the parent clone
exhibited endogenous TCR pairing competition and sub-optimal TCR density. Overall, it
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is clear that limiting or enhancing TCR expression can have dramatic effects on antigen
recognition and TCR cross-reactivity.
We also performed a peptide titration to determine if the elimination of TCR
pairing competition alters the requirement of CD8 for enhanced functional avidity. We
evaluated IL-2 release by Jurkat76 cells in response to peptide-stimulation,
concentrations ranging from 10 – 0.0001 μM (Fig. 34). Based on similarly estimated EC50
values, functional avidity seemed to be independent of CD8 TCR-pMHC stabilization and
lck recruitment upon stimulation with WT and “moderate affinity” mutants I1412L,
V1408T, V1408L, and I1412V. “Lower affinity” ligands A1409T, 8S/9G/12L, and
8S/9S/12L/14S depended more on CD8 signaling in order to achieve maximum
magnitude of cytokine release, but maintained relatively similar functional avidities
compared to CD8α’β’ Jurkat76 cells. We previously showed that in TCR-transduced
Jurkat cells (Fig. 20), functional avidity of CD8- Jurkat cells was modestly reduced in WT
and V1408L stimulation, but all other “moderate affinity” ligands had very low
functional avidity with estimated EC50 values ranging between 10-1 µM. In the absence
of TCR chain pairing, the estimated EC50 values were only a log-fold lower for CD8Jurkat76 cells (Fig. 34) suggesting that CD8 not as important for high functional avidity
with enhanced TCR density.
We also evaluated the impact of TCR density (as a function of TCR chain pairing)
on antigen recognition by comparing the ability of HCV1406 TCR-transduced Jurkat and
Jurkat76 cells to bind tetramers. A panel of tetramers containing WT or mutant HCV
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Figure 34. CD8 signaling is not necessarily required for enhanced functional avidity in
the absence of TCR chain pairing competition. Jurkat76 cells (black diamonds) were
transduced to express either full length CD8αβ (white squares) or truncated CD8α’β’
(gray triangles). Each group was transduced with a retrovirus encoding the HCV1406 TCR
and co-cultured with T2 cells loaded with peptides at various concentrations. IL-2
release by Jurkat cells was measured by ELISA. Means of triplicate measurements are
shown. Compare to Figure 20 for functional avidity of Jurkat±CD8 cells. These data are
representative of three independent experiments.
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NS3:1406-1415 epitopes folded around HLA-A2 was kindly provided by the NIH
Tetramer Core Facility at Emory University (Atlanta, Georgia). Tetramers containing
mutant epitope 8S/9G/12L were not provided by the Core. We performed a steady-state
binding assay with each tetramer, concentrations ranging from 10-7 – 10-12 M, and
calculated the specific staining by HCV1406 TCR-transduced Jurkat or Jurkat76 cells by
subtracting %Tetramer+ non-transduced cells from %Tetramer+ transduced cells. Often,
non-TCR-transduced Tetramer+ populations were due to non-specific tetramer binding
by CD8 [384]. TCR-transduced Jurkat cells were identified using the CD34 marker in our
retroviral vector. Jurkat76 cells endogenously express CD34, so TCR-transduced cells
were instead identified by the expression of CD3; Jurkat76 cells will only express surface
CD3 when a TCR is expressed on the surface.
Steady-state tetramer binding curves are shown in Figures 35-36 representing
Jurkat76 or Jurkat cells, respectively. HCV1406 TCR-transduced Jurkat76 cells bound WT
tetramer very efficiently, with nearly 90% of TCR-transduced CD8+ Jurkat76 cells bound
to tetramer (Fig. 35). A lower percentage of TCR-transduced cells, however, bound
tetramers containing mutant epitopes at saturating concentrations, and decreases in
tetramer binding generally trended with decreases in TCR-pMHC affinity. The presence
of CD8 enhanced the EC50 of tetramers only one log-fold or less throughout.
Interestingly, the presence of TCR chain pairing in HCV1406 TCR-transduced Jurkat cells
affected the ability to bind tetramer (Fig. 36). Vertical axes are scaled to 100% tetramer
bound TCR-transduced Jurkat cells for easy comparison to Jurkat76 cells (Fig. 35). Nearly
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Figure 35. Steady-state binding of WT or mutant HCV NS3:1406-1415 tetramers by
HCV1406 TCR-transduced Jurkat76 cells. Jurkat76 cells (black diamonds) were
transduced to express full length CD8αβ (white squares). Both groups were transduced
with a retrovirus encoding the HCV1406 TCR and stained with tetramers containing WT
or mutant HCV NS3:1406-1415 epitopes at concentrations ranging from 10-7 – 10-12 M.
Cells were counterstained for CD3 and analyzed for mCherry expression (CD8). Specific
tetramer binding by HCV1406 TCR-transduced Jurkat76 cells was calculated as
%CD3+Tetramer+ - %CD3-Tetramer+. These data are representative of two independent
experiments.

162

Figure 36. Steady-state binding of WT or mutant HCV NS3:1406-1415 tetramers by
HCV1406 TCR-transduced Jurkat cells. Jurkat cells (black diamonds) were transduced to
express full length CD8αβ (white squares). Both groups were transduced with a
retrovirus encoding the HCV1406 TCR and stained with tetramers containing WT or
mutant HCV NS3:1406-1415 epitopes at concentrations ranging from 10-7 – 10-12 M.
Cells were counterstained for CD3 and analyzed for mCherry expression (CD8). Specific
tetramer binding by HCV1406 TCR-transduced Jurkat cells was calculated as
%CD34+Tetramer+ - %CD34-Tetramer+. These data are representative of two
independent experiments.
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50% fewer TCR-transduced Jurkat cells bound tetramer than Jurkat76 cells for each
tetramer evaluated. Additionally, while tetramers containing mutant peptides A1409T,
I1412N, and 8S/9S/12L/14S bound both CD8- and CD8+ Jurkat76 cells (ranging from 4060% at saturating concentrations), they bound only 20% or less of HCV1406 TCRtransduced CD8+ Jurkat cells, and did not bind CD8- Jurkat cells. These differences in
tetramer binding are consistent with functional assays shown in Figure 33, further
suggesting that TCR chain pairing competition can have a substantial impact on antigen
recognition and TCR cross-reactivity.
The relationship between TCR expression levels and tetramer binding was also
evaluated for HCV1406 TCR-transduced Jurkat76 (Fig. 37a) and Jurkat (Fig. 37b) cells.
For simplicity, staining of WT, V1408L, I1412V, and I1412N tetramers are shown at
limited concentrations. Please see The Appendix for all tetramers and concentrations
evaluated for both Jurkat cell lines. In HCV1406 TCR-transduced Jurkat76 cells, a linear
relationship existed between CD3 (TCR) expression and WT tetramer binding at
saturating concentrations (10-7 M). As the concentration of tetramer decreased, the
relationship became less linear, and the ability to bind tetramer was more dependent
on higher levels of TCR expression. Dependence on higher TCR density was exaggerated
when evaluating TCR vs tetramer staining of lower affinity ligand I1412N (168 µM,
compared to WT 17 µM). At saturating concentrations (10 -7 M) the distribution of CD3
and tetramer positive cells suggests a higher threshold of TCR is necessary for tetramer
binding. Furthermore, it is clear that a higher density of TCR is required to bind I1412N
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a)

b)

Figure 37. Influence of TCR-pMHC affiity and TCR chain pairing competition on
tetramer binding. (a) Jurkat76 or (b) Jurkat cell lines were transduced to express full
length CD8αβ. Both groups were transduced with a retrovirus encoding the HCV1406
TCR and stained with tetramers containing WT or mutant HCV NS3:1406-1415 epitopes
at concentrations ranging from 10-7 – 10-12 M. Cells were also stained for CD3 or CD34.
The relationship between TCR density and tetramer binding was evaluated using CD3
(Jurkat76 cells) or CD34 (Jurkat cells) as a surrogate marker for TCR transgene
expression.
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tetramer at lower concentrations compared to WT tetramer. Interestingly, TCR
expression and tetramer binding between mutant ligands V1408L and I1412V were not
consistent despite nearly identical affinity measurements (60 and 63 μM, respectively).
For comparison, fewer HCV1406 TCR-transduced Jurkat cells bound tetramers compared
to Jurkat76 cells and the distributions of TCR-transduced cells binding tetramers are
remarkably different in the presence of TCR chain pairing competition (Fig. 37b). This is
also reflected in the lower overall percentages of TCR-transduced Jurkat cell bound to
tetramer shown in Figure 36.
In summary, both tetramer binding and functional studies suggest that TCR
density plays a critical role in antigen recognition. When TCR density is high enough, it
can allow for CD8-independent antigen recognition, despite a log-fold change in TCRpMHC affinity. This evidence further supports that the ability of a T cell to recognize
antigen does not solely depend on TCR-pMHC affinity.
Significance
The ability to fully understand what factors govern antigen recognition by T cells
and TCR cross-reactivity may help improve TCR-based therapeutics. While affinity is
generally accepted as the most important factor dictating antigen recognition, the field
is relying on affinity-enhancement of TCRs to presumably augment their efficacy in TCR
gene-modified T cells. Therefore, it is critical to evaluate the true importance of affinity.
Appreciating how TCR antigen recognition is affected by TCR-pMHC affinity will help
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modulate the field’s approach in optimizing affinities to enhance or limit cross-reactivity
of TCRs.
The data described in this chapter surprisingly suggest that TCR-pMHC affinity
may not be the most important influence on antigen recognition. While decreases in T
cell reactivity (especially in CD8- T cells) trended with decreases in TCR-pMHC affinity,
cytokine release were not always proportional to changes in affinity. Additionally,
mutant peptides with similar or equal affinities sometimes elicited substantially
different IFNγ or IL-2 release. Other cellular parameters, including ligand density, TCR
density, and CD8 co-receptor signaling, greatly impacted antigen recognition and
functional avidity. Additionally, modification of any of these parameters altered
functional response, sometimes independent of TCR-pMHC affinities. Collectively, these
data suggest that TCR-pMHC affinity is not necessarily the driving force behind T cell
function.
Through this point, we have admittedly evaluated T cell function based on the
release of a single cytokine. We also acknowledge the potential for T cells to act as
multi-functional effector cells. Thus, the evaluation of one cytokine may not accurately
reflect changes in overall T cell function. In the next chapter, we aim to evaluate the
polyfunctionality of T cells and to relate changes in polyfunctional phenotypes to
alterations in TCR-pMHC interactions.

CHAPTER SIX
ANALYSIS OF POLYLFUNCTIONAL PHENOTYPES BY
CROSS-REACTIVE HCV1406 TCR GENE-MODIFIED T CELLS
Rationale
We have suggested that affinity may not necessarily play the most central role in
determining antigen recognition. In fact, it is clear that T cell function relies on a
complex relationship between TCR-pMHC affinity, CD8 signaling, antigen density, and
TCR density. We have defined the importance of these interactions by evaluating IFNγ
or IL-2 release by HCV1406 TCR-transduced PBL and Jurkat cells, respectively. While
standard assays in the field measure the production of a single cytokine to define T cell
reactivity [385-393], it is important to acknowledge that T cells are multi-functional
effectors.
Historically, effector T cells have been classified into type 1 (Th1, Tc1) or type 2
(Th2, Tc2) T cells based on the production of signature cytokines (i.e. IFNγ, IL-2, and
TNFα for type 1; IL-4 and IL-13 for type 2) [394]. These functional profiles have also been
related to therapeutic efficacy of individual T cell populations [395-399]. In general, a T
cell population that has a type 1 phenotype is considered to have better anti-tumor
efficacy than T cells with a type 2 phenotype [395, 396]. However, both type 1 and type
2 responses have been shown to play important roles in viral infections [400-402]. More
recently, other T cell subsets have been implicated in facilitating anti-tumor or anti-viral
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responses. For example, IL-9-producing CD4+ T cells (Th9 cells) facilitated CD8+ CTLmediated anti-tumor immunity in a melanoma mouse model [403]. Furthermore, the
presence of T cell subsets producing IL-17 (Th17, Tc17) or IL-22 has been recently
associated with spontaneous HCV viral clearance [404]. The presence of multiple T cell
subsets secreting varying combinations of cytokines suggest the evaluation of a single
type 1 cytokine may not accurately characterize the reactivity of a T cell culture.
In fact, investigators have shown that in patients with advanced stage IV
malignant melanoma who received a therapeutic vaccine, analysis of intracellular IFNγ
induction in PBL-derived T cells showed no correlation in survival advantage [405].
However, evaluation of an additional cytokine (IL-2) by flow cytometry found an
association in clinical outcome. Namely, there was enhanced survival in patients with
induction of IL-2+IFNγ- T cells. These studies support the hypothesis that evaluation of a
single pro-inflammatory cytokine may hinder the proper biologic evaluation of T cells in
a given experimental system. Flow cytometry-based approaches staining for multiple
intracellular cytokines offer alternatives to more appropriately evaluate the true biology
of a T cell culture and differential T cell responses. In this chapter, we describe how the
inclusion of more than one functional parameter when evaluating antigen recognition
can change or enhance the biologic message. We also evaluate how alterations in TCRpMHC interactions can influence polyfunctional T cell responses.
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Evaluating Bi-Functional HCV1406 TCR-Transduced T Cells
While single cytokine release assays are standard in the field, we wanted to
begin our assessment of multi-functional T cell populations by simultaneously evaluating
IFNγ production and cytolytic activity by HCV1406 TCR-transduced T cells. Target cell
lysis is important in facilitating anti-tumor and anti-viral immunity [406] and thus a
reasonable second functional parameter in evaluating antigen reactivity. Although
CD107a is a surrogate marker for degranulation [406], traditional chromium release
assays would prevent us from simultaneously measuring cytokine production and
correlating with lytic behavior on a per-cell basis. In this way, we simultaneously
measured intracellular IFNγ production and surface CD107a expression to assess the
impact of variant HCV NS3:1506-1415 pMHC on T cell function.
Heterogeneity of Bi-Functional CD4+ and CD8+ T Cell Responses Is Not Evident In Bulk
Culture Analysis
We first characterized bi-functional responses of HCV1406 TCR-transduced T
cells against WT HCV NS3:1406-1415 peptide-loaded T2 cells. Figure 38 displays
percentages of lytic-only (CD107a+IFNγ-), IFNγ producing-only (CD107a-IFNγ+) or bifunctional (CD107a+IFNγ+) phenotypes. T cells were analyzed as a bulk culture or gated
on CD4+CD8- or CD4-CD8+ TCR-transduced T cells. Assessing bulk culture reactivity
suggests of the 49% of TCR-transduced T cells that are reactive, with nearly equal
proportions only producing IFNγ (15%), only being lytic (15%), or are bi-functional (20%).
Subsequent gating on CD4+ or CD8+ T cells revealed how proportionally different these
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Figure 38. Bi-functional T cell reactivity assay demonstrates T cell subset
heterogeneity. PBL from a normal donor were transduced with a retroviral vector
encoding the HCV 1406 TCR. HCV TCR-transduced T cells were co-cultured for 5 hours
with T2 cells loaded with tyrosinase:368-376, HCV NS3:1406-1415, or no peptide in the
presence of monensin, brefeldin-A, and anti-CD107a. Co-cultures were then stained for
T cell surface markers and IFNγ. (a) TCR-transduced T cells were identified by CD34+
phenotype (Bulk culture, left panel) and subsequently gated as CD4 +CD8- (CD4, middle
panel) or CD4-CD8+ (CD8, right panel). Each population was evaluated with a biaxial
comparison of CD107a and intracellular IFNγ. (b) Percentages of each CD107a vs IFNγ
quadrant were converted into pie charts. CD107a+ IFNγ- (lytic-only, blue); CD107a+IFNγ+
(bi-functional lytic and IFNγ producing, red); CD107a-IFNγ+ (IFNγ producing-only, green);
CD107a-IFNγ- (nonreactive, gray). Pie charts reflect a minimum of 2,000 cells (average
4,000 cells). These data are representative of a single donor from three independent
experiments using three different donors each.
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subsets behave. This representative example shows that of CD4+ T cells, 32% only
produce IFNγ, 7% are only lytic, but 18% exhibit dual functions. Conversely, CD8 + T cells
are predominantly bi-functionally lytic and IFNγ-producing (38%), but with smaller
populations being only lytic or only producing IFNγ (24% and 8%, respectively).
Additionally, the fact that there were a higher percentage of non-reactive CD4+ T cells
supports our previous claim that the presence of CD8 can impact overall function.
Together, this analysis provides a unique perspective on T cell function than evaluation
of either IFNγ or lysis alone.
Bi-Functional T Cell Populations Are Disproportionately Affected by Alterations in
pMHC
We have previously shown that the magnitude of IFNγ release differs between
mutant peptide stimulations. We subsequently evaluated whether changes in TCRpMHC interactions could affect T cell function as measured by both IFNγ and CD107a.
Figure 39 displays percentages of lytic-only (CD107a+IFNγ-), IFNγ producing-only
(CD107a-IFNγ+) or bi-functional (CD107a+IFNγ+) TCR-transduced CD4+ or CD8+ T cells
after stimulation with naturally occurring mutant HCV NS3:1406-1415 peptides. Mutant
peptides are grouped into “moderate affinity” (middle column) and “lower affinity”
(right column) in decreasing affinity (top to bottom). Representative flow cytometry
data are provided in The Appendix.
We observed again that CD4+ T cell functional responses are restricted to variant
ligands I1412L, V1408T, V1408L, and I1412V. We defined reactivity in these assays when
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Figure 39. HCV1406 TCR-transduced CD4+ and CD8+ T cells have varying bi-functional
responses against naturally occurring mutant HCV NS3:1406-1415 peptides. HCV1406
TCR-transduced PBL were co-cultured for 5 hr with T2 cells loaded with WT and mutant
HCV NS3:1406-1415 peptides or tyrosinase:368-376 peptide as a control, T cells were
analyzed by flow cytometry for T cell surface markers, CD107a expression, and
intracellular IFNγ. Percentages lytic and/or IFNγ producing TCR-transduced CD4+ (left
pie) or CD8+ T (right pie) cells are displayed as pie charts for corresponding stimulation
conditions. Variant peptides are grouped into “moderate affinity” (middle column of
each panel) and “lower affinity” (right column of each panel) in decreasing order of
affinity (top to bottom). Pie charts reflect a minimum of 2,000 cells (average 4,000 cells).
Reactivity is defined by greater than twice the percentage of total reactive cells against
background (tyrosinase) stimulation. These data are representative of a single donor
from three independent experiments using three different donors each.
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the total percentage of functional cells was greater than twice background (tyrosinase)
stimulation. It was clearly evident that alterations in TCR-pMHC interactions affected
the overall percentage of reactive cells. While 57% of TCR-transduced CD4+ T cells
stimulated with WT peptide were reactive, this amount decreased when T cells were
stimulated by any of the mutant peptides. Interestingly, however, the decrease in
reactive T cells was not necessarily proportional to the decrease in TCR-pMHC affinity as
V1408L (46 µM)-stimulated T cells exhibited nearly twice as many reactive T cells when
stimulated by V1408T (60 µM) peptide-loaded T2 cells. Additionally, mutant I1412V
stimulated nearly 50% less reactive T cells than V1408L, despite having nearly identical
affinities (63 and 60 µM, respectively).
Remarkably, when the overall percentage of reactive T cells was reduced, the bifunctional population disproportionately decreased compared to either monofunctional population. For example, when CD4+ T cells were stimulated with I1412L
compared to WT peptide-loaded targets, the mono-functional lytic-only population was
modestly reduced by 15% (7% compared to 6%) and the IFNγ-only population was
reduced by 16% (32% compared to 27%). However, bi-functional cells decreased by 51%
(18% compared to 9%) (Table 11). Interestingly, a reduction in bi-functional populations
sometimes occurred despite comparable affinities. V1408L and I1412V have measurable
TCR-pMHC affinities of 60 and 63 µM, respectively. Yet, their bi-functional responses
compared to WT were drastically different. Compared to WT stimulation, V1408L
peptide-loaded T2 cells elicited 95% as many lytic-only cells, 89% as many IFNγ-only
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Table 11. Percent of WT reactivity in mono- and bi-functional populations upon
stimulation with HCV NS3:1406-1415 mutant peptides.
Epitope

CD4+ TCR-Transduced T Cells

CD8+ TCR-Transduced T Cells

Lytic only IFNγ only Lytic/IFNγ Lytic only

IFNγ only Lytic/IFNγ

WT
100
100
100
100
100
100
I1412L
84.7
84.3
48.7
112.3
73.3
75.5
V1408T
58.4
54.4
29.8
98.3
90.1
76.9
V1408L
94.6
89.3
79.7
116.9
75.7
86.6
I1412V
50.1
56.2
34.5
96.9
104.7
72.5
A1409T*
47.0
21.7
10.5
63.8
81.7
37.5
I1412N*
45.0
13.6
8.7
87.4
92.9
51.6
†
8S/9G/12L*
52.5
15.9
11.5
20.6
42.4
5.0
8S/9S/12L/14S*
71.8
13.3
4.5
83.3
62.2
40.8
+
†
+
+
*Non-reactive against CD4 T cells; Non-reactive against CD4 or CD8 T cells
Percentages reflect the ratio of mutant:WT antigen stimulations for each functional
phenotype. WT is normalized at 100%. These data are representative of a single donor
from three independent experiments using three different donors each.
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producing cells, and an 80% decrease in bi-functional populations. However, I1412V
with essentially the same affinity as V1408L stimulated roughly 50% fewer monofunctional cells, and curbed the presence of bi-functional cells by nearly two thirds
compared to WT stimulation (Table 11). Together, these data suggest that alterations in
TCR-pMHC interactions can disproportionately alter bi-functional T cell responses.
Similar trends in altered responses held true for CD8+ T cells as well. Stimulation
with I1412L peptide-loaded targets elicited a modest change in overall reactivity from
70% to 62% total reactive T cells. Interestingly, the entire 8% decrease in overall
reactivity is lost in the bi-functional population. This trend is even more dramatic when
comparing TCR-transduced CD8+ T cells against “lower affinity” ligands (A1409T, I1412N,
and 8S/9S/12L/14S). When CD8+ T cells were stimulated by the WT antigen, bifunctional populations were roughly 50% greater than lytic only cells. But when the TCRpMHC interaction is at a lower affinity, the proportion of bi-functional CD8+ T cell was
less than or equal to lytic-only cells. As mentioned, a summary of each phenotype’s
percent change compared to WT stimulation, emphasizing a larger percent change in bifunctional populations, can be found in Table 11. Overall, these findings support the
hypothesis that alterations in TCR-pMHC interactions (sometimes independent of
affinity) elicit varied functional responses. These data also suggest that when measuring
two functional parameters simultaneously, blunted T cell reactivity disproportionately
affects bi-functional T cells and is not necessary influenced by changes in TCR-pMHC
affinity.
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Recognition of Naturally Processed NS3 Is Restricted to HCV1406 TCR-Transduced CD8+
T Cells
The data described above compare changes in bi-functional phenotypes in light
of high antigen density (peptide-loaded T2 cells). In the last chapter, we provided
evidence that antigen density played a role dictating antigen recognition. Here, we
establish a new “lowest antigen density” model using COS/A2 cells engineered to
expressing the full length NS3 protein with WT or mutant 1406-1415 epitopes (Fig. 40).
In NS3+ COS/A2 cells, the 1406-1415 epitope must be naturally processed before
competing with endogenous peptides for available MHC-I. This system allows us to
measure the effects of even lower antigen density on T cell bi-functionality.
Figure 41 illustrates that reactivity against WT naturally processed antigen is
limited to CD8+ T cells. Recall, we previously defined that for an antigen to be arbitrarily
reactive, the total percentage of functional cells must be greater than twice background
(here, COS/NS3) stimulation. Compared to HCV minigene+ HepG2 cells, which
stimulated both CD4+ and CD8+ TCR-transduced T cells (Figs. 14,29), COS/A2 cells
express a lower density of antigen. These data suggest that CD8 is most necessary at
lowest levels of antigen density, which would be predicted based on the function of
CD8.
Interestingly, naturally processed mutant epitope recognition was also restricted
to HCV1406 TCR-transduced CD8+ T cells. Only V1408T, V1408L, and I1412V qualified as
reactive, despite I1412L exhibiting the lowest TCR-pMHC affinity out of this group of
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Figure 40. Generation of COS/A2 expressing naturally processed HCV NS3 with WT and
naturally occurring mutant NS3:1406-1415 epitopes. COS cells and COS/A2 cells were
transfected with a pcDNAIII vector encoding full length HCV NS3 protein containing WT
or variant NS3:1406-1415 epitopes fused to GFP by a T2A linker. Representative
transfection efficiency as measured by GFP expression is shown. Mean fluorescence
intensity of each total population (MFI-1) and the GFP+ population (MFI-2) are listed as:
(MFI-1|/MFI-2).
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Figure 41. HCV1406 TCR-transduced CD4+ and CD8+ T cells have limited bi-functional
reactivity against HCV NS3:1406-1415 naturally processed antigen. HCV1406 TCRtransduced PBL were co-cultured for 5 hr with COS/A2 cells transiently transfected to
express full length WT HCV NS3 or HCV NS3 with various mutant 1406-1415 epitopes. T
cells were analyzed by flow cytometry for T cell surface markers, surface CD107a
expression, and intracellular IFNγ. Percentages lytic and/or cytokine producing TCRtransduced CD4+ (left pie) or CD8+ (right pie) T cells are displayed as pie charts for
corresponding stimulation conditions. Variant peptides are grouped into “moderate
affinity” (middle column of each panel) and “lower affinity” (right column of each panel)
in decreasing order of affinity (top to bottom). Pie charts reflect a minimum of 2,000
cells (average 4,000 cells). Reactivity is defined by greater than twice the percentage of
total reactive cells against background (tyrosinase) stimulation. These data are
representative of a single donor from three independent experiments using three
different donors each.
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mutant ligands. Additionally, mutant V1408T elicited a greater percentage of reactive
cells compared to WT antigen (37% compared to 28%). These data provide further
evidence that TCR-pMHC affinity may not be the most critical influence on T cell
function.
A Decrease in Ligand Density Preferentially Diminishes Bi-Functional Responses
A dramatic decrease in bi-functional T cells was also evident when comparing
peptide versus naturally processed antigen stimulations (Fig. 42). Over half (38% out of
70%) of total reactive TCR-transduced CD8+ T cells were bi-functional when stimulated
with WT peptide-loaded T2 cells. But when stimulated with naturally processed antigen,
bi-functional populations were reduced to 29% of the peptide-elicited response. Lyticonly and IFNγ-only populations were only reduced by 54% and 50%, respectively. This
trend is consistent for the remainder of reactive naturally processed antigens
(summarized in Table 12). These data not only support the claim made in the previous
chapter that decreased ligand density impacts antigen recognition, but that a decrease
in antigen density also contributes to a preferential loss of bi-functional T cell responses.
A Two-Parameter Analysis Enhances Our Understanding of Antigen Recognition over a
One-Parameter Evaluation
As mentioned earlier, traditional techniques used to assess T cell reactivity
usually rely on the evaluation of a single pro-inflammatory cytokine secreted by a mixed
culture of lymphocytes. Interestingly, we found that evaluation of a single cytokine
measured by ELISA is limited in its interpretation. Decreases in the magnitude of a
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Figure 42. A decrease in HCV NS3 ligand density preferentially decreases bi-functional
HCV1406 TCR-transduced CD8+ T cells. HCV1406 TCR-transduced PBL were co-cultured
for 5 hr with T2 cells loaded with WT and mutant HCV NS3:1406-1415 peptides
(“Peptide”, left pie) or COS/A2 cells transiently transfected to express full length WT
HCV NS3 or HCV NS3 with mutant 1406-1415 epitopes (“NS3”, right pie). Cells were
analyzed by flow cytometry for T cell surface markers, CD107a expression, and
intracellular IFNγ. Percentages of lytic and/or cytokine producing TCR-transduced CD8+ T
cells are displayed as pie charts for each stimulation conditions. Variant peptides are
grouped into “moderate affinity” (middle column of each panel) and “lower affinity”
(right column of each panel) in decreasing order of affinity (top to bottom). Pie charts
reflect a minimum of 2,000 cells (average 4,000 cells). Reactivity is defined by greater
than twice the percentage of total reactive cells against background (tyrosinase)
stimulation. These data are representative of a single donor from three independent
experiments using three different donors each.
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Table 12. Percent of peptide-stimulated reactivity in mono- and bi-functional
populations upon stimulation with HCV NS3 naturally processed antigen.
Epitope

CD8+ TCR-Transduced T Cells
Lytic only

IFNγ only

Lytic/IFNγ

WT
54.9
56.8
27.6
I1412L
16.5
70.5
9.4
V1408T
69.1
94.6
49.5
V1408L
18.3
106.2
10.7
I1412V
46.5
67.1
32.2
A1409T
17.5
57.6
9.5
I1412N
13.5
52.4
6.8
8S/9G/12L*
53.4
182.7
67.0
8S/9S/12L/14S
24.6
69.6
15.3
*Non-reactive; Percentages reflect the ratio of naturally processed antigen:peptide
stimulation for each functional phenotype. These data are representative of a single
donor from three independent experiments using three different donors each.

182
response suggest that either there are less overall reactive T cells, or that an equal
number of reactive T cells are producing less cytokine. This confusion can be resolved by
two-parameter analysis using flow cytometry (Fig. 43a). Additionally, IFNγ ELISAs fail to
identify that in dampened cytokine release, CD8+ T cells contribute to almost all of the
cytokine production (Fig. 43b). By simultaneously measuring intracellular IFNγ and
surface CD107a, we also demonstrated that HCV1406 TCR-transduced CD4+ and CD8+ T
cells display different proportions of mono- and bi-functional populations in light of
changes in the TCR-pMHC interaction as well as antigen density. Taken together,
comparing magnitudes of a single cytokine release within a bulk T cell culture may
oversimplify changes in reactivity. However, even a two-parameter assessment using
CD107a and IFNγ may not most accurately depict the impact of altered TCR-pMHC
interactions on T cell function. Therefore, the addition of more markers will likely better
reflect the functional phenotypes in a T cell population.
Seven-Dimensional Comparisons Provide Complicated Analysis
We expanded our assessment of altered TCR-pMHC interactions’ impact on T cell
function by using multi-dimensional flow cytometry to measure six intracellular
cytokines (IFNγ, TNFα, IL-2, IL-4, IL-17A, IL-22) and lytic marker CD107a. A multifunctional evaluation such as this may better reflect the changes in functional
phenotypes of a T cell population than one or two parameters. We wanted to be able to
compare differences in polyfunctional profiles between transduced CD4 + and CD8+ T
cells across various HCV NS3:1406-1415 peptide and HCV+ tumor stimulation conditions.
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a)

b)

Figure 43. Comparing bulk-culture single cytokine release assay versus two-parameter
FACS-based analysis provides a much different functional interpretation. IFNγ cytokine
release analyzed by ELISA by a bulk (mixed CD4+ and CD8+ HCV1406 TCR-transduced T
cell) culture is compared with bi-functional reactivity assessed by flow cytometry.
Affinity measurements for TCR-pMHC interactions are displayed below pie charts in red
(a) Reactivity against peptide-loaded T2 cells. (b) Reactivity against naturally processed
antigen.
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The analysis of seven functional parameters after gating on our lymphocyte
population markers generated 128 possible combinations of positivity/negativity for
these functional markers. Compounding the analysis were multiple peptide or tumor
stimulation conditions between two T cell subsets (CD4+ and CD8+). This yielded a
grossly complex dataset that was difficult to analyze with basic flow cytometry software.
For example, practical limitations in FlowJo, a standard software for flow
cyotmetry analysis, generally restrict the visualization of data to one or two parameters
at a time. Analysis of seven functional parameters required a matrix of 21 pairwise
dotplots for a single stimulation condition (Fig. 44). Although this matrix is limited in its
scope, we can deduce simple observations. Figure 44 displays a representative example
of pairwise comparisons in CD8+ TCR-transduced T cells stimulated with WT HCV
NS3:1406-1415 peptide-loaded T2 cells. All seven functional markers are present, but in
varying proportions. While a limited number of TCR-transduced cells produced IL-17A
and IL-22 (7.2% and 2.4%, respectively), larger proportions were positive for TNFα,
CD107a, IL-4, IFNγ, and IL-2 (ranging from 42% to 20% in decreasing order). Evaluating
two parameters simultaneously revealed interesting expression patterns. For example,
pairwise comparisons between IL-2 and TNFα demonstrated that 90% of IL-2+ cells were
also positive for TNFα, but that less than half of the TNF+ cells were also positive for IL-2.
This may suggest that IL-2 production is strictly associated with TNFα production, but
that some T cells’ TNFα production is independent of IL-2. Additionally, pairwise
comparisons in FlowJo demonstrated that while 24% of the CD8+ T cells were IFNγ+,
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Figure 44. Seven-parameter comparative analysis in FlowJo. PBL-derived T cells from a
normal donor were transduced with the HCV1406 TCR retroviral vector. TCR-transduced
T cells were enriched using anti-CD34 immunomagnetic beads. T cells were co-cultured
for 5 hr with T2 cells loaded with 10 µg/mL of HCV NS3:1406-1415 peptide or
tyrosinase:368-376 peptide. Cells were stained for CD3, CD4, CD8, CD34 and surface
CD107a and intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22 using
immunofluorescence. Gating and analysis was performed in FlowJovX. Uni-dimensional
histograms and biaxial dotplots depict single or pairwise functional comparisons in
CD34+CD8+ HCV1406 TCR-transduced T cells. Gates set against background (tyrosinase)
stimulation can be found in The Appendix, Figure 73.
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nearly equally as many IFNγ - cells were positive for either CD107a or TNFα. This
highlights the important point that evaluation for only IFNγ would incorrectly label a
large proportion of the T cells as “non-reactive”. However, analysis in FlowJo does not
easily display how many other cytokines might be expressed by IFNγ- cells.
Most surprising were T cell populations that expressed unexpected combinations
of cytokines. IL-4, a type 2 cytokine, is generally thought to be restricted to type 2 T
cells, whereas type 1 cytokines (IFNγ, TNFα, and IL-2) are restricted to type 1 T cells [64].
However, our analysis indicated that a substantial number of CD8+ T cells are doubly
positive for IL-4 and a type 1 cytokine. For example, of the 29% of IL-4+ T cells, nearly
one third were also positive for IFNγ, over one third also expressed IL-2, and nearly two
thirds also stained for intracellular TNFα. These data contradict what is normally
accepted and reported in the literature concerning type 1 and type 2 T cell populations.
Perhaps evaluation of T cell function on similarly large scales could clarify the biology of
T cell reactivity.
Portrayal of this data in FlowJo allows for simple comparisons, but would require
an inordinate number of pairwise dotplots to compare variant peptide or tumor
stimulations. In fact, it would require 756 dotplots to compare WT and mutant peptide
and naturally processed antigen stimulation between CD4+ and CD8+ T cells. This makes
meaningful interpretations of the data quite challenging. Limited to pairwise
comparisons also does not resolve how many other non-type 2 cytokines IL-4+ T cells
may also express. Similarly, pairwise comparison does not easily reveal how many
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cytokines are expressed by IFNγ- cells that would be “lost” in traditional assays. We
attempted higher resolution of multi-dimensional analysis within FlowJo, by Boolean
gating all 7 parameters to generate frequencies in each of the 128 phenotypes (2n, n =
number of parameters). FlowJo cannot easily accommodate these multi-parameter
comparisons, so we summed the frequencies of populations into categories of 0 to 7
functional parameters positive. By categorizing phenotypes into pie charts according to
the number of functional parameters expressed, we can make clearer comparisons
between CD4+ and CD8+ T cell responses across mutant epitope stimulations (Fig 45).
We found that HCV TCR-transduced CD4+ and CD8+ T cells contained a similar
percentage of antigen reactive T cells when stimulated with the WT HCV NS3:1406-1415
peptide (50.3% versus 56.5%, respectively). Both populations also exhibited a similar
number of functional markers (1 marker-13.1% vs 14.4%; 2 markers-14.5% vs 13.3%; 3
markers-11.5% vs 14.6%; 4 markers-7.0% vs 9.4%; 5 markers-3.1% vs 3.8%,
respectively). At this point, however, we still lack the resolution to detect what
combinations of cytokines are present in each category. Despite similarities in between
CD4+ and CD8+ TCR-transduced T cells upon WT peptide stimulation, there were
observable differences between polyfunctional populations across altered TCR-pMHC
interactions. For example, “moderate affinity” ligand I1412L exhibited only a slight
decrease in antigen reactive CD8+ T cells compared to WT stimulation (56.5% compared
to 51.1%). But this mutation led to a dramatic decrease in antigen reactive CD4+ T cells
(50.3% to 33.2%) (Table 13). I1412L stimulation also induced relatively modest changes
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Figure 45. Number of functional markers produced by HCV 1406 TCR-transduced T
cells when stimulated with naturally occurring mutant HCV NS3:1406-1415 peptides.
Human PBL-derived T cells were transduced to express the HCV 1406 TCR. TCRtransduced T cells were enriched using anti-CD34 immunomagnetic beads. T cells were
co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each peptide and stained
for CD107a expression and intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22. Cells
were also stained for CD3, CD4, CD8, and CD34 to measure the individual transduced T
cell subsets. Each pie wedge represents the percent of cells producing no (gray), 1 (red),
2 (green), 3 (yellow), 4 (blue), 5 (orange), 6 (purple), or 7 (pink) functional markers.
These data are representative of a single donor from three independent experiments
using three different donors each.
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Table 13. Frequencies of polyfunctional populations upon stimulation with HCV NS3:1406-1415 mutant peptides.
Epitope
WT
I1412L
V1408T
V1408L
I1412V
A1409T†
I1412N†
8S/9G/12L†
8S/9S/12L/14S†
Epitope

0

1

49.7
66.8
85.9
63.1
83.7
91.5
92.7
93.5
93.4

13.1
11.6
6.3
11.9
7.6
5.0
4.9
4.1
4.3

0

1

CD4+ T cell Functional Markers (%+)*
2
3
4
5
14.5
10.1
4.6
11.7
4.4
2.0
1.5
1.7
1.5

11.5
5.9
2.0
7.0
2.4
0.9
0.6
0.5
0.6

7.0
3.6
0.8
3.9
1.2
0.4
0.3
0.2
0.2

3.3
1.5
0.2
1.8
0.5
0.1
0.1
0.0
0.1

CD8+ T cell Functional Markers (%+)*
2
3
4
5

6

7

0.9
0.5
0.0
0.5
0.1
0.1
0.0
0.0
0.0

0.2
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.0

6

7

WT
43.5
14.4
13.3
14.6
9.4
3.8
0.9
0.1
I1412L
48.7
13.0
12.9
13.0
7.9
3.7
0.8
0.1
V1408T
56.4
12.5
11.1
11.5
6.1
2.3
0.2
0.0
V1408L
48.3
13.7
13.3
12.8
8.2
3.1
0.7
0.1
I1412V
53.7
12.2
12.3
11.6
6.7
2.8
0.5
0.1
A1409T
72.9
9.5
7.1
5.8
3.2
1.2
0.2
0.0
I1412N
65.7
10.8
9.0
7.6
4.9
1.6
0.5
0.1
8S/9G/12L†
94.4
2.7
1.7
0.8
0.3
0.1
0.0
0.0
8S/9S/12L/14S
74.9
8.6
6.6
5.9
2.8
1.1
0.1
0.0
†
*Percentages reflect frequency of cells positive for only the number of parameters indicated in each column; Non-reactive.
These data are representative of a single donor from three independent experiments using three different donors each.
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in polyfunctional frequencies compared to WT stimulation in CD8+ T cells. Percentages
differed anywhere from 1.6-0.1% in each category (1 marker-14.4% vs 13.0%; 2 markers13.3% vs 12.9%; 3 markers-14.6% vs 13.0%; 4 markers-9.4% vs 7.9%); 5 markers-3.8% vs
3.7%). There was more of a dramatic decrease, however, in the number of
polyfunctional markers among CD4+ T cells. Percentages differed as much at nearly 50%
compared to WT (1 marker-13.1% vs 11.6%; 2 markers-14.5% vs 10.1%; 3 markers11.5% vs 5.9%; 4 markers-7.0% vs 3.6%; 5 markers-3.3% vs 1.5%) (Table 13).
Interestingly, differences in polyfunctional percentages were more pronounced in
higher order polyfunctional categories (3, 4, and 5 functional parameters). Additionally,
differences in polyfunctional population frequencies were even more pronounced in
CD4+ T cells stimulated with V1408L and I1412L peptides. Although similar in affinity to
that of V1408T and I1412V, their polyfunctional profiles were substantially reduced, to
fewer than 2.5% of the cells producing 3, 4, or 5 functional makers. This is consistent
with previous observations that variant TCR-pMHC interactions with similar affinities do
not necessarily correlate with similar biologic outcomes.
A similar decrease in higher order polyfunctional categories (≥3 parameters) is
seen in CD8+ T cells stimulated with “lower affinity” mutants (A1409T, I1412N,
8S/9S/'12L/14S) compared to WT. These data support observations discussed earlier
where “lower affinity” ligands had pronounced effects on bi-functional CD107a+IFNγ+
greater than either mono-functional population. This provides further evidence that
perturbations in TCR-pMHC interactions have a biased effect on polyfunctional
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populations. Taken together, these results indicate that multi-parameter per-cell
analysis of T cell reactivity is able to resolve differences that standard assays fail to
detect.
Despite these meaningful interpretations, analysis in FlowJo still lacked the
ability to graphically portray individual polyfunctional phenotypes or display how altered
TCR-pMHC interactions impact their relative abundance. We addressed this issue by
evaluating a series of software packages in their ability to visualize and interpret our
complex, high dimensional datasets. Software evaluated included GemStone [311],
SPADE [312], FlowSOM [316], viSNE [317], and FLOCK [319]. Detailed analysis methods,
advantages and disadvantages, and representative graphical output for each tool using
our datasets are described in Chapter Two for your reference. Based on our extensive
evaluation of these software packages, tandem analysis is Pestle/SPICE was the userfriendliest and provided the most interpretable graphical output. Thus, the rest of the
discussion will focus on polyfunctional phenotypes analyzed with SPICE.
T Cell Polyfunctional Responses Are Extremely Diverse
Boolean gating within FlowJo followed by tandem analysis in Pestle/SPICE data
processing software packages adequately visualized individual polyfunctional
populations. One of the first observations was the heterogeneity in polyfunctional
populations and their frequencies between CD4+ and CD8+ TCR-transduced T cells.
Figure 46 quantitatively compares the frequencies of polyfunctional phenotypes of CD4+
and CD8+ TCR-transduced T cells stimulated with WT NS3:1406-1415 peptide-loaded T2

% TCR-transduced T cells

% TCR-transduced T cells
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Figure 46. Polyfunctional heterogeneity between WT HCV NS3:1406-1415 peptidestimulated CD4+ and CD8+ HCV1406 TCR-transduced T cells. Boolean-gated frequencies
within FlowJo were formatted within Pestle and exported into SPICE. Bar heights
compare frequencies of CD4+ (red) and CD8+ (blue) TCR-transduced T cell polyfunctional
populations after stimulation with NS3:1406-1415 WT peptide-loaded T2 cells. The bar
graph has been limited to include only populations above 0.25%. Please refer to The
Appendix, Figure 74, for frequencies of all 128 possible phenotypes. These data are
representative of three independent experiments using three different donors each.
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cells. For simplicity, a cut off has been set to only display frequencies of at least 0.25%
for either CD4+ or CD8+ T cells. Please refer to The Appendix for original output showing
frequencies of all 128 combinatorial phenotypes. It is clearly evident how
heterogeneous CD4+ and CD8+ T cells behave. For example, the two most dominant
phenotypes for both CD4+ and CD8+ are IFNγ+TNFα+ and TNFα+-only (remaining
parameters negative). But a number of phenotypes exist in CD4+ T cells that are not
evident in CD8+ T cells (TNFα+IL-4+, TNFα+IL-17A+, IL-2+IFNγ+TNFα+IL-4+). Additionally,
certain phenotypes were present in the CD8+ T cell subsets but not in CD4+ T Cells
(CD107a+TNFα+IL-4+, IL-2+CD107a+IL-17A+, IL-2+CD107a+IL-4+IL-22+). It is interesting how
many phenotypes are actually present and how variable the frequencies are between
CD4+ and CD8+ T cells. Analysis in SPICE finally provides us to resolution to make these
highly complex observations.
Another useful comparison tool in SPICE is a heat-map-like feature, known as a
cool plot. Cool plots allow us to compare changes in the frequencies of polyfunctional
phenotypes in light of altered TCR-pMHC interactions. Figure 47 displays a complete
cool plot showing frequencies (denoted by shade of blue) of polyfunctional phenotypes
(read by +/- combinations of each of the 7 functional parameters in columns). Figure 47
specifically compares the changes in polyfunctional phenotype frequencies of HCV1406
TCR-transduced CD8+ T cells after stimulation by WT and variant HCV NS3:1406-1415
peptide-loaded T2 cells. The respective cool plot for this PBL donor’s TCR-transduced
CD4+ T cells can be found in The Appendix. This representation evaluates frequencies of
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Figure 47. SPICE-generated cool plot comparing changing frequencies of T cell polyfunctional phenotypes in light of altered TCRpMHC interactions. HCV 1406 TCR-transduced T cells were co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each WT
and mutant HCV NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8, CD34, and CD107a surface expression as well as
intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22. Boolean gating for each functional marker was performed in FlowJo.
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Resulting multivariate datasets were formatted and background subtracted (tryosinase stimulation) in Pestle, and cool plot overlay
was generated in SPICE. Evaluation along the x-axis (red box) determines frequency (shade of blue) of TCR-transduced cells for each
of the 128 phenotypes. Each column is a separate phenotype denoted by +/- for each functional parameter. Evaluation along the yaxis (purple box) determines changes in frequency upon variant peptide stimulation for a given phenotype. Unique populations of
simultaneously type 1 and type 2 cytokine producing cells are denoted in green boxes. Populations negative for IFNγ are surround by
an orange box. TCR-pMHC interactions are ranked from bottom to top by decreasing affinity. These data are representative of three
independent experiments using three different donors each.
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all 128 possible phenotypes for a given stimulation condition read across the x-axis (red
box). It can also compare changing frequencies of an individual functional phenotype
across mutant epitope stimulations in the y-direction (purple box). Alterations in TCRpMHC interactions are ranked from bottom to top by decreasing TCR-pMHC affinities.
We can finally gain a clearer picture of the polyfunctional potential of these genemodified T cells and how polyfunctionality fluctuates with altered TCR-pMHC
interactions. First, it is clear that while 128 phenotypes are possible given sevenparameter analysis, not all phenotypes are observed. Second, we again detect surprising
cytokine combinations produced by individual cells. Highlighted in green boxes are IL-4+
cells (a type 2 cytokine) that also express at least one additional type 1 cytokine (IL-2,
TNFα, or IFNγ) and/or are lytic. Third, we can start to delineate differences in
polyfunctional responses in light of altered TCR-pMHC interactions by comparing
changing frequencies in the y-direction. Fourth, is it clearly evident how many reactive T
cells would be unaccounted for if only IFNγ were measured. IFNγ- populations
(surrounded by an orange box in Figure 47) accounted for surprisingly the majority of
the CD8+ T cells in the population. Once again, examining more cytokines than just IFNγ
reveals a much more complete picture of a T cell culture. Polyfunctional analysis also
suggests that the field’s conception of T cell function and the classification of T cells into
restricted cytokine-producing populations (type 1 vs type 2, etc.) may be drastically
oversimplified.
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A clearer interpretation is achieved when cool plots are condensed to display
only detectable populations in each culture. Figure 48 shows condensed cool plots for
both CD4+ (Fig. 48a) and CD8+ (Fig. 48b) HCV1406 TCR-transduced T cells stimulated
with HCV NS3:1406-1415 mutant peptides. TCR-pMHC interactions are ordered from
bottom to top by decreasing affinity. Condensed cool plots also highlight the
heterogeneity between CD4+ and CD8+ T cell responses. Additionally, while lower
affinity TCR-pMHC interactions yield overall lower frequencies, not each polyfunctional
population is affected equally, nor are changes in polyfunctional responses directly
correlated with affinity. For example, TNFα +-only population fluctuated much more in
CD4+ TCR-transduced T cells despite the strength of the mutant TCR-pMHC interactions
(I1412L, V1408T, V1408L, I1412V) being relatively similar (32-63 µM) (Fig. 48a). Higher
order phenotypes (3 or 4 functional markers) were also restricted to WT, I1412L, and
V1408L peptide stimulations. These results suggest that certain pMHC ligands may be
recognized differently by the TCR (despite similar affinities) leading to a less diverse
polyfunctional response.
A similar trend is seen when comparing functional frequencies of CD8+ TCRtransduced T cells (Fig. 48b). For example, the frequencies of the CD107a+-only
population were very consistent with roughly 5% of CD8+ T cells present in nearly all
mutant peptide stimulations. However, IFNγ+TNFα+ (all other parameters negative) CD8+
TCR-transduced T cells exhibit a higher degree of change. There was less variability in
response to the “moderate affinity” group of TCR-pMHC interactions, but V1408L
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a)

b)

Figure 48. Polyfunctional phenotypes are heterogeneous and fluctuate with altered
TCR-pMHC interactions. Human PBL-derived T cells were transduced to express the
HCV1406 TCR. T cells were co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of
each WT and mutant HCV NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8,
CD34, and CD107a surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL17A, and IL-22. Multivariate analysis was performed using FlowJo, Pestle, and SPICE
software packages. Condensed cool plots display frequencies of polyfunctional
populations of (a) CD4+ or (b) CD8+ TCR-transduced T cells shown in increasing order of
polyfunctionality (right to left). Each column is a separate phenotype denoted by +/- for
each functional parameter. TCR-pMHC interactions are ranked from bottom to top by
decreasing affinity. Complete cool plots are shown in Figures 47 and 75. These data are
representative of three independent experiments using three different donors each.

199
induced lower frequencies of reactive T cells in almost all phenotypes compared to
I1412L, V1408L, or I1412V. Interestingly, “lower affinity” pMHC (A1409T,
I1412N, and 8S/9S/12L/14S) induced a fewer number of detected phenotypes overall.
Generally, the absence of higher order polyfunctional populations (4 or 5 functional
markers) correlated with lower TCR-pMHC affinity. Furthermore, the frequency of all
functional phenotypes was decreased when T cells were stimulated with lower affinity
compared to moderate affinity ligands. Overall, portraying data in SPICE-generated cool
plots provided a remarkable tool to characterize the polyfunctionality of T cells. We can
very easily observe the polyfunctional heterogeneity between CD4+ and CD8+ T cells and
the varying impact that alterations in TCR-pMHC interactions have on the spectrum and
frequency of polyfunctional populations.
Heterogeneity in Polyfunctional Responses Exists Among PBL Donors
We examined whether polyfunctional phenotypes against our panel of mutant
pMHC were donor-dependent by evaluating polyfunctionality in HCV TCR-transduced T
cells derived from PBL of additional donors. Representative condensed cool plot of CD4+
or CD8+ HCV TCR-transduced T cells from two different donors are displayed in Figures
49-50, respectively. Full cool plots for these and other donors can be found in The
Appendix. Interestingly, functional T cell phenotypes were not the same between
different donors despite being transduced with the same TCR and stimulated with the
same ligands. For example, Figure 48 displays cool plots highlighting differences
between T cell functional phenotypes of two donors’ CD4+ TCR-transduced T cells
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against HCV NS3:1406-1415 peptide-loaded T2 cells. Compared to Donor 2, Donor 1’s
TCR-transduced CD4+ T cells (Fig. 49a) were less reactive overall (56.5% vs 78.2% total
reactive T cells) and less heterogeneous (fewer functional phenotypes present; 12 vs 18)
(Fig. 49b). Additionally, Donor 1 exhibited functional phenotypes lacking in Donor 2 (i.e.
TNFα+IL-4+ (approximately 8% of WT peptide-stimulated)). Similarly, certain phenotypes
were absent in Donor 1 that were present in Donor 2 (i.e. IL-22+TNFα+IL-17A+
(approximately 4% of WT peptide-stimulated)). Donor 2 was also more polyfunctional
upon stimulation with WT peptide. For example, donor 2 exhibited 8 quad-functional
populations compared to Donor 1 having only 1 quad-functional population.
Polyfunctional profiles of additional donors have been evaluated and representative
cool plots can be found in The Appendix. These observations suggest that the number
and type of functional phenotypes between PBL donors are not necessarily consistent.
Similar trends were observed between TCR-transduced CD8+ T cells of Donor 1
(Fig. 50a) and Donor 2 (Fig. 50b). Donor 1 also had polyfunctional CD8+ TCR-transduced
T cell populations missing in Donor 2 (bi-functional TNFa+IL-2+ (approximately 2% of WT
and “moderate affinity”-stimulated T cells)). Conversely, Donor 2 quad-functional
TNFα+IL-17A+CD107a+IFNγ+ population (ranging from 2-6% of total cells) was absent in
Donor 1. These donors exhibited similar numbers of individual polyfunctional
populations present (equal at 19), but varied in the number of simultaneous parameters
detected. For example, Donor 1 had fewer higher order polyfunctional (3 parameters or
less) populations (5 mono-functional, 5 bi-functional, 5 tri-functional, 3 quad-functional,
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a)

b)

Figure 49. Heterogeneity of HCV1406 TCR-transduced CD4+ T cells in two PBL donors. T
cells from two PBL donors were transduced to express the HCV 1406 TCR. T cells were
co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each WT and mutant HCV
NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8, CD34, and CD107a
surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22.
Multivariate analysis was performed using FlowJo, Pestle, and SPICE software packages.
Condensed cool plots display frequencies of polyfunctional populations CD4+ TCRtransduced T cells of (a) Donor 1 and (b) Donor 2 shown in increasing order of
polyfunctionality (right to left). Each column is a separate phenotype denoted by +/- for
each functional parameter. TCR-pMHC interactions are ranked from bottom to top by
decreasing affinity. Complete cool plots are shown in The Appendix, Figures 75-76.
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a)

b)

Figure 50. Heterogeneity of HCV1406 TCR-transduced CD8+ T cells in two PBL donors. T
cells from a second PBL donor were transduced to express the HCV 1406 TCR. T cells
were co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each WT and mutant
HCV NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8, CD34, and CD107a
surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22.
Multivariate analysis was performed using FlowJo, Pestle, and SPICE software packages.
Condensed cool plots display frequencies of polyfunctional populations CD8 + TCRtransduced T cells of (a) Donor 1 and (b) Donor 2 shown in increasing order of
polyfunctionality (right to left). Each column is a separate phenotype denoted by +/- for
each functional parameter. TCR-pMHC interactions are ranked from bottom to top by
decreasing affinity. Complete cool plots are shown in Figure 47 and in The Appendix,
Figure 77.
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and 1 penta-functional phenotypes), whereas Donor 2 demonstrated much more higher
order (4 or greater parameters) populations (3 mono-functional, 4 bi-functional, 4 trifunctional, 3 quad-functional, 4 penta-functional, and 1 hexa-functional phenotypes).
These observations suggest that PBL can be comprised of very heterogeneous T cell
populations within a single culture and between donors. Despite being engineered with
the same TCR and stimulated with the same pMHC, both number and frequency of
polyfunctional populations can dramatically differ but general trends between altered
ligand reactivity remained the same.
Such heterogeneity is difficult to explain, but may begin to offer explanations for
different patients responses to therapies. For instance, if a more polyfunctional
response is more advantageous, than Donor 2’s T cells may perform better
therapeutically. However, if a certain individual phenotype is a “better” anti-tumor
phenotype (i.e. IL-2+TNFα+IL-4+) Donor 1 may have the advantage because this
population is present in approximately 5% of reactive CD8+ T cells against WT and
multiple mutant antigens, but is absent all together in Donor 2. This inherent
heterogeneity between donors is an interesting observation and concept, but further
investigation into identifying which functional populations are “better” for anti-tumor or
anti-viral responses is needed.
Reduced Ligand Density Dampens Polyfunctional Responses
Earlier, we described that reduced ligand density had a dramatic effect on T cell
function. As a follow up to this concept, we evaluated if there were altered
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polyfunctional responses against HepG2 cells engineered to express naturally processed
NS3 variants (Fig. 51). Similar to previous experiments, CD4+ T cells were non-reactive
against this “lowest density” naturally processed antigen, but CD8+ T cells demonstrated
polyfunctional responses against WT and “moderate affinity” ligands I1412L, V1408T,
V1408L, and I1412V (Fig. 52a). Remarkably, there was a dramatic reduction in
polyfunctional phenotypes compared to peptide-stimulated CD8+ T cells (Fig. 52b).
Peptide-stimulated cells exhibited a robust response comprised of 19 different
functional phenotypes ranging from mono-functional to hexa-functional (6
simultaneous parameters). Conversely, tumor-stimulated CD8+ T cells were restricted to
only 9 different functional phenotypes, the majority (6/9) being limited to mono- or bifunctional. There were only 2 tri- and 1 quad-functional populations present. Penta-and
hexa-functional populations that made up roughly 25% of peptide-stimulated
phenotypes were now completely absent. Tumor stimulation also seemed to
preferentially reduce higher order polyfunctional populations and restricted the
heterogeneity of responses. This suggests that a lower level of antigen density may
result in incomplete T cell activation.
To further evaluate the effects of decreasing antigen density on polyfunctional T
cell responses, we stimulated HCV TCR-transduced T cells with T2 cells loaded with the
WT NS3:1406-1415 peptide at concentrations ranging from 10 µg/mL to 10-11 µg/mL.
We also stimulated HepG2 cells expressing naturally processed WT NS3 (“lowest
density” of ligand) or HepG2 cells exogenously loaded with 10 µg/mL WT peptide to
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Figure 51. Generation of HepG2 cells expressing naturally processed HCV NS3 with WT
and naturally occurring mutant NS3:1406-1415 epitopes. HepG2 cells were transduced
retroviral vectors encoding full length HCV NS3 protein containing WT or variant
NS3:1406-1415 epitopes fused to GFP by a T2A linker. Cells were sorted for high and
uniform GFP expression. WT antigen was slightly downregulated after multiple
passages. Mean fluorescence intensity of each population is listed in parentheses.
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a)

b)

Figure 52. NS3+ HepG2 stimulation reveals a markedly reduced polyfunctional
response. T cells from two PBL donors were transduced to express the HCV 1406 TCR. T
cells were co-cultured for 5 hours with HepG2 cells engineered to express full length
HCV NS3 with WT of variant 1406-1415 epitopes. Cells were stained for CD3, CD4, CD8,
CD34, and CD107a surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL17A, and IL-22. Multivariate analysis was performed using FlowJo, Pestle, and SPICE
software packages. Condensed cool plots display frequencies of polyfunctional
populations CD8+ TCR-transduced T cells stimulated by (a) HCV NS3+ HepG2 cells or (b)
Peptide-loaded T2 cells. Functional phenotypes are shown in increasing order of
polyfunctionality (right to left). Complete cool plots are in The Appendix, Figures 77,79.
Data are representative of three independent experiments using three different donors.
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augment ligand density (Fig. 53). We found that a reduction in ligand concentration
from 10 to 10-3 µg/mL eliminated nearly all functional responses in CD4+ TCR-transduced
T cells. Interestingly, the IL-4+-only population maintained prevalence throughout, which
might suggest that production of IL-4 has lowest the threshold of TCR-pMHC contacts
for initiation. CD8+ TCR-transduced T cells on the other hand exhibited a greater
tolerance for reduced antigen density, with gradual reductions in frequency across
multiple functional phenotypes. Interestingly, higher order polyfunctional populations (4
or 5 parameters positive) were more susceptible to changes in ligand density as they
were eliminated when stimulated with lower concentrations (10-5-10-7 µg/mL)
compared to mono- or bi-functional populations that were still present when stimulated
with 10-11 µg/mL of antigen.
NS3+ HepG2 cells expressing naturally processed antigen, on the other hand,
stimulated minimal polyfunctional responses, suggesting the density of ligand may be
less than that of 10-11 µg/mL peptide-loaded T2 cells. Remarkably, exogenously loading
HepG2 cells with 10 µg/mL peptide, increasing relative ligand density, rescued the
frequency and range of polyfunctional phenotypes. Polyfunctional responses were now
comparable to stimulation by “highest density” T2 cells. Increasing antigen density on
HepG2 cells even restored polyfunctional responses in CD4+ T cells that had minimal
reactivity against naturally processed antigen. Overall, these data support the notion
that ligand density not only plays a role in binary T cell reactivity, but highly influences
polyfunctional responses, especially higher order polyfunctional T cells.
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a)

b)

Figure 53. Influence of ligand density on polyfunctional phenotypes. PBL-derived T
cells transduced with the HCV1406 TCR retroviral vector were co-cultured with T2 cells
loaded with WT HCV NS3:1406-1415 peptide ranging from 10 – 10-11 µg/mL. T cells were
also co-cultured with HepG2 cells expressing naturally processed full length NS3 protein
or HepG2 cells exogenously loaded with 10 µg/mL NS3:1406-1415 peptide. Cells were
stained for extracellular markers and intracellular cytokines; multivariate analysis was
performed in FlowJo, Pestle, and SPICE software packages. Condensed SPICE-generated
cool plots display frequencies of polyfunctional populations for (a) CD4+ and (b) CD8+
TCR-transduced T cells. Complete cool plots are shown in The Appendix, Figures 84-85.
These data are representative of independent experiments using two different donors.
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Hierarchical Clustering Relates Polyfunctional Phenotypes
to Alterations in TCR-pMHC Interactions
While it is clear that there are differences in polyfunctional phenotypes against
our panel of naturally occurring HCV NS3:1406-1415 variants, it would be helpful to
relate these changes to alterations in TCR-pMHC affinity. To do this, we utilized a
classical bioinformatic approach known as hierarchical clustering analysis, which clusters
phenotypic patterns which are most similar to each other. It was made popular in the
era of gene expression microarray data analysis where both tissue samples and genes
would be clustered to identify genes that could distinguish between tissue subtypes
[321]. In our experimental data, hierarchical clustering ranked the frequencies of T cell
functional phenotypes as well as their relatability using dendograms. Phenotype
patterns that do not occur are in a sense relegated to the bottom of the clustering
analysis output, providing an easy way to focus on pertinent data.
The hierarchical clustering analysis shown here is a tailored version, visualizing
only the phenotypes present in a CD8+ TCR-transduced T cell culture stimulated with T2
cells, loaded with each HCV NS3:1406-1415 peptide (Fig. 54), corresponding to Donor 1
cool plots shown in Figures 47-48. Complete hierarchical clustering for multiple donors’
CD4+ and CD8+ TCR-transduced T cell stimulations can be found in The Appendix.
Hierarchical clustering also relates pMHC ligands by their induced functional
phenotypes. So, ligands that stimulated a similar intensity or number of functional
phenotypes are represented closer together in the dendogram than pMHC ligands that
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Figure 54. Bioinformatic hierarchical clustering relates polyfunctional responses to TCR-pMHC affinity. A hierarchical clustering
analysis using FlowJo Boolean gated frequencies organizes polyfunctional phenotype by frequency and relatedness (left
dendograms) by peptide-stimulated TCR-transduced CD8+ T cells. This analysis can also demonstrate response relatedness between
HCV NS3:1406-1415 peptide stimulations (top dendograms). An affinity value for each variant TCR-pMHC interaction is denoted in
red. Output has been modified to portray only positively identified phenotypes. Please refer to The Appendix, Figure 88 for complete
output.
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stimulated less intense or more dissimilar functional phenotypes. Comparing
hierarchical clustering of pMHC ligands with TCR-pMHC affinity measurements (red
font) demonstrated that the strength or diversity of a T cell response is not necessary
dependent on affinity. While “moderate” and “lower” affinity variants tended to be
related in larger groups, dendograms did not order individual mutant pMHC ligands
strictly by their KD values. This relatedness (grouping) of pMHC ligands was conserved in
multiple peptide-stimulated donors (Figs. 54-55). Interestingly, the relatedness
(grouping) of pMHC ligands changed upon tumor stimulation (Fig. 56), suggesting that
the alterations in TCR-pMHC interactions can have a different impact on functional
outcomes at lower densities. While TCR-pMHC affinity is routinely thought to be the
most influential factor governing antigen recognition, we demonstrate yet again, that
this is not entirely true.
Significance
It is clear that the evaluation of T cell reactivity based on a single cytokine
readout is not a completely accurate representation of the biology of the T cell culture.
We first established this by evaluating two distinct functions, lytic activity and cytokine
production, by measuring surface CD107a and intracellular IFNγ by flow cytometry. We
were able to observe functional heterogeneity between CD4+ and CD8+ HCV TCRtransduced T cells. We also established that alterations in TCR-pMHC interactions and
changes in ligand density preferentially decreased bi-functional CD107a+IFNγ+
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Figure 55. A second PBL donor relates mutant peptide responses similarly but with different clustering of polyfunctional
phenotypes. A hierarchical clustering analysis using FlowJo Boolean gated frequencies organizes polyfunctional phenotype by
frequency and relatedness (left dendograms) by peptide-stimulated TCR-transduced CD8+ T cells in a second PBL donor. This analysis
portrays the same relatedness between HCV NS3:1406-1415 peptide stimulations evaluated in a previous donor (top dendograms).
Affinity values for each variant TCR-pMHC interaction are denoted in red. Output has been modified to portray only positively
identified phenotypes. Please refer to Appendix, Figure 90 for complete output.
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Figure 56. Hierarchical clustering also relates tumor-stimulated responses. A hierarchical clustering analysis using FlowJo Boolean
gated frequencies organizes polyfunctional phenotype by frequency and relatedness (left dendograms) by HepG2 or NS3 + HepG2
cell-stimulated TCR-transduced CD8+ T cells in a second PBL donor (peptide response displayed in Figure 55). This analysis portrays
the relatedness between naturally processed antigen stimulations (top dendograms). An affinity value for each variant TCR-pMHC
interaction is denoted in red. Output has been modified to portray only positively identified phenotypes. Please refer to The
Appendix, Figure 92 for complete output.
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populations over either mono-functional phenotype. Large changes in total reactivity
and individual phenotype frequencies occurred, in some cases, despite similar TCRpMHC affinities. These data provided further evidence that affinity does not entirely
dictate antigen recognition.
We then expanded our assessment of T cell polyfunctionality to include
additional cytokines TNFα, IL-2, IL-4, IL-17A, and IL-22, which yielded highly complex
multi-dimensional data sets. Analysis in software packages FlowJo, Pestle, and SPICE
allowed us to graphically compare functional responses of HCV TCR-transduced T cells
against our panel of naturally occurring mutant peptides. We found that CD4+ and CD8+
TCR-transduced T cells exhibited a much greater degree of phenotypic and functional
complexity than previously appreciated. It was also clear that altered TCR-pMHC
interactions influenced these diverse responses. This observed large degree of
functional diversity may give T cells a remarkable degree of flexibility in responding to
pathogens or tumor. Furthermore, at a single cell level, most of the traditional
functional classifications (type 1, type 2, etc.) do not always hold true. These results
suggest that polyfunctional analysis of T cells was able to perceive differences that
standard assays fail to detect. Observations using human TCR-transduced T cells are
intriguing because they represent the kinds of T cell populations we transfer to patients.
Heterogeneity between PBL donors demonstrated differences in phenotypes identified
as well as overall polyfunctionality. Expansive evaluation of T cell polyfunctionality in the
context of anti-viral or anti-tumor responses may allow for better treatment
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correlations, biomarkers for predictive outcomes, or the ability to select for or design an
“optimal” phenotype of T cells to be used in ACT.
However, it is still unclear how alterations in TCR-pMHC interactions dictate
changes in polyfunctional phenotypes. While hierarchical clustering analysis supports
our hypothesis that TCR-pMHC affinity is not necessarily correlated with antigen
recognition, we still lack a firm explanation for this phenomenon. The next chapter
attempts to give weight to all these data in light of what is accepted in the field. We will
speculate on structural observations that may help rationalize discrepancies in
polyfunctional outcomes. We will also discuss how our novel observations may
influence what should be considered when optimizing TCRs for gene-modification of T
cells used in ACT.

CHAPTER SEVEN
CONCLUSIONS
Introduction
Adoptive cell transfer using TCR gene-modified T cells is an exciting and rapidly
evolving field. Numerous in vitro and in vivo studies discussed in Chapter One have
demonstrated various levels of feasibility, safety, and efficacy using TCR-engineered T
cells to treat cancer and viral infections. Although evidence suggests their use can be
effective, how effective and how to improve these therapeutics are still remaining
questions.
Various means of improving the efficacy of TCR-engineered T cells, previously
discussed, include cytokine and chemokine support, modifying retroviral vectors to
promote pairing of introduced TCR α and β chains, and affinity-enhancement of the TCR.
Because the affinity of TCR-pMHC interaction is thought to play the central role in
defining T cell specificity and sensitivity , most of the field has adopted the theory that
creating affinity-enhanced TCRs results in better functioning T cells. Although
physiologic TCR-pMHC affinities traditionally range anywhere from 1-100 µM [11], the
use of yeast and phage display can generate TCRs with affinities in the nM to pM range
[3, 4]. However, enhanced affinity creates the opportunity for cross-reactivity. In fact, it
has been shown in vitro that high affinity TCRs are much more tolerant of TCR contact
216
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residue substitutions and dramatically increase the number of stimulatory peptides
[407]. Additionally, a clinical trial using a MART-1-specific TCR with a KD of only 30 µM
demonstrated serious adverse events due to on-target/off-tumor activity [184].
Moreover, a murine-derived, affinity-enhanced MAGE-3-specific TCR caused lethality in
another clinical trial due to off-target cross-reactivity with structurally similar epitopes
[211, 213].
While TCR cross-reactivity was unwanted and detrimental in these cases, crossreactive TCRs may offer therapeutic benefits if the antigens targeted are susceptible to
mutation from genomic instability. Thus, the proper choice and design of therapeutic
TCRs mandates a broader understanding of the basic principles governing antigen
recognition by a T cell. In light of what is known about TCRs and T cell function,
numerous factors still need to be addressed. These include: (1) what kinetic or cellular
factors are most important in facilitating antigen recognition; (2) how is T cell function
affected by alterations in TCR-pMHC interactions; (3) how can we structurally rationalize
the cross-reactivity of a TCR; and (4) how might such cross-reactivity augment or inhibit
therapeutic benefit.
The studies discussed in this dissertation aimed to address the above questions.
Below we revisit key findings identified in each chapter and discuss how they contribute
to an enhanced understanding of antigen recognition and T cell function. We also point
out what questions are still unanswered and what needs to be addressed to advance
the development of safe and efficacious TCR-engineered T cells for ACT.
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HCV1406 TCR Displays Anti-Tumor Activity In Vivo
For any adoptive immunotherapy to be a viable treatment option, it must be
clearly evident that antigen-reactive T cells are capable of being generated. Additionally,
physiologically relevant targets need to be recognized by functional T cells. We believe
that we have fulfilled these criteria. We demonstrated that we can engineer T cells with
an HLA-A2-restricted, HCV NS3:1406-1415-reactive, CD8-independent TCR (HCV1406
TCR). We also showed that PBL-derived T cells engineered to express HCV1406 TCR are
capable of recognizing naturally processed HCV NS3 antigen presented by HCC cell lines
in vitro and can mediate the regression of established HCV+ tumors in vivo.
To date, only a limited number of naturally occurring CD8-independent TCRs
have been cloned and characterized. The ability of the HCV1406 TCR to transfer
reactivity to both effector and helper T cells is advantageous for an effective
immunotherapy candidate. HCV1406 TCR-transduced CD4+ and CD8+ PBL-derived T cells
recognized both peptide-loaded targets and a variety of HCV+ tumor cells lines. Our in
vivo tumor regression model further supports our in vitro data that this TCR is capable of
recognizing HCV+ tumors. Further analysis of differential adoptive transfer of CD8 + T cells
with and without CD4+ T cells may better distinguish the importance of generating CD4 +reactive T cells for eliminating tumor, which may influence treatment modality in
patients. Since one of the fundamental problems typical of chronic or recurrent HCV
infections is a weak or absent HCV-specific CD4+ T cell response [363, 364, 408, 409], the
ability to engineer CD4+ T cells capable of secreting cytokines and exhibiting cytolytic
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activity may be extremely beneficial for an effective treatment. Taken together, we have
established a proof-of-principle that we can generate TCR gene-modified CD4+ and CD8+
PBL-derived T cells capable of impacting on the growth of HCV+ tumor targets and may
be a useful tool to treat patients with HCV-associated diseases, such as HCC.
While other studies have examined AFP [410-412], ferritin [413], NY-ESO-1 [414418] or Glypican 3 [417, 419-424] as biomarkers or therapeutic targets for HCC, we have
chosen to investigate HCV for its nonself nature, its immunogenicity, and the fact that
HCV is a major risk factor for the development of HCC. While the role of HCV proteins in
hepatocarcinogenesis is not well described, HCV is mainly thought to cause HCC via
indirect pathways including chronic inflammation, cell death, proliferation, and cirrhosis
[425-428]. Consequently, it is possible that HCV TCR-transduced T cells would target
both normal and malignant hepatocytes, potentially leading to severe adverse events,
as noted by another group investigating HCV TCR-redirected T cells [222]. This
accompanied with cirrhosis and liver dysfunction in many HCC patients may limit a
systemic infusion of HCV TCR-transduced T cells. Thus, clinical trials for this
immunotherapy are designed to involve CT or ultrasound guided intratumoral injection
in a manner similar to transarterial chemoembolization or radioembolization. A similar
intratumoral technique was used successfully in one of our previous clinical trials [207].
Such carefully thought approaches would help preclude significant exposure of normal
hepatocytes to the HCV TC- transduced T cells and minimize adverse events.
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In summary, our results are encouraging that HCV1406 TCR gene-modified T cells
could serve as an immunotherapeutic candidate for HCV-associated HCC. However, the
propensity for HCV to generate immune escape variants due to its genomic instability
[279, 352-356] may require an effective TCR to recognize mutated epitopes. Therefore,
it is important to assess the cross-reactivity of HCV-reactive TCRs against naturally
occurring and epidemiologically relevant mutant epitopes to better evaluate their
therapeutic benefit. Characterizing TCRs cross-reactive against mutagenic HCV antigens
not only serves as a model for designing therapeutics against diseases with genomic
instability, but also serves as a model to study the kinetic and biologic principles
governing antigen recognition.
Cross-Reactive TCRs May Be Therapeutic Against
Diseases with Genomic Instability
Immune evasion by viruses and cancer cells has been a critical barrier to
mounting effective host immune responses and has been problematic for the
development of successful immunotherapies including ACT. A combination of
viral/cancer genomic instability and immense selective pressure by successful immune
effectors can lead to such escape variants. Manipulating the immune system to
selectively eliminate its target while maintaining flexibility to combat genomic
instability, a driving force behind immune escape, is the ultimate therapeutic goal. As
discussed, we hypothesize that TCRs flexible enough to facilitate T cell recognition of
mutated epitopes may serve as a vehicle to achieve this goal.
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We addressed this hypothesis by establishing a model to evaluate the
therapeutic benefit of cross-reactive TCRs to combat diseases with genomic instability.
As discussed, the HCV genome contains several regions that are genetically unstable and
mutate readily [357, 358], making HCV an excellent model for genomic instability. To
create our model, we selected panels of naturally occurring and epidemiologically
relevant mutants of two immunogenic epitopes to assess the cross-reactivity of a pair of
HCV-reactive TCRs. The cross-reactivity observed by two independently isolated TCRs
against two different, but highly antigenic HCV epitopes argues strongly that the ability
of a TCR to be cross-reactive against a spectrum of mutant antigens is a generalizable
phenomenon.
We were originally interested in the cross-reactive potential of HCV1406 TCR
because it was an allo-reactive TCR [302]. Interestingly, we found that HCV1406 TCRtransduced T cells recognized numerous naturally occurring HCV NS31406-1415
epitopes identified in the GenBank. Aside from being naturally occurring, it is important
to evaluate the epidemiologic prevalence of these mutations in infected individuals.
Such validation would enhance the clinical relevance of the HCV1406 TCR, and would be
an important point to consider for establishing the therapeutic merit of any crossreactive TCR. A QuickAlign search of the Los Alamos HCV Sequence Database, which
houses 918 recorded worldwide HCV genome sequences from infected individuals,
provided a tool to perform this analysis.
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While the WT and eight variant epitope sequences studied for NS3:1406-1415
account for 42.38% of all recorded sequences in the Los Alamos HCV Sequence
Database, they comprise 80.38% of the recorded genotype 1a sequences, most
applicable to the United States [373]. As discussed, cross-reactivity against seven out of
the eight mutant epitopes by TCR-transduced CD8+ effectors nearly doubled the amount
of recorded sequences recognized compared to the prevalence of the WT epitope
(43.46%). Additionally, CD8-independent recognition of WT and four mutant epitopes
suggests HCV1406 TCR is a high affinity receptor and may facilitate CD4+ T cell cytokine
support against 78.42% of recorded sequences. Thus, HCV1406 TCR’s cross-reactivity
profile greatly enhances coverage against observed mutant epitopes. Furthermore, the
generation of both helper and effector T cells allows for a novel population of MHC-class
I restricted T helper cells to contribute to a broadened immune response.
We also characterized the cross-reactivity of a second, non-allo-restricted, TCR
against a second immunodominant HCV epitope NS3:1073-1081. Gene transfer of
HCV1073 TCR into T cells also facilitated CD8-independent recognition of multiple
naturally occurring and epidemiologically relevant mutant epitopes. As discussed, the
NS3:1073-1081 epitope for genotype 1a is well conserved with 90.2% of the recorded
genomes in the Los Alamos Database exhibiting the WT CINGVCWTV epitope. However,
genotype 1b is dominated by the I1074V mutant at 45.57% , WT comprising only 41.59%
of recorded sequences. Cross-reactivity of the HCV1073 TCR against WT and I1074V
epitopes alone could provide enhanced coverage for 94.46% and 89.3% of genotypes 1a

223
and 1b, respectively, most relevant to the United States’ and Europe’s viral prevalence
[373]. Based on the prevalence of mutations studied, our HCV model suggests T cells
engineered with such cross-reactive TCRs may provide therapeutic benefit while limiting
selection for escape variants [365].
In light of observations that cross-reactive TCRs might enhance recognition
against epidemiologically prevalent mutant targets, it is important to understand the
biology behind TCR cross-reactivity. How peptide amino acid changes are tolerated or
weaken the ability of the T cell to recognize pMHC are important points to consider
when identifying or designing an immunotherapeutic candidate.
In our model for genomic instability, we have combined our functional studies
with TCR-pMHC structural modeling. Our structural models allowed us to generate
rational hypotheses for cross-reactivity by the HCV1406 and HCV1073 TCRs. Generally,
we found amino acid substitutions that do not impact function occur in regions with few
or no TCR or MHC contacts, or alternatively, are conservative substitutions that are not
predicted to alter contacts.
Presumably, other TCRs in patients from which the viruses harboring the various
NS3 mutant sequences propagated made more crucial TCR contacts at these positions,
permitting viral escape. It is logical to predict that HCV1406 and HCV1073 TCRs exhibit a
greater flexibility than TCRs in patients that would have allowed these immune escape
variants to exist and persist. However, because HCV14073 TCR was isolated in a patient
with a chronic HCV infection [166] this may not always be the case. Such TCRs may also
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not be able to accommodate every possible mutation (i.e. HCV1406 TCR non-reactivity
against variant 8S/9G/12L). However, if immune pressure is cross-reactive enough or
there are multiple clonal cross-reactive T cell responses in an infected individual, it may
limit the ability for a virus to avoid such a diverse immune pressure.
One might predict viral mutations affecting proteosomal processing or peptide
binding to MHC (namely anchor residues) would be most beneficial for immune evasion
should it reduce or eliminate the ability of the peptide to be properly presented by
MHC-l. However, in the case of NS3:1406-1415, there were only 6 out of 918 recorded
substitutions involving anchor positions 2 or 10. What would seemingly be an
advantageous mutation for the virus may have been restricted if these residues are
important for NS3 function or necessary for overall viral fitness. Verification of our
structure-based hypotheses as well as a more detailed examination of potential
structural alterations not predicted by our modeling would be helpful to understand
implications of altered pMHC on T cell function.
Overall, in our HCV model for genomic instability, we have characterized CD8independent recognition of multiple naturally occurring mutant epitopes for two HCVcross-reactive TCRs. The reported HCV genome sequence data greatly adds clinical
relevance to the potential therapeutic use of either or both of these receptors in ACT.
Furthermore, preliminary experiments evaluating cross-reactivity of T cell clones raised
from chronically infected versus spontaneously resolved patients support the
hypothesis that HCV-cross-reactive TCRs could have an impact on clearance of HCV
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infection or its associated disease. Aside from therapeutic implications for HCV and its
associated disease, this approach serves as a helpful roadmap to identify or develop
therapeutic cross-reactive TCRs. It may also allow us to better understand our immune
response towards diseases with genomic instability.
TCR-pMHC Affinity Does Not Necessarily Dictate T Cell Function
Although our structural modeling of HCV1406- and HCV1073 TCR-pMHC
interactions helped explain altered T cell reactivity against naturally occurring mutant
epitopes, it does not provide a true mechanism for what facilitates antigen recognition.
It is important to consider what kinetic and/or cellular parameters help facilitate antigen
recognition in light of altered TCR-pMHC interactions. A better understanding of what
influences antigen recognition may help modify TCRs to specifically enhance or inhibit
TCR cross-reactivity to improve efficacy and maximize safety.
TCR-pMHC affinity is generally thought to play the most central role driving T cell
specificity and reactivity [1]; therefore, it was logical to compare T cell reactivity against
each variant pMHC with the affinity of each TCR-pMHC interaction. Because the two
cysteine residues in NS3:1073-1081 peptides inhibited biochemical characterization, we
proceeded with analysis of only HCV1406 TCR with WT and variant NS3:1406-1415
epitopes. To correlate TCR-pMHC affinity with T cell function, we compared the
equilibrium KD for each TCR-pMHC to the magnitude of IFNγ release by TCR-transduced
CD4+ or CD8+ T cells. Measurable affinities grouped the peptides into categories of
“moderate affinity” compared to 17 μM for WT (I1412L, V1408T, V1408L, and I1412V,
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ranging from 32-63 μM) and “lower affinity” (A1409T, I1412L, and 8s/9G/12L, ranging
from 120-169 μM). The TCR-pMHC affinity for mutant 8S/9S/12L/14S was unable to be
measured but was grouped into this category based on predicted affinity from its amino
acid substitutions and its CD8-dependent recognition.
We found that affinity seemed to trend with antigen recognition, as WT and
“moderate affinity” mutants were CD8-independent, and “lower affinity” variants were
generally CD8-dependent. These observations seemed consistent with the field’s
interpretation of affinity’s importance on antigen recognition. However, the magnitude
of T cell responses did not completely agree with this theory. As discussed, TCRtransduced CD4+ T cells secreted less IFNγ against V1408T and I1412L compared to
mutants with similar affinites. Furthermore, I1412N and 8S/9G/12L have virtually
identical affinity measurements (168 and 169 μM, respectively), but recognition of
I1412N was CD8-dependent and 8S/9G/12L was not recognized. These functional
observations are quite inconsistent with what would have been predicted based solely
on affinity measurements.
Responses by CD8- T cells should more accurately reflect affinity’s influence on
functional recognition because SPR measurements take place in the absence of CD8.
However, the functional avidity of HCV1406 TCR-transduced CD4+ T cells against mutant
NS3:1406-1415 epitopes did not always correlate with the affinity of the TCR-pMHC
interactions. This discord between TCR-pMHC affinity and T cell reactivity contradicts
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what is accepted by many in the field and surprisingly suggests that TCR-pMHC affinity
may not be the most important influence on T cell function.
One potential explanation for these inconsistencies is that affinity
measurements by SPR may not necessary necessarily reflect the true affinity of the
physiologic TCR-pMHC interaction. SPR is performed in three-dimensional (3D) space
with soluble TCRs and pMHCs. However, physiologically the TCR and pMHC are
anchored on two-dimensional (2D) membranes of opposing cells [429]. One major
caveat of 3D measurements by SPR is that soluble TCRs fail to account for the possible
regulations imposed by the complex T-cell membrane environment. These include
reduced spatial degrees of freedom of molecular motion and the presence of coreceptors [430]. Consequently, affinity rates in physiologic 2D may be vastly different
from what is measured in typical 3D assays.
To overcome the limitation of 3D affinity measurements, methods have been
developed to establish binding partners anchored onto 2D surfaces These include the
mechanically based micropipette adhesion frequency assay [431], the thermal
fluctuation assay [431], biomembrane force probes [432], as well as FRET-based singlemolecule microscopy [433]. Mechanically-based 2D binding measurements of TCRpMHC interactions revealed dramatically different kinetic parameters than 3D
measurements, and 2D measurements displayed a better correlation with T cell
responses [431, 434]. In addition, 2D techniques enable the measurement of TCRpMHC-CD8 tri-molecular interactions. Such analysis revealed signaling-dependent
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cooperation between the TCR and CD8 for pMHC binding, which synergistically
enhanced discrimination of peptides of varying potencies [435]. Implementation of 2D
methodologies to generate refined binding data may serve as a better correlative
marker for understanding HCV1406 TCR cross-reactivity. Additionally, 2D techniques
should be seriously considered when evaluating all therapeutic TCRs as more evidence
suggests 3D affinity measurements do not accurately correlate with T cell function or
predict TCR cross-reactivity.
It is also important to point out that differences in peptide-MHC affinity are also
thought to have an effect on antigen recognition and the effectiveness of an immune
response [436], but to what degree is unclear. All HCV NS3:1406-1415 peptides
evaluated bound HLA-A2 similarly, but not identically. Additionally, thermal stability
measurements generated by CD used to evaluate peptide-MHC binding is a proxy for
affinity. Further studies in the field are necessary to improve the evaluation peptideMHC-I binding interactions and to relate small changes in peptide-MHC binding to
differences in T cell functional responses.
CD8 Co-Receptor Expression and Signaling, Antigen Density,
and TCR Density Impact T Cell Function and Cross-Reactivity
It is also possible that TCR-pMHC affinity, whether measured in 3D or 2D, is not
the most important parameter governing T cell reactivity. Weak correlations between
TCR-pMHC affinity and T cell function led us evaluate the importance of other
parameters that may influence antigen recognition. Because there seemed to be a
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cutoff in CD8-dependence relative to affinity (somewhere between 63 μM (I1412L) and
120 μM (A1409T)), we further evaluated the influence of CD8 on antigen recognition
and TCR cross-reactivity.
It is generally accepted that CD8 enhances T cell sensitivity by stabilizing, or
affinity-enhancing, the TCR-pMHC interaction [378]. However, others have shown that
lck-recruitment to the TCR/CD3 complex by CD8 is essential for T cell function [305]. To
test the importance of both structural stabilization and signaling by CD8, we compared
mutant antigen recognition by TCR-transduced Jurkat cells expressing no CD8, full length
CD8 (CD8αβ), or a truncated version (CD8α’β’) which lacks the intracellular lck-binding
domain. Interestingly, these cell lines exhibited unanticipated cross-reactive profiles.
Mutant epitopes characterized as CD8-independent by primary T cell functional studies
elicited similar cytokine release in Jurkat cells regardless of the CD8 function. However,
recognition of “lower affinity” CD8-dependent variants required both the extracellular
portion and intracellular lck-binding domain of CD8. Thus, it is not only the TCR-pMHC
stabilization by CD8 that dictates T cell function, but the recruitment of lck augmenting
TCR/CD3 signaling also plays an important role. This further supports the notion that
TCR-pMHC affinity is not necessarily the most influential parameter driving T cell
function.
The importance of CD8’s individual functions has been highly debated. One study
concluded that only the extracellular domains of CD8αβ are sufficient for HLA class Irestricted TCR-transduced CD4+ T cells to have optimal antigen recognition [437].
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However, others argued that CD8 signaling can be required for antigen recognition
depending on the strength of the TCR [305]. Additionally, a gp100-reactive T cell clone
designated T4H2 was a CD4-/CD8- T cell that efficiently recognized HLA-A2+ gp100+
human melanoma cells in vitro [44, 164]. However, when the T4H2 TCR was cloned and
expressed in human T cells, it surprisingly required CD8 expression for tumor cell
recognition [44]. Perhaps each TCR may need to be independently evaluated for its
reliance on individual functional components of CD8 to assess its specific requirements
for antigen recognition.
It is important to recognize that in addition to the CD8 co-receptor, the
sensitivity of T cells is known to be modulated by varied expression of other accessory
and/or co-stimulatory molecules including CD28, LFA-1, ICAM-1, OX40, CD80 and TNF
family members like 4-1BB [438]. It is also possible that upregulated expression of key
early signal transduction molecules such as lck and ZAP70 could lower the threshold for
T-cell triggering [384]. Alternatively, molecules such as CD45 or SHP-1 that negatively
regulate signal transduction [439] could also alter the level of antigen density required
for full T-cell activation [440, 441]. Thus, it is important to investigate how surface,
adhesion, and signaling molecules other than CD8 can influence antigen recognition and
cross-reactivity.
In addition to CD8, we also wanted to evaluate the importance of antigen
density on TCR cross-reactivity. Antigen density may influential because clinical reports
of on-target/off-tumor or off-target effects by high affinity TCR-gene modified T cells
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have been attributed to the detection of low levels of antigen [184, 211]. Additionally,
peptide-loaded T2 cells do not represent physiologic levels of antigen a T cell would
encounter on a tumor or virally-infected cell. To evaluate the influence of antigen
density on TCR cross-reactivity, we arbitrarily defined three levels of antigen density.
We consider peptide-loaded TAP- T2 cells to be the “highest” antigen density because
exogenously loaded peptides saturate surface MHC-I in the absence of endogenously
processed peptides. TAP+ HepG2 cells expressing HCV NS3:1406-1415 epitopes as
minigenes require the epitopes to be expressed, minimally processed, and to compete
for MHC-I with all other endogenously processed peptides, serving as our “lowest”
density. Exogenously loading peptide onto TAP+ HepG2 cells eliminates any internal
processing, but the peptide has to outcompete endogenous peptides occupying surface
MHC-I. Peptide-loaded HepG2 cells serve as our “intermediate” density between
peptide-loaded T2 cells and antigen-expressing HepG2 cells. Comparing reactivity
against these three systems allows for an arbitrary evaluation of the influence of antigen
density on TCR cross-reactivity.
As described, cross-reactive profiles were markedly reduced against lower
antigen levels. For example, at an “intermediate” density of antigen, CD4+ TCRtransduced T cells secreted 100-fold less IFNγ against HepG2 cells peptide-loaded with
V1408L compared to I1412V, despite having virtually identical TCR-pMHC affinities (60
and 63 µM, respectively). However, there was only a consistent 2-fold difference in IFNγ
release between V1408L and I1412V peptide-loaded T2 cells. Recognition of antigen-
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expressing HepG2 cells (our “lowest” antigen density) was reduced even more. For
example, CD4+ TCR-transduced T cells secreted IFNγ when stimulated with the WT HCV+
HepG2 cells but lost reactivity against any mutant epitope; CD8+ T cells were only
reactive against “moderate affinity” mutants that were CD8-independent in a high
antigen density T2 cell system. These observations suggest antigen density can have a
profound effect on antigen recognition, and that differences in IFNγ secretion are not
always reconciled by differences in TCR-pMHC affinity.
Because antigen density exhibited an important influence on TCR crossreactivity, we wanted to evaluate if TCR density has a similar impact on antigen
recognition. We first evaluated the impact of TCR density on antigen recognition by
taking advantage of the CD34 cassette in our retroviral vectors. CD34 expression
represents a surrogate marker for TCR transgene expression (Foley, unpublished, [304]).
Evaluation of IFNγ expression in high, medium, and low transgene-expressing T cells by
flow cytometry revealed a TCR density-dependent response in CD8+ T cells. Highest TCR
expression correlated with high expression of IFNγ, and lowest levels of TCR expression
correlated with low, but still above background, IFNγ production. Conversely, CD4+ T
cells were much more dependent on high levels of TCR expression to produce IFNγ
against most CD8-independent variant peptides, which have comparable affinities to
WT. These findings further support that affinity measurements do not predict the
requirement for TCR expression for function. These data also suggest that TCR density
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also plays an important role in antigen recognition, sometimes independent of TCRpMHC affinity.
A potential explanation for TCR density-dependence is provided by the biology of
a TCR-gene-modified T cell. In TCR-engineered T cells and Jurkat cells, endogenously
expressed TCRs limit the functional expression of introduced TCRs through mismatched
chain pairing between endogenous and introduced TCR α and β chains. Additionally, the
introduced receptor is limited by available CD3ζ for which it competes with the
endogenous TCR. Thus, the nature of a TCR-engineered T cells limits optimal density of
an introduced TCR. Because it is thought that the occupancy of a TCR may determine
the magnitude of the T cell response [2], situations of inefficient TCR pairing may be
detrimental to T cell function and may influence TCR cross-reactivity. So, if an altered
peptide ligand requires a greater number of TCRs to be occupied by pMHC to generate a
strong enough signal to induce activation, variations in TCR density may play key a role
in its recognition.
To test this hypothesis, we performed parallel experiments using TCRtransduced Jurkat76 cells, which lack an endogenous TCR. This allows us to directly
assess the impacts of TCR chain mispairing and competition for CD3 on antigen
recognition. Jurkat76 cells were also engineered to express no CD8, full length CD8αβ,
or truncated CD8α’β’ to simultaneously assess the importance of the co-receptor in light
of absent chain pairing competition. Surprisingly, “lower affinity” CD8-dependent
ligands were now recognized in the absence of CD8. This suggests that enhancing

234
introduced TCR chain pairing can alleviate the requirement of CD8 and can enhance TCR
cross-reactivity. The most surprising observation was that CD8αβ Jurkat76 cells
(exhibiting high TCR density and fully functional CD8) were reactive against neverbefore-recognized mutant 8S/9G/12L. This key observation highlights the important
interplay between TCR density, TCR-pMHC stabilization by CD8, and CD8-dependent
signaling and how these factors directly influence antigen recognition irrespective of
affinity.
Overall, the influence of TCR density on antigen recognition suggests that affinity
measurements measured by SPR (a system that lacks TCR pairing competition) may not
accurately reflect TCR-pMHC interactions in TCR-gene-modified T cells. Furthermore,
modification of TCR pairing, without altering its affinity, can have dramatic effects on
cross-reactivity and the requirement for co-receptors. This is an important point to
reflect on because many approaches refining TCR engineered T cells involves
modification of the retroviral vector or the TCR itself to enhance expression, chain
pairing, and/or association with CD3. As discussed in Chapter One, techniques used to
enhance uniform TCR expression include introduction of 2A self-cleaving viral sequences
to promote stoichiometric TCR chain expression or codon optimization to improve
mRNA translation [192, 193]. Additionally, a host of approaches used to modify the TCR
to promote chain pairing include, but are not limited to, introducing additional disulfide
bridges into the constant regions of each chain [176], adding leucine zippers at end of
the cytoplasmic tails [174], or murinization of the constant regions [170, 198-202].
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While these approaches are thought to make better effectors by enhancing the pairing
of introduced TCRs, it has not been considered how modifying pairing efficiency could
induce or alter the cross-reactivity of TCRs. Yet, our data suggest that enhancing the
pairing of an introduced TCR could have a dramatic impact on the recognition of related
antigens. Certainly, this may not be a desired result and could cause unwanted toxicities
in patients treated with pairing-enhanced TCRs. Conversely, such strategies to enhance
pairing that would also enhance cross-reactivity could be advantageous in diseases with
genomic instability. Thus, the importance of TCR chain pairing on cross-reactivity should
now be considered when designing TCRs for ACT.
Antigen Recognition Cannot Be Assessed
Based on a Single Functional Parameter
As described earlier, T cells are often classified by their functional profile (type 1
vs type 2, etc.), which have been related to therapeutic efficacy [395-399]. Specifically, T
cells with type 1 responses are considered to facilitate better anti-tumor efficacy [395,
396], and play an important role in T-cell mediated viral clearance [400-402]. However,
emerging other T cell subsets have been implicated in enhancing anti-tumor and antiviral immunity [401-404]. In light of these generalizations, immune monitoring primarily
evaluates one type 1 cytokine, namely IFNγ, to characterize the reactivity of bulk T cell
cultures. In fact, up until this point, our analyses concerning the importance of affinity,
CD8, ligand density, and TCR density on antigen recognition have been performed by
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evaluating the release of a single cytokine. It may be important, however, to evaluate
more than one functional parameter to appropriately characterize T cell reactivity.
Our simultaneously evaluation of intracellular IFNγ and surface CD107a
revealed a much different biologic message than single cytokine release by a bulk T cell
culture. We described that CD4+ and CD8+ T cells behave in different functional
proportions and that changes in pMHC ligands, sometimes independently of affinity,
disproportionately affected bi-functional IFNγ+CD107a+ populations. These preliminary
observations suggested that the evaluation of a single cytokine might underestimate
the complexity of T cell function and misrepresent the impact of altered TCR-pMHC
interactions on T cell responses.
To evaluate the importance of assessing multiple functional parameters, we
expanded our evaluation of T cell polyfunctionality by flow cytometry to include
CD107a and six cytokines (IFNγ, TNFα, IL-2, IL-4, IL-17A, and IL-22). The resulting multidimensional datasets were immensely difficult to analyze by standard analysis
software. Comparing combinations of seven functional parameters generated 128
discrete functional phenotypes for a single antigen stimulation. Increasing the number
of stimulation conditions or T cell subsets (CD4+ vs CD8+) only complicated this
analysis. Comparisons of over half a dozen software packages enabled us to generate
simple and interpretable graphical output using SPICE which allowed us to draw
meaningful conclusions. While no software package is perfect, the field is continuously
developing and evaluating new tools equipped to analyze such complex datasets [442].
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Initial comparisons of CD4+ and CD8+ TCR-transduced T cell reactivity against
WT NS3:1406-1415 peptide-loaded targets revealed a much greater degree of
phenotypic and functional complexity than is appreciated by the field, suggesting T cell
responses have been oversimplified. Furthermore, we noticed that traditional
functional classifications of type 1 vs type 2 responses do not always hold true. For
example, certain populations of CD4+ or CD8+ TCR-transduced T cells produced
unexpected combinations of cytokines, including IFNγ, IL-2, TNFα, and IL-4 in a single
cell. Comparing T cell functional responses against altered pMHC ligands revealed that
the frequency of polyfunctional populations did not always correlate with changes in
affinity. Additionally, alterations in TCR-pMHC interactions seemed to preferentially
affect higher order polyfunctional populations (≥3 simultaneous functions).
Furthermore, we observed that higher order polyfunctional phenotypes are
completely lost when T cells were stimulated by HCV+ tumor cells. A stark contrast in
polyfunctional phenotypes between peptide- and naturally processed antigenstimulations further highlights the importance of ligand density on the quality of the T
cell response. It would be interesting to evaluate if modifications to the TCR that
enhanced chain pairing (increasing TCR density) could compensate for lower densities
of antigen. This may offer a solution to restore a robust polyfunctional response
against tumor cells expressing lower levels of antigen. It may also, however,
inadvertently increase the risk of off-target effects.
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Overall, these observations using human TCR-transduced T cells are intriguing
because they represent the kinds of T cell populations we transfer into patients.
Heterogeneity in polyfunctional populations among PBL donors demonstrated that
different donors had different functional phenotypes as well as different ranges in
numbers of functional parameters per cell. Expansive evaluation of T cell
polyfunctionality in the context of individuals’ anti-viral or anti-tumor responses may
allow for better treatment correlations or biomarkers for predictive outcomes. It might
be predicted that a T cell performing multiple functions may provide a more effective
immune response. However, if a T cell is performing additional functions at the expense
of the overall magnitude of a given response, a more polyfunctional phenotype may be
less advantageous. For instance, if a T cell is restricted to producing ten functional units
and secretes five different cytokines, the magnitude of a response (two units of each
cytokine) might be lower compared to a T cell secreting only two different cytokines
(five units of each). If the strength of the response is more important than the its
diversity, a T cell with a less diverse functional phenotype may be more therapeutic.
However, if the diversity of a response is more important than magnitude of respective
functions, a T cell producing more cytokines may be more therapeutic.
In vivo modeling will be helpful in testing these hypotheses. TCR-engineered T
cells adoptively transferred into tumor-bearing mice can be isolated from tumors or
lymphoid compartments, assessed for functional profiles ex vivo, and compared to the
tumor status of each animal. If T cells isolated from regressing tumors have distinctly
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different functional phenotypes than those isolated from stable or growing tumors, this
may indicate which functional phenotypes are providing better anti-tumor activity.
Additionally, T cells can be isolated into individual functional phenotypes using cytokine
affinity matrices [443-446]. T cells with certain functional phenotypes can be selectively
adoptively transferred into tumor-bearing mice and evaluated for which functional
phenotype(s) are most effective at reducing tumor growth. The strategies described
above may help elucidate the importance of certain functional phenotypes and how
they can contribute to effective immune responses.
Together, incorporation of multiple functional parameters in immune monitoring
may better assess the true biology of T cell cultures. This level of functional
characterization could also allow us to isolate cells with certain polyfunctional
phenotypes to test in vivo which functional profiles are better for anti-tumor or antiviral immunity. A more complete understanding of the different populations of T cells
delivered to patients might also enable us to select for or design T cells with an
“optimal” polyfunctional profile. This would be an immensely powerful tool to enhance
the efficacy and safety of TCR-engineered T cells used in ACT.
It is important to point out that these observations would have never been
established had we limited our characterization of T cell reactivity to standard assays
evaluating a single cytokine. While evaluation of T cell polyfunctionality by multiparameter flow cytometry is not necessarily a novel concept, most evaluations,
however, have been limited to 2-4 parameters [447-451]. Very few studies have
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assessed up to seven functional parameters, but advancement in reagents,
instrumentation and multivariate data analysis is making this more feasible [452]. Some
groups are evaluating larger numbers of fluorescent markers to evaluate T cell
populations, but studies focusing on functionality are limited. A novel technology
surpassing the practical limitations of flow cytometry, cytometry by time-of-flight
(CyTOF), uses metal-labeled probes and mass spectrometric analysis to facilitate the
measurement of 36 or more parameters in a single-cell with minimal crosstalk between
channels [453]. Implementation of CyTOF has enabled researchers to evaluate
previously unfeasible numbers of cellular parameters simultaneously. One study used
the simultaneous detection of 16 surface markers, 6 tetramers, and 10 intracellular
stains to evaluate combinatorial cytokine expression in virus-specific CD8+ T cells within
the continuum of cellular differentiation [454]. Others have used this approach to
evaluate differential immune and drug responses across a human hematopoietic
continuum [455]. Expansion of our functional panel using CyTOF to include lineage,
memory, and effector markers, as well as phospho-signaling proteins or transcriptions
factors may help provide explanations for unexpected cytokine combinations, but would
admittedly exponentially complicate the analysis. Furthermore, scarcity of available
instrumentation, cost of reagents, and careful optimization required make CyTOF
analysis currently a less feasible approach. Nonetheless, our multi-parameter flow
cytometric analysis of T cell polyfunctionality greatly alters the interpretation of antigen
recognition compared to standard single parameter evaluations.
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A More Complete Understanding of Antigen Recognition and TCR Cross-Reactivity
May Rely on Structural Interpretation of the TCR-pMHC Interface
As a whole, we have evaluated various kinetic and cellular parameters driving
antigen recognition, TCR cross-reactivity, and T cell polyfunctionality. We have also
come to the realization that while affinity is thought to play the most important role, it
may be quite overvalued. In light of these observations, we still lack a complete
understanding of (1) what is truly different about the altered ligand interactions, and (2)
how that translates into varied polyfunctional responses.
The concept of altered peptide ligands having differential effects on T cell
function was first described by Evavold and Allen [456]. In this seminal report, a
conservative substitution (E73D), removing one methylene group of an amino acid
anchoring side chain impaired proliferation but not IL-4 production in T cells.
Subsequent studies involving additional T cell clones indicated that TCRs have the
capacity of differential signaling, leading to a spectrum of functional responses and
events [296, 457-460]. Many of the explanations of altered T cell function were initially
rationalized by changes in affinity due to small changes in pMHC topology [461]. Yet, in
our studies, changes in TCR-pMHC affinity (or even interactions with similar affinities)
were not always correlative with polyfunctional responses. Others have since suggested
that altered peptides may induce small conformational changes in the TCR engaging
altered pMHC, leading to ranges of TCR-initiated signals, sometimes independent of
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measurable affinity [462-464]. Thus, structural studies highlighting the TCR-pMHC
interface may provide a better explanation for unanticipated functional outcomes.
Efforts to better understand functional effects of altered peptide ligands have
relied heavily on solving crystal structures of TCR-pMHC interactions. These evaluations
provide the resolution necessary to detect important TCR contact points with peptide
and/or MHC, identifying key hydrogen bonds or van der Waals contacts thought to
influence antigen recognition. Comparing crystal structures of TCRs engaged with
altered peptide ligands have revealed obvious or subtle changes in pMHC topography,
resulting in altered TCR conformations thought to be responsible for profound biological
effects [465-467].
It is important to realize that the true mechanism behind altered T cell function
lies at the origin of the interaction, the interface of the TCR-pMHC. Therefore, we
cannot begin to fully understand how HCV1406 TCR cross-reactivity dictates functional
outcome without evaluating structurally what happens at this TCR-pMHC interface. We
have previously provided computational modeling of the interactions between our HCV
TCRs and WT pMHCs to help explain changes in binary function and potency of response
influenced by the CD8 co-receptor. Since then we have discussed at length many
parameters other than affinity we feel are involved in dictating T cell activation and
polyfunctionality. But as mentioned, to identify the true mechanism calls for crystal
structure analysis. Thus, to visualize the TCR-pMHC interface and rationalize functional
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effects upon alteration of the peptide, we turned to the solved the crystal structure of
HCV1406 TCR with WT HCV NS3:1406-1415/HLA-A*0201.
The crystal structure of the TCR-pMHC now allows us to highlight TCR contact
residues important for a productive interaction. Figure 57 illustrates the crystal
structure overview of the TCR interaction with pMHC as well as the pMHC topology with
HCV1406 TCR’s CDR loop footprint. A closer examination of hydrogen bonds and van der
Waals contacts with TCR and WT peptide is shown in Figure 58 and summarized in Table
14. Interestingly, only CDRα loops are involved in hydrogen bond-mediated recognition
of the peptide itself (Fig. 58). CDR1α loop residue S33 interacts strongly with the lysine
residue at position one, which explains why an alanine substitution at this position
abrogated functional responses by TCR-transduced PBL and Jurkat cells (See Appendix).
Additionally, CDR3α loop residue D102 forms hydrogen bonds with peptide positions 4,
6, and 7 (A1409T, G1411, and I1412, respectively). The importance of these interactions
may help resolve differences in recognition of mutants A1409T, I1412L, I1412V, and
I1412N. If this S33-p4 interaction is important for TCR recognition of pMHC, an amino
acid class substitution from a nonpolar alanine to a polar threonine (A1409T) could
require TCR and/or peptide rearrangements to resolve atomic clashes. If this were to
only weaken the TCR-pMHC interaction, CD8-dependence would only require the
extracellular domain stabilizing TCR-pMHC. But because recognition of A1409T also
requires the lck-binding domain of CD8, perhaps an interface rearrangement induces a
conformational change in the TCR leads to differential TCR/CD3 signaling requirements.
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Figure 57. Crystal structure overview of HCV1406 TCR : WT HCV NS3:1406-1415 / HLAA2. (a) Side view of the TCR-pMHC complex (ribbond diagram). TCRα chain (orange);
TCRβ chain (purple); HLA-A2 heavy chain (gray); β2m chain (blue); WT peptide is drawn
in stick representation with carbon atoms in yellow, nitrogen atoms in blue, and oxygen
atoms in red. (b) Footprint of the HCV1406 TCR CDR loops over the WT HCV NS3:14061415 peptide. Same color scheme as part a. Crystal structure data was kindly provided
by Yuan Wang in the Baker Lab (University of Notre Dame).
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Figure 58. Hydrogen bonds and van der Waals contacts between HCV1406 TCR CDR loops and WT HCV NS3:1406-1415 / HLA-A2.
(a) Hydrogen bonds between TCR and pMHC. Only CDRα loops are involved into peptide recognition. CDR1α (orange), CDR3α
(purple); hydrogen bonds are represented by red dotted lines; TCR residues are identified by a one-letter amino acid designation
followed by position number and chain designation. (b) van der Waals contacts (purpled dotted lines) between HCV1406 TCR CDR
loops with pA4 (A1409). Same color scheme as in part a. (c) van der Waals contacts (purple dotted lines) between HCV1406 TCR CD$
loops with pI7 (I1412L). Same color scheme as in part a. Red arrows highlight altered residues in naturally occurring mutant
epitopes. Crystal structure data was kindly provided by Yuan Wang in the Baker Lab (University of Notre Dame).
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Table 14. Interactions between HCV1406 TCR CDR loops and WT HCV NS3:1406-1415
peptide in the TCR-pMHC complex.
TCR CDR loop residue
CDR1α

S33
E34

Hydrogen bonds/
salt bridges (bold)
O:pK1(Nζ)
Oγ:pK1(Nζ)

van der Waals
contacts
pK1

pK1
pA4
D36
pA4
Y37
pL5
Y38
pL5
CDR3α
D102
N:pA4(O)
pA4
Oδ1:pG6(N)
pA5
δ2
O :pG6(N)
pG6
δ2
O :pI7(N)
pI7
CDR3β
G96
pN8
P97
pL5
pN8
Crystal structure data was kindly provided by Yuan Wang in the Baker Lab (University of
Notre Dame).
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That being said, in the absence of receptor pairing competition, CD8- Jurkat76 cells can
recognize this mutant, suggesting that augmentation of TCR density can overcome or
accommodate for any structural changes associated with this substitution.
Similarly, we studied three altered pMHC ligands with substitutions at position 7.
I1412L and I1412V are both CD8-independent with similar KD measurements and
conservative substitutions. Yet I1412L, with a 2-fold higher affinity, consistently blunted
CD4+ T cell responses. It is less clear how the subtraction of a single methyl group
(I1412V) could have a greater detrimental affect than the same number of hydrocarbons
but in different branching orientation (I1412L) despite similar (yet two-fold higher)
affinity. As these residues are hydrophobic and buried in the binding groove of HLA-A2,
it is plausible that the orientation of the hydrocarbon side chains could alter the overall
topology of the pMHC. Because hydrogen bonds’ energetic dependence on the
stereochemistry and geometry of the bond is crucial [468], a minor change in a single
hydrocarbon side chain orientation could have a significant effect on TCR
conformational change. Thus, identification of important TCR-peptide hydrogen bonds
helps rationalize differential antigen recognition, but a complete explanation is not yet
clear.
TCR and peptide interactions are also influenced by van der Waals contacts
between CDR3α loop residue D102 with peptide positions 4-7 (Fig. 58b-c). While
individually weaker compared to hydrogen bonds, van der Waals interactions when
presented in large numbers across broad interfaces “sum” to substantial binding
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energies between TCR and pMHC [469]. Thus, variants with substitutions at positions 4
(A1409) and 7 (I1412) could disrupt the integrity of van der Waals forces, leading to
conformational changes and differences in functional responses without a large impact
on affinity. Similarly, while variants I1412N and 8S/9G/12L have essentially the same
affinity, 8S/9G/12L remains unrecognized by HCV1406 TCR-transduced T cells. Perhaps
despite identical affinities, the number of mutations or the position in which they occur
could dramatically alter the conformation of the pMHC topography, not predicted by 3D
affinity. In fact, it is reasonable to predict an altered conformation could affect the
efficiency of TCR signaling, or require a greater threshold of TCR contacts or number of
occupied TCR for functional recognition. This might explain why CD8αβ Jurkat76 cells
(enhancing introduced TCR chain pairing and TCR signaling) could overcome structural
perturbations and mediate T cell recognition of 8S/9G/12L.
Additionally, TCR interactions with HLA-A2, including hydrogen bonds, salt
bridges, and van der Waals contacts are also important (summarized in Table 15). Two
CDRs of the α chain and all three CDRs of the β chain contact a myriad of residues
throughout HLA-A2. It is plausible that variant peptides could alter pMHC conformation
and disrupt TCR interaction with MHC independently of peptide contacts. Taken
together, information gathered from crystal structure analysis offer us the opportunity
to explain the structural importance of certain residues’ influence on downstream
function.

249
Table 15. Interactions between HCV1406 TCR CDR loops and HLA-A2 in the TCR-pMHC
complex.
TCR CDR loop residue
CDR1α

E34
S35
D36

CDR2α

Y38
Y59

CDR2α
CDR1β
CDR2β

K60
D103
D30
Y50

CDR3β

G51
V52
N53
S54
E56
R95
P97
Y98

Hydrogen bonds/
salt bridges (bold)
Oξ1:K66(Nζ)
Oξ2:K66(Nζ)
δ1

γ

O :T163(O )
Oδ2:T163(Oγ)

Nζ:E154(Oξ2)
Oδ1:K146(Nζ)

van der waals
contacts
K66α1
T163α2
Y159α2
T163α2
Q155α2
E154α2
Q155α2
A158α2
E154α2
R65α1
K146α2
A69α1
Q72α1
V76α1
V76α1
R75α1
V76α1
Q72α1

Nη1:A149(O)

Q155α2
O :A150(O)
A150α2
η
ζ2
O :Q155(N )
H151α2
Q155α2
Crystal structure data was kindly provided by Yuan Wang in the Baker Lab (University of
Notre Dame).
η
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However, it is still not clear how conservative (i.e. I1412L vs I1412V) or more
radical (I1412N vs 8S/9G/12L) mutations resulting in similarly paired affinities can
induce modestly or starkly different polyfunctional outcomes. To confirm our
predictions, comparison of crystal structures of HCV1406 TCR with each mutant peptide
bound to HLA-A2 is required. While out of the scope of this dissertation, this is a logical
next step to discern any true conformational changes that might induce differential T
cell functions. Even so, based on some mutants’ minor and conservative amino acid
changes (some with merely the addition or change in place of a single hydrocarbon),
such conformational changes might be so subtle that a crystal structure may not provide
enough resolution to detect them. But combining a series of crystal structures with
alternative 2D kinetic and thermodynamic analyses may help determine what changes
at the TCR-pMHC interface influence TCR cross-reactivity and ultimately T cell function.
Nonetheless, structure-function studies like the ones outlined here are important to
better understand the principles behind antigen recognition and the consequences of
alterations in TCR-pMHC. Appreciation of important TCR-pMHC contact points and their
impact on downstream function might allow for structure-guided design of TCRs
enhancing or limiting contacts with peptide or MHC in order to enhance or limit a T cells
specificity [266, 270, 470].
Concluding Remarks
To improve T cell-based immunotherapy, we need to better understand the
basic requirements for antigen recognition and what parameters govern antigen
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specificity, TCR cross-reactivity, and T cell function. Experimental questions addressed in
this dissertation utilized traditional and novel approaches to characterize (1) the
requirements for cross-reactive antigen recognition by HCV1406 TCR gene-modified T
cells and (2) the functional consequences of altered TCR-pMHC interactions. The
characterization of HCV1406 TCR cross-reactivity against naturally occurring mutant HCV
NS3:1406-1415 epitopes fundamentally serves as a model to study antigen recognition.
While it is important to acknowledge that because HCV1406 TCR was allo-restricted, it
was by definition cross-reactive. But this should not limit any value from the work as a
whole because in a sense all T cells are inherently cross-reactive. As thymic education
requires antigen recognition by a T cell for positive selection, certainly pathogenic
peptides with which TCRs engage in the periphery are not presented in the thymus. The
principles behind thymic education as well as the existence of allo-specific T cells [471,
472] would suggest that TCRs must be cross-reactive to some extent and that the lockand-key principle of TCR-specificity is outdated. Aside from characterization of TCR
cross-reactivity, this dissertation examines the basic principles behind antigen
recognition and how TCRs can facilitate drastically different functional responses against
naturally occurring mutant peptides.
Overall, contrary to what is generally accepted in the field, we found that TCRpMHC affinity is not necessarily the most important role dictating antigen recognition
and T cell function. Other cellular parameters, including ligand density, TCR density, and
co-receptor signaling greatly influenced recognition of altered ligands, providing a new

252
working model for antigen recognition (Fig. 59). Additionally, modifying any of these
parameters could dramatically change functional responses, sometimes independently
of affinity. We also found that the field’s interpretation of TCR cross-reactivity or
antigen recognition may be narrowed and misguided when evaluation of T cell function
is limited to a single cytokine. Functional phenotyping by seven-parameter flow
cytometry revealed that T cell functional profiles are more complex than were
previously believed. Evaluation of a single functional phenotype, such as IFNγ, also does
not accurately reflect the functional behavior of a T cell culture, especially when
comparing altered TCR-pMHC interactions. But as the technology improves, the
evaluation of seven functional parameters for any immune cell type will be inadequate.
While more information may be learned from multi-parameter analyses, its analysis will
inherently be more complex, but it will more accurately reflect the true nature of the
immune response.
Together, these studies suggest that the field is grossly oversimplifying the
biology of T cells and the fundamentals of antigen recognition. It is important to note,
however, that the data presented in this dissertation challenge longstanding
assumptions not because the field is ignorant of them, but rather that no one has
evaluated these questions in as much detail as is presented here. A sound explanation
of our observations may depend on a clearer understanding of what is happening
structurally at the TCR-pMHC interface combined with novel, emerging strategies
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Figure 59. A new working model for kinetic and cellular parameters influencing
antigen recognition and T cell function. Schematic diagram illustrating factors involved
in T cell activation upon TCR-pMHC ligation. While (a) affinity of the TCR-pMHC
interaction is thought be the most influential factor governing antigen recognition,
studies in this dissertation suggest that is not the case. (b) Antigen and (c) TCR densities
also play important roles, and augmentation of either one can modulate TCR crossreactivity. Additionally, (d) CD8 co-receptor has been shown to stabilize the TCR-pMHC
interaction, but its (e) ability to augment TCR/CD3 signaling by recruiting lck is essential
for low affinity interactions. A complex interplay of these, and other factors, play a role
in dictating the (f) polyfunctional output of T cells which facilitate anti-tumor and antiviral immune responses. Evaluating single-cell polyfunctional response, rather than
single cytokine release by a bulk T cell culture greatly enhances biologic interpretation.
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evaluating TCR-pMHC binding. Only then can we truly rationalize how single amino acid
substitutions relay such substantial changes in functional output. Once resolved, such
comprehension will not only help steer rational, structure-guided design of TCRs to
generate better functioning T cells, but it will also impact the way in which we study
other immune cell and receptor types, approach epitope discovery, and evaluate
vaccine design. In this way, we have provided a new foundation in which to evaluate the
design and implementation of novel immunotherapies.
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Figure 60. Rosetta score vs. modeling stage for modeling the HCV1406 (top) and
HCV1073 (bottom) TCR-pMHC complexes.
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Figure 61. Comparison of TCR density and HCV NS3:1406-1415 (WT) tetramer staining
by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used
to stain 1x106 cells.
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a)

b)

Figure 62. Comparison of TCR density and HCV NS3:1406-1415 (I1412L) tetramer
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used
to stain 1x106 cells.
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a)

b)

Figure 63. Comparison of TCR density and HCV NS3:1406-1415 (V1408T) tetramer
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used
to stain 1x106 cells.
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a)

b)

Figure 64. Comparison of TCR density and HCV NS3:1406-1415 (V1408L) tetramer
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used
to stain 1x106 cells.
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a)

b)

Figure 65. Comparison of TCR density and HCV NS3:1406-1415 (I1412V) tetramer
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used
to stain 1x106 cells.
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a)

b)

Figure 66. Comparison of TCR density and HCV NS3:1406-1415 (A1409T) tetramer
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used
to stain 1x106 cells.
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a)

b)

Figure 67. Comparison of TCR density and HCV NS3:1406-1415 (I1412N) tetramer
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used
to stain 1x106 cells.
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a)

b)

Figure 68. Comparison of TCR density and HCV NS3:1406-1415 (8S/9S/12L/14S)
tetramer staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate
marker for HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate
marker for HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of
tetramer used to stain 1x106 cells.
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Figure 69. Evaluation of CD107a and intracellular IFNγ expression by CD4+ HCV1406
TCR-transduced T cells stimulated with variant HCV NS3:1406-1415 peptides. HCV1406
TCR-transduced PBL were co-cultured for 5 hr with T2 cells loaded with WT and mutant
HCV NS3:1406-1415 or tyrosinase:368-376 peptides and stained for
immunofluorescence. CD3+CD34+CD4+CD8- T cells were identified and evaluated for
CD107a vs IFNγ expression. These data were used to create pie charts displayed in
Figures 39.
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Figure 70. Evaluation of CD107a and intracellular IFNγ expression by CD8+ HCV1406
TCR-transduced T cells stimulated with variant HCV NS3:1406-1415 peptides. HCV1406
TCR-transduced PBL were co-cultured for 5 hr with T2 cells loaded with WT and mutant
HCV NS3:1406-1415 or tyrosinase:368-376 peptides and stained for
immunofluorescence. CD3+CD34+CD4-CD8+ T cells were identified and evaluated for
CD107a vs IFNγ expression. These data were used to create pie charts displayed in
Figures 39-40.
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Figure 71. Evaluation of CD107a and intracellular IFNγ expression by CD4+ HCV1406
TCR-transduced T cells stimulated with variant naturally processed HCV NS3. COS cells
were transfected to express full length WT HCV NS3 and COS/A2 cells were transfected
to express full length HCV NS3 with WT or variant 1406-1415 epitopes. HCV1406 TCRtransduced PBL were co-cultured with transfected COS cells for 5 hr and stained for
immunofluorescence. CD3+CD34+CD4+CD8- T cells were identified and evaluated for
CD107a vs IFNγ expression. These data were used to create pie charts displayed in
Figure 41.
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Figure 72. Evaluation of CD107a and intracellular IFNγ expression by CD8+ HCV1406
TCR-transduced T cells stimulated with variant naturally processed HCV NS3. COS cells
were transfected to express full length WT HCV NS3 and COS/A2 cells were transfected
to express full length HCV NS3 with WT or variant 1406-1415 epitopes. HCV1406 TCRtransduced PBL were co-cultured with transfected COS cells for 5 hr and stained for
immunofluorescence. CD3+CD34+CD4-CD8+ T cells were identified and evaluated for
CD107a vs IFNγ expression. These data were used to create pie charts displayed in
Figures 41-42.
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Figure 73. FlowJo-generated seven-parameter pairwise matrix displaying how gates
are set against tyrosinase:368-376 peptide stimulation. Gates were set for non-specific
(tyrsoinase) peptide stimulation and applied to HCV1406 TCR-transduced T cells
stimulated WT HCV NS3:1405-1415 peptide-loaded T2 cells. Compare to Figure 44.
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Figure 74. Polyfunctional profiles of CD4+ vs CD8+ HCV1406 TCR-transduced T cells after stimulation with WT HCV NS3:1405-1415
peptide-loaded T2 cells. Compare to Figure 46 for condensed SPICE-generated bar graph. Percentages represent frequencies after
background subtraction from tyronsiase peptide stimulation.
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Figure 75. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV
NS3:1405-1415 peptide-loaded T2 cells (Donor 1). Compare to Figures 48-49 for condensed cool plots. Percentages represent
frequencies after background subtraction from tyronsiase peptide stimulation.
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Figure 76. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV
NS3:1405-1415 peptide-loaded T2 cells (Donor 2). Compare to Figure 49 for condensed cool plot. Percentages represent
frequencies after background subtraction from tyronsiase peptide stimulation.
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Figure 77. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV
NS3:1405-1415 peptide-loaded T2 cells (Donor 2). Compare to Figures 50-51 for condensed cool plots. Percentages represent
frequencies after background subtraction from tyronsiase peptide stimulation.
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Figure 78. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3
expressing HepG2 cells (Donor 2). T cells are non-reactive above background. Percentages represent frequencies after background
subtraction from HCV- HepG2 peptide stimulation.
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Figure 79. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3
expressing HepG2 cells (Donor 2). Compare to Figure 52 for condensed cool plot. Percentages represent frequencies after
background subtraction from HCV- HepG2 peptide stimulation.
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Figure 80. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV
NS3:1405-1415 peptide-loaded T2 cells (Donor 3). Percentages represent frequencies after background subtraction from tyronsiase
peptide stimulation.
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Figure 81. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV
NS3:1405-1415 peptide-loaded T2 cells (Donor 3). Percentages represent frequencies after background subtraction from tyronsiase
peptide stimulation.
[277]

[278]

Figure 82. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3
expressing HepG2 cells (Donor 3). Percentages represent frequencies after background subtraction from HCV - HepG2 peptide
stimulation.
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Figure 83. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3
expressing HepG2 cells (Donor 3). Percentages represent frequencies after background subtraction from HCV - HepG2 peptide
stimulation.
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Figure 84. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with a peptide titration of WT HCV
NS3:1406-1415 (Donor 3). Compare to Figure 53. Percentages represent frequencies after background subtraction from tyronsiase
peptide stimulation.
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Figure 85. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with a peptide titration of WT HCV
NS3:1406-1415 (Donor 3). Compare to Figure 49. Percentages represent frequencies after background subtraction from tyronsiase
peptide stimulation.
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Figure 86. Comparison of CD4+ T cell polyfunctional profiles between TCR-independent and TCR-dependent T cell activation
(Donor 2). HCV1406 TCR-transduced CD4+ T cells were stimulated with peptide-loaded T2 cells or PMA/Ionomycin. Percentages
represent frequencies after background subtraction from tyronsiase peptide stimulation.
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Figure 87. Comparison of CD8+ T cell polyfunctional profiles between TCR-independent and TCR-dependent T cell activation
(Donor 2). HCV1406 TCR-transduced CD8+ T cells were stimulated with peptide-loaded T2 cells or PMA/Ionomycin. Percentages
represent frequencies after background subtraction from tyronsiase peptide stimulation.
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Figure 88. Hierarchical clustering of peptide-stimulated responses of TCR-transduced
CD8+ T cells (Donor 1).
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Figure 89. Hierarchical clustering of peptide-stimulated repsonses of TCR-transduced
CD4+ T cells (Donor 1).

WT

V1408L
Mut1

Mut3
I1412L

Mut4
I1412V

Mut7
V1408T

Mut5
I1412N

Mut2
A1409T

8S/9S/12L/14S
Mut8

8S/9G/12L
Mut6

Tyro
Tyro

[286]

n

CD107a,
IFN , CD107a, TNF ,
IFN ,
IFN , TNF ,
IFN , CD107a,
CD107a, TNF ,
IFN , CD107a, IL-17A, TNF ,
IL-2, IFN , CD107a, TNF ,
IL-4,
CD107a, IL-4,
CD107a, TNF , IL-4,
IL-2, CD107a, TNF ,
IL-2, CD107a, TNF , IL-4,
TNF ,
IL-2, IFN , CD107a, IL-17A, TNF ,
IL-2, IFN , CD107a, TNF , IL-4,
IL-2, IFN , CD107a, IL-17A, TNF , IL-4,
IL-2, CD107a, IL-4,
IL-2, CD107a, IL-17A, TNF , IL-4,
IFN , CD107a, IL-17A, TNF , IL-4,
CD107a, IL-17A,
CD107a, IL-17A, TNF ,
IL-2, CD107a,
IFN , CD107a, TNF , IL-4,
IFN , IL-17A, TNF ,
IL-17A,
IL-2,
CD107a, IL-17A, TNF , IL-4,
IL-2, TNF ,
IL-2, CD107a, IL-17A, TNF ,
IL-2, TNF , IL-4,
CD107a, IL-17A, IL-4,
IL-2, IFN , TNF ,
IL-2, IL-4,
IFN , CD107a, IL-4,
TNF , IL-4,
IL-2, IFN , CD107a,
IFN , CD107a, IL-17A,
IFN , IL-4,
IL-22,
IL-2, IFN ,
IL-2, IFN , TNF , IL-4,
IL-2, IFN , CD107a, IL-4,
IL-2, CD107a, IL-17A, IL-4,
IFN , TNF , IL-4,
IFN , CD107a, IL-17A, TNF , IL-22,
IL-2, IFN , IL-17A, TNF ,
IL-2, IFN , IL-4,
IL-2, IFN , CD107a, IL-17A, TNF , IL-4, IL-22,
IL-2, CD107a, TNF , IL-4, IL-22,
IFN , CD107a, IL-17A, IL-4,
IL-17A, IL-4,
IL-2, CD107a, IL-17A,
IL-2, IFN , CD107a, IL-17A, IL-4,
IL-2, IFN , CD107a, IL-17A,
IFN , IL-17A, TNF , IL-4,
IL-17A, TNF ,
IL-2, CD107a, IL-17A, TNF , IL-4, IL-22,
IL-2, IL-17A,
IL-2, IFN , CD107a, IL-17A, IL-4, IL-22,
IL-2, IFN , IL-17A, TNF , IL-4,
IFN , CD107a, IL-17A, TNF , IL-4, IL-22,
IL-2, IL-17A, TNF , IL-4,
IFN , IL-17A,
IL-2, IFN , CD107a, IL-17A, TNF , IL-22,
IL-2, IFN , CD107a, TNF , IL-22,
IFN , CD107a, TNF , IL-22,
IFN , IL-17A, TNF , IL-22,
IFN , IL-17A, IL-4,
IL-2, IFN , IL-17A, IL-4,
IL-17A, TNF , IL-4,
IL-2, CD107a, IL-4, IL-22,
IFN , CD107a, TNF , IL-4, IL-22,
CD107a, TNF , IL-4, IL-22,
CD107a, IL-4, IL-22,
IL-2, IFN , CD107a, TNF , IL-4, IL-22,
IFN , TNF , IL-22,
IFN , CD107a, IL-22,
IL-2, CD107a, TNF , IL-22,
IL-2, IL-17A, TNF ,
CD107a, TNF , IL-22,
CD107a, IL-17A, TNF , IL-22,
IFN , TNF , IL-4, IL-22,
IL-2, IFN , IL-4, IL-22,
IL-2, IFN , CD107a, IL-4, IL-22,
IFN , CD107a, IL-17A, IL-4, IL-22,
IL-2, TNF , IL-4, IL-22,
IL-2, IL-4, IL-22,
IL-2, IL-17A, TNF , IL-4, IL-22,
IL-2, IFN , IL-17A, TNF , IL-4, IL-22,
IL-2, IFN , IL-17A, IL-4, IL-22,
IL-2, IFN , CD107a, IL-22,
IFN , IL-17A, IL-22,
IFN , IL-17A, TNF , IL-4, IL-22,
IL-2, IFN , IL-17A,
IL-2, CD107a, IL-17A, TNF , IL-22,
IL-2, IL-17A, IL-4,
IFN , CD107a, IL-4, IL-22,
IL-2, IFN , IL-17A, TNF , IL-22,
IL-4, IL-22,
IL-17A, IL-22,
IL-17A, TNF , IL-22,
TNF , IL-22,
IL-2, IFN , IL-22,
IL-2, IFN , TNF , IL-22,
IL-17A, IL-4, IL-22,
IL-2, CD107a, IL-17A, IL-4, IL-22,
IFN , IL-22,
CD107a, IL-17A, TNF , IL-4, IL-22,
CD107a, IL-17A, IL-4, IL-22,
TNF , IL-4, IL-22,
CD107a, IL-22,
CD107a, IL-17A, IL-22,
IL-17A, TNF , IL-4, IL-22,
IL-2, IL-22,
IL-2, TNF , IL-22,
IL-2, CD107a, IL-22,
IL-2, CD107a, IL-17A, IL-22,
IL-2, IL-17A, IL-22,
IL-2, IL-17A, TNF , IL-22,
IL-2, IL-17A, IL-4, IL-22,
IL-2, IFN , TNF , IL-4, IL-22,
IL-2, IFN , CD107a, IL-17A, IL-22,
IL-2, IFN , IL-17A, IL-22,
IFN , IL-4, IL-22,
IFN , CD107a, IL-17A, IL-22,
IFN , IL-17A, IL-4, IL-22,

Figure 90. Hierarchical clustering of peptide-stimulatednresponses of TCR-transduced
CD8+ T cells (Donor 2).
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Figure 92. Hierarchical clustering of tumor-stimulated responses of TCR-transduced
CD8+ T cells (Donor 2).
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Figure 93. Hierarchical clustering of tumor-stimulated responses of TCR-transduced
CD4+ T cells (Donor 2).
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Figure 94. Cross-reactivity against alanine-substituted HCV NS3:1406-1415 peptides by
HCV1406 TCR-transduced PBL-derived T cells. PBL from two normal donors were
transduced with the HCV1406 TCR retroviral vector and were enriched for CD34expressing cells. T2 cells were loaded with 10 µg/mL HCV NS3:1406-1415, alanine
substituted peptides (isoleucine substitutions at positions 4 and 9), or tyrosinase:368376. IFNγ release was determined by ELISA. Mean and standard deviation of triplicate
measurements are shown. These data are a representative of two independent
experiments using two donors each.

[291]
a)

b)

Figure 95. HCV1406 TCR-transduced Jurkat and Jurkat76 cells exhibit similar crossreactive profiles against alanine-substituted HCV NS3:1406-1415 peptides. (a) Jurkat or
(b) Jurkat76 cells were transduced with the HCV1406 TCR retroviral vector. Transduced
cells were enriched for CD34-expression. T2 cells were loaded with 10 µg/mL HCV
NS3:1406-1415, alanine substituted peptides (isoleucine substitutions at positions 4 and
9), or tyrosinase:368-376. IFNγ release was determined by ELISA. Mean and standard
deviation of triplicate measurements are shown. These data are representative of two
independent experiments.

[292]
Table 16. Comparison of cross-reactive profiles against alanine-substituted HCV
NS3:1406-1415 peptides.
WT Jurkat
Epitope

Sequence

PBL*

CD8–

CD8+

Jurkat76
CD8–

CD8+

YMDGTMSQV
Tyrosinase
HCV1406wt KLVALGINAV
+++
+++
+++
+++
+++
ALVALGINAV
K1406A
KAVALGINAV
L1407A
++
+++
+++
++
++
KLAALGINAV
V1408A
++
++
+++
+
+
KLVILGINAV
A1409I
++
+
++
+
++
KLVAAGINAV
L1410A
++
+
++
+
++
KLVALAINAV
G1411A
KLVALGANAV
I1412A
+
+
KLVALGIAAV
N1413A
+++
+++
+++
+++
+++
KLVALGINIV
A1414I
+++
+++
+++
+++
+++
KLVALGINAA
V1415A
+++
+++
+++
+++
+++
*Two donor average
+++ = >75% WT reactivity; ++ = 25-75% WT reactivity; + = 25-5% WT reactivity; - <5% WT
reactivity
These data portray comparisons of cytokine release shown in Figures 94-95 and are a
representative of two independent experiments.
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